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Abstract 
Neonates born to mothers with an active gonorrhoea infection can develop serious sight 
threatening eye infections. The causative agent, Neisseria gonorrhoeae, is passed to the neonate 
during birth, and infects the eyes of the neonate. The condition, ophthalmia neonatorum, develops 
0-14 days after birth and initially presents as a painful inflammation of the eye with yellowish 
purulent discharge from one or both eyes. One preventative action used by some countries is the 
use of an ophthalmic prophylaxis which is usually an ophthalmic ointment which contains an 
antibiotic. This its self can cause chemical conjunctivitis. 
This study evaluates the potential to use a fatty acid or fatty acid derivative as the active 
antimicrobial agent in an ophthalmic prophylaxis. A panel of thirty-seven initial candidates were 
screened for anti-gonococcal properties. Seven of this panel were selected and tested against for 
ocular irritation potential using in vitro models and anti-gonococcal properties tested further in 
simulated tear fluid. Finally a single candidate, monocaprin, was selected as the main drug 
candidate. Ophthalmic formulations of liquid and semi-solid dosage forms were made and 
evaluated. Liquid dosage forms performed the best in in vitro tested and were further evaluated in 
cell culture and explanted models. The cell culture model suggested that monocaprin could be used 
to prevent infection 90 minutes after the cell were inoculated with the bacteria. An explanted 
corneal infection model was used to assess the potential formulations. It was shown that the anti-
gonococcal properties of the drug candidate were inhibited on the ocular surface but this this could 
be countered by increasing the amount of monocaprin in the formulation. The formulations 
containing 0.188 % and 0.25 % (w/w) monocaprin were in some cases able to totally clear 
inoculations of higher cell numbers on the surface of the eye.  
Passage on agar plates containing monocaprin showed that increasing resistance due to genomic 
mutation is not likely and that existing mechanisms of fatty acid resistance did not give cross-
resistance to monocaprin. However, duplicate samples passaged on monocaprin both acquired 
identical mutations in the dksA gene which may confer a small decrease in susceptibility. Also, work 
done on the processing of natural sources of fatty acids showed that treatment of coconut oil by 
use of a purified lipase or a lipase secreting yeast produced powerful anti-gonococcal substances. 
This could has the potential to be used in developing nations treat gonococcal and other bacterial 
infection.  
Overall, the work in thesis demonstrates that there is potential in the use a fatty acid or fatty acid 
derivative, most likely monocaprin, to be used as the active antimicrobial agent in an ophthalmic 
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prophylaxis but more evaluation in terms of in vivo testing is required to demonstrate that the 
higher levels of monocaprin do not cause irritation to the eye. 
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1.1 Neisseria gonorrhoeae and its diseases 
1.1.1 History of gonorrhoea  
In 1879, a young German physician by the name of Albert Ludwig Sigesmund Neisser reported that 
he had successfully stained a bacteria that was present in 46 smear samples [1]. Thirty-five of the 
smears were from men and nine from women with purulent urethritis with two of the smears 
coming from patients with acute ophthalmia. He described a bacterium shaped as a “figures of 
eight” in methyl violet stained samples. He was also successful in culturing the organism in a meat-
extract gelatine medium. The genus of this bacteria would be named after him and the bacteria he 
isolated became Neisseria gonorrhoeae. The discovery was a landmark in the area of sexually 
transmitted infections (STIs) as so little was known at that time. 
One hundred years previous to Albert Neisser, it was thought that gonorrhoea and syphilis were 
the same disease. Both diseases were sexually transmitted, presenting within days of sexual 
intercourse. It was also common for the same individual to have both diseases which could be 
successfully treated at the same time. However, Benjamin Bell, the first Scottish scientific surgeon, 
published in 1793 a detailed work of clinical presentations of the two diseases, how they differed 
and how to best treat them [2]. He argued that they were separate diseases and pointed particularly 
to the fact that syphilis could be treated with mercury while gonorrhoea could not. He also argued 
that gonorrhoea remained a localised infection while syphilis spread to other parts of the body: 
 
“At present, it is only necessary to observe, that gonorrhoea consists of a discharge of puriform 
matter from the urethra; which, even by those who support the contrary opinion, is now admitted 
to be, in almost every instance, a local affection, and that it very rarely contaminates the general 
habit of the body.” 
 
After Neisser was successful in culturing what he thought was the causative agent, he could not 
reproduce the disease by infecting healthy individuals. It now seems likely that either what he 
initially cultured was not Neisseria gonorrhoeae but a commensal species of Neisseria or that isolate 
lost virulence upon culture [3]. The first person to successfully infect a patient and replicate clinical 
presentation was Max Bockhart [4]. He inoculated the urethra of a male patient with creeping 
paralysis with a pure culture of the bacteria [5]. After three days a small amount of discharge was 
observed. The patient was then given half a litre of beer and the discharge increased. The patient 
died ten days post inoculation due to the creeping paralysis. Upon autopsy, the patient had acute 
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urethral inflammation. Due to the crudeness of this experiment a more refined experiment was 
needed to fully prove Koch’s postulate. 
Particular note must go to Ernst Von Bumm who also made a significant contribution. He noted that 
there were many bacteria that were morphologically similar to the presumed causative agent that 
were isolated from healthy individuals [3]. He carefully isolated the organism and infected two 
female patients using a platinum wire [6]. However, later attempts failed. Koch’s postulate was 
finally clearly proven in 1891 by Ernst Wertheim; he noted the problem of the fastidious nature of 
the gonococcus and used serum-peptone agar to successfully culture the organism [7]. He infected 
five men with the bacteria and all five developed gonorrhoea.   
A few years prior to Neisser’s discovery, another major development was made in the area of 
gonorrhoea knowledge. A German gynaecologist, Emil Noeggerath proposed in 1876 that a “latent 
gonorrhoea” state existed in women [8]. He initially presented his findings to the American 
Gynecological Society in New York City and was met with sharp criticism from attendees [9]. His 
theory was heavy debated for a few years. However, his latent gonorrhoea theory was later more 
readily accepted, especially in Europe. Bell, in his earlier account of gonorrhoea had commented 
that he didn’t know why gonorrhoea commonly affected men more than women. It is now known 
that asymptomatic infections are common, especially in women. 
Ocular inflammation in gonorrhoea patients has been common in the past. This gonorrhoeal 
ophthalmia was thought by some to be due to dissemination of the infection from the genitalia to 
the eyes [10]. Others, such as Jean Astruc, a physician to King Louis XV, believed it was spread from 
direct contact [11]. He noted that a young man who had acute symptoms of gonorrhoea, had 
washed his eyes daily in his own fresh urine as he perceived that this would improve his sight [12]. 
Needless to say he developed gonorrhoeal ophthalmia and had a purulent discharge from his eyes. 
1.1.2 Ophthalmia neonatorum and its history 
Ophthalmia neonatorum is used to describe conjunctivitis during the first 28 days of life, also 
referred to as neonatal conjunctivitis [13]. More commonly it is used to describe conjunctivitis that 
is caused by transfer of infections agents from the mother to the eyes of the neonate during passage 
though the birth canal. It causes a painful inflammation of the eye with yellowish purulent discharge 
(See Figure 1.1). If left untreated or if standard treatment fails, it can cause corneal scarring and 
corneal perforation which can lead to permanent blindness. Before the 20th century, ophthalmia 
neonatorum was common and severe infections would lead to blindness [14]. In fact, it is thought 
that this was the cause of about a quarter of all blindness. However, this trend changed in the latter 
two decades of the 19th century [14]. 
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A German doctor named of Carl Credé, who was chair of obstetrics in Leipzig, came up with a 
method that would radically reduce the number of cases of ophthalmia neonatorum. In 1874 the 
incidence rate in his maternity wards was 13.6%. Many of these had to be treated with silver nitrate 
which had been commonly used since the 1830’s. However, this treatment did not always prevent 
blindness in cases of severe infections. What Credé proposed in his hospital was to wash and 
thoroughly clean the closed eyes of the new born and then treat with a single dose of 2 % silver 
nitrate shortly after birth before the onset of ophthalmia neonatorum. After enforcement of this 
post-natal practice, the incidence rate dropped to 0.15 %.  
Today, the two most common aetiological agents of ophthalmia neonatorum are N. gonorrhoeae 
and Chlamydia trachomatis. However, it is more likely that N. gonorrhoeae was the causative agent 
in Credé’s hospital due its sensitivity to silver nitrate. Gonococcal opthalmia neonatorum usually 
has a faster onset than C. trachomatis opthalmia neonatorum and is usually more aggressive [15].  
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Figure 1.1 Picture of a typical ophthalmia neonatorum case. The discharge from the eye dries to 
form a yellow crust around the eye. This example was taken from the digital medicine website: 
http://digitalmedicine.com.np/. 
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1.1.3 Ophthalmia neonatorum prophylaxis in the antibiotic age 
Although Credé prophylaxis dramatically reduced the incidence rates of ophthalmia neonatorum 
for many years, it was later criticised by some for causing chemical conjunctivitis [16]. It caused 
chemical conjunctivitis in 90 % of infants treated, 3-6 hours after administration [17], although the 
majority of these cases would clear up after 24 hours. In addition, there were questions about its 
effectiveness against C. trachomatis [18, 19]. Figure 1.2.A shows historical records of the number 
of cases of ophthalmia neonatorum in England and Wales from 1914 to 1981. These are all cases of 
ophthalmia neonatorum and not limited to gonococcal ophthalmia neonatorum. The number of 
cases of ophthalmia neonatorum showed a steady decrease from 1920 onwards. While the use of 
silver nitrate was justifiable in the times of a high prevalence of gonorrhoea and high incidence rate 
of ophthalmia neonatorum, the severity of the treatment was less justifiable in times of low 
prevalence. The use of silver nitrate for prophylactic treatment of ophthalmia neonatorum was 
discontinued in UK hospitals in the mid-1950s [20, 21]. Despite this, the incident rate of ophthalmia 
neonatorum continued to fall.  
Silver nitrite, despite being a relatively good prophylactic drug, had limited success as a treatment 
once ophthalmia neonatorum had developed. The potential for antibiotics for use in prevention 
and treatment of ophthalmia neonatorum was realised early. In August 1930,  a doctor working at 
Sheffield Royal Infirmary, Cecil Paine, used a crude extract from the fungus Penicillium notatum to 
treated a case of ophthalmia neonatorum in a three-week-old male baby [22]. Although certain 
details are missing, the eyes were described to be clean seven days after initial treatment was 
started.  After the first large-scale release of antibiotics in the mid-1940s, a solution of 
benzylpenicillin was trialled in 1947 as a possible replacement to silver nitrate [23]. Although the 
trial was originally successful, it required three daily dosages, was not effective against C. 
trachomatis and could possibly cause complications in penicillin sensitive individuals. 
Sulphonamides were later trialled at the beginning of the 1950’s but this was no more effective 
than silver nitrate. At about the same time, tetracycline’s were also used in trials [24]. 
After some time in development, it was found that a single dose of 1 % tetracycline ointment was 
effective to prevent development of ophthalmia neonatorum. The ointment performed better that 
silver nitrate with an estimated risk of 0.012 % of treatment failure compared with 0.063 % for silver 
nitrate [25]. Although tetracycline is effective against C. trachomatis in vitro, there were concerns 
that the ointment was less effective at preventing chlamydial ophthalmia neonatorum [18]. 
However, use of the 1 % tetracycline ointment was included in the Centers for Disease Control and 
Prevention (CDC) sexually transmitted diseases treatment guidelines of 1982 and last appeared in 
2006; recommendation of the treatment was absent from the 2010 guidelines [26-28].  
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In the 1960s, use of 0.5 % erythromycin appeared. This was identified as having a lower rate of 
treatment failure than that of silver nitrate [29]. It was also shown to be effective against chlamydial 
ophthalmia neonatorum [30]. Like the tetracycline ointment, it was included in the 1982 CDCs 
sexually transmitted diseases treatment guidelines and now is the only recommended treatment 
in the 2015 treatment guidelines [26, 31]. 
1.1.4 Neisseria gonorrhoeae 
N. gonorrhoeae is a Gram negative cocci bacteria which are kidney bean shaped and are usually 
arranged as diplococci (see Figure 1.3.A). They are catalase and oxidase positive [32]. They are 
classified as being non-motile as they do not have flagella but possess type IV pili which can cause 
a twitching motility. The pili are also important for initial attachment to host cells (see section 
1.1.10). N. gonorrhoeae is an obligate human pathogen as they are not found in any other animal 
or found surviving in the environment.  They are relatively fastidious, requiring excess sugars and 
iron to maintain growth. One of the most commonly used media for isolation is Thayer-Martin agar 
[33]. On this medium they form smooth, round, moist, uniform grey/brown colonies (see Figure 
1.3.B) [32]. This medium is made from pancreatic digest of casein, selected meat peptone and corn 
starch. It also contains heat-treated haemoglobin which gives the medium a brown appearance. 
Haemoglobin-free media are also available. Thayer-Martin agar is supplemented with vancomycin, 
colistin and nystatin (VPN); with the optional addition of trimethoprim, for primary isolation [34, 
35]. Unlike other bacteria, gonococci are often more difficult to culture in liquid medium than with 
solid agar medium. However, liquid media developed more recently has shown to support growth 
[36, 37]. N. gonorrhoeae is capnophilic requiring an increased amount of CO2 to grow [38]. Optimal 
conditions for growth are is 36 °C ±1 °C with 3% to 7% CO2 [39]. The addition of 0.1 % sodium 
bicarbonate to solid medium has been shown to be able replace the need for additional CO2 gas 
with some isolates [40, 41]. The cells contain autolysins which shorten the cells viability when 
stationary phase is reached [42, 43].  
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Figure 1.2 Reported cases of ophthalmia neonatorum in England and Wales. (A) Number of 
reported between 1914 and 1981. (B) Number of cases between 1982 and 2009. Ophthalmia 
neonatorum ceased to be a notifiable disease after 6th April 2010 [44, 45].  
Chapter 1 – Introduction 
9 
 
 
Figure 1.3 Images of Neisseria gonorrhoeae. (A) SYTO 9 stained gonococcal cells attached to a 
human corneal epithelial cell. Notice the kidney bean shape of the cells which prefer to cluster into 
pairs. The white bar represents 10 µm. (B) Colonies of N. gonorrhoeae growing on a GC agar plate 
after 48 hours incubation. The colonies appear slightly opaque and can be difficult to spot under 
certain conditions. The larger colonies in this picture are up to 3 mm in diameter. Both of these 
pictures were produced from work in Chapter 4. 
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1.1.5 Gonorrhoea and other N. gonorrhoeae infections 
Although N. gonorrhoeae can infect any human mucosal layer, it most commonly infects the adult 
urogenital tract [46]. In men, it can cause urethritis with symptoms which may include a white, 
yellow or green discharge from the penis, pain or a burning sensation when urinating (dysuria) and 
inflammation of the foreskin [47]. In rare cases it can also cause epididymitis, a pain or tenderness 
of the epididymis, a curved structure at the back of the testicles. If left untreated it can lead to a 
possible reduction in fertility. Symptoms usually develop 2-5 days post infection but can develop as 
long as 30 day after infection [48]. Asymptomatic infections occurs in about 10 % of men [48].  
In women, symptoms can include inflammation of the cervix (cervicitis) with a thin or watery, green 
or yellow vaginal discharge, intermenstrual bleeding, itchiness (pruritus), and dysuria [47]. If 
untreated, the infection can spread to the upper genital tract and cause pelvic inflammatory disease 
(PID). Symptoms of PID may include: abdominal pain; abnormal discharge; intermenstrual bleeding; 
postcoital bleeding; fever; lower back pain; and in some cases nausea [49]. PID is estimated to occur 
in 10-20 % cases of untreated gonorrhoea [50]. PID can lead to long-term pelvic pain, ectopic 
pregnancies and infertility. The infertility is a result of scarred and narrowed fallopian tubes. 
Asymptomatic infections are far more common in females than males. The exact percentage of 
infections which are asymptomatic vary depending upon the population which is sampled. Between 
2001 and 2006 in England and Wales more than 50% of women that attended selected 
genitourinary medicine (GUM) clinics had no symptoms of N. gonorrhoeae infection. This is likely 
to be underestimate as the populations would be biased by people visiting the clinics due to 
showing symptoms. In another study, 66.7 % to 100 % women from China, India, Peru, Russia, and 
Zimbabwe reported no symptoms when screened for N. gonorrhoeae infection [51]. However, as 
this study used certain social groups within the general population, it would be biased toward 
asymptotic infections as those with symptom would likely seek medical attention. Therefore the 
actually rate of asymptotic infections is probably somewhere between 50-100 %.  
Anorectal infection can occur in both males and females but are far more prevalent in males. 
Symptoms include anal pruritus, rectal pain, mucopurulent discharge, and feeling of constantly 
needing to pass stools (tenesmus). Infection are asymptomatic in 50 % of individuals [48]. 
Pharyngeal infections are asymptomatic in more than 90 % cases [52]. They can act as an important 
route of transmission [53].  
Adult ocular gonococcal infections are rare but in recent years are presenting more commonly in 
young adults, especially in males [54, 55]. Clinical signs can include hyperaemia, eye lid swelling and 
purulent discharge. Infection of the cornea can lead to keratitis, ulceration, descemetocoele 
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formation and ultimately perforation. Corneal perforation risks blindness but sight may be saved 
with corneal grafting (keratoplasty) [56, 57]. As these infections are relatively rare compared to 
other causes of eye infections they are often incorrectly treated [57].  
Disseminated gonococcal infection can include acute septic arthritis. This condition is rare in Europe 
but more common in the US [58]. Ankles, knees, wrists, and hands are the common sites which are 
affected [55]. 
1.1.6 Prevalence and incident rates of gonorrhoea 
Gonorrhoea is a global problem with 106.1 million cases reported to the World Health Organisation 
(WHO) in 2008 (see Figure 1.4) [59]. This makes it the most common bacterial sexually transmitted 
infection (STI) globally, just ahead of C. trachomatis. Approximately 40 % of all reported cases were 
from the Western Pacific WHO reporting region. This region comprises of 37 countries from 
developed countries such as Australia, Japan, New Zealand, the Republic of Korea, China and 
Singapore to developing nations such as Viet Nam, Malaysia, and the Philippines [60]. Despite the 
high number of cases of this reporting region, it doesn’t have the highest incidence rate. The African 
WHO reporting region has the highest incident rate with over 100 cases per 1,000 population. In 
simple terms, this means that one in ten people will have a gonococcal infection in a year. The 
African WHO reporting region is made up of 47 countries. Roughly, it consists of all countries on the 
African continent excluding Morocco, Tunisia, Libya, Egypt, Sudan, and Somalia [61]. In all reporting 
regions apart from the European region, there are more male cases than female. The reason why 
this trend is not seen in the European region is unknown but may be due to some of these countries 
more actively testing female populations. 
In England, gonorrhoea is the second most common bacterial STI, with the most common being C. 
trachomatis infections [62]. In 2014, there were 34,958 reported cases to Public Heath England. 
That is an increase of 98 % from 2005 and is the sixth year in a row that there has been an increase 
in the number cases (see Figure 1.5). The most common age groups for reported gonorrhoea cases 
is 25-34 year old for males and 20-24 year old females (see Figure 1.6.A). 
In England in 2014, 53.23 % of all cases were found in males who are described as “men who have 
sex with men” (MSM), see Figure 1.6.B. This group contains males who have sex with other males, 
regardless of whether or not they have sex with women or do not identify with being homosexual 
or bisexual [63]. Unfortunately, there are no estimates for the size of this population so the 
incidence rate can’t be calculated. However, as MSM are classed as a social minority [63], the 
prevalence is therefore going to be greater in this population than in either of the heterosexual 
populations. The level of prevalence in this population highlights the problem if antimicrobial 
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resistance appears in this group. Interestingly the number of cases in heterosexual males and 
females are about equal in the England and Wales.  
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Figure 1.4 Global gonorrhoea cases reported to the World Health Organisation in 2008 categorised 
into reporting regions [59]. (A) Number of cases reported for each region. (B) Incidence rate, 
number of cases per 1000 people in the population. The Western Pacific region reported the highest 
number of cases with over 40,000,000 cases in 2008. However, the African Region has the greatest 
number of cases for its population size. Unusually, the European region has a greater number of 
female cases than male cases 
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Figure 1.5 Reported cases of gonorrhoea in England between 2005 and 2014 [64]. (A) Number of 
cases reported. (B) Incidence rate, number of cases per 1000 people in the population. 
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Figure 1.6 Breakdown of reported cases in England in 2014 [65]. (A) Breakdown of number of cases 
for different age groups for males and females. Note that the greatest number of cases for males is 
25-34 and 20-24 for females. (B) Breakdown of cases into sexual orientation. By far, the most cases 
occurred in men who have sex with men  
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1.1.7 Antimicrobial resistance 
N. gonorrhoeae infections are at a great risk of becoming untreatable [66]. Figure 1.7 shows a 
timeline of the recommended antimicrobials used for treatment and the development of resistance 
mechanisms. Resistance to antimicrobials started with sulphonamides which were one of the first 
antimicrobial used for treatment of gonorrhoea [67]. Sulfanilamide and sulfapyride were commonly 
used from the early 1940s. By the end of the decade, over 90 % of isolates were resistant [68]. 
Penicillin took over from sulphonamides as the best treatment for gonococcal infections. However, 
low-level resistance due to chromosomal mutations was soon seen leading to a continuous increase 
in dose. In hindsight, the initial low dosage and incremental increases helped the bacteria develop 
resistance. Outbreaks would occur in the 1960s of increased resistant isolates and in 1976 plasmid 
mediated resistance by production a β-lactamase was seen [69]. The main plasmid, blaTEM-1 encoded 
a TEM-1-type β-lactamase that would hydrolyse the β-lactam ring of penicillins and cephalosporins. 
These isolates would be termed penicillin producing gonococci (PPNG). Use of penicillin continued 
and in 1980 highly resistant non-PPNG were reported [70]. 
However good β-lactam are at any period in time to treat N. gonorrhoeae infections, an alternative 
is always required for patients with a sensitivity to them. For a long time, since the late 1940s, 
tetracyclines provided this alternative. However, chromosomal resistance started to develop and 
by the mid-1980s tetM determinants which resulted in high-level resistance were reported [71]. 
After this, their use was not recommended. 
Spectinomycin was another alternative to penicillin which was initially sold as a specific treatment 
for gonorrhoea in the 1960s. Chromosomal mutation in the 16S rRNA gene resulted in decreased 
susceptibility [72]. Also, mutations in rpsE gene encoding the ribosomal protein S5 also confers a 
decreased susceptibility [73]. Spectinomycin also has a low efficacy in the treatment of pharyngeal 
gonorrhoea [74]. Use of spectinomycin as a first-line treatment was abandoned in the 1980s. With 
the failure of tetracycline and spectinomycin, the new generation of broad spectrum 
fluroquinolones quickly filled a gap in the mid to late 80s. Initially they were very effective when 
they were first introduced. However, increasing resistance in N. gonorrhoeae to ciprofloxacin was 
first reported in 1990 in North America [75, 76]. The decreased susceptibility was due to mutations 
in the gyrA and parC genes [77, 78]. Ten years later the CDC no longer recommended 
fluoroquinolones for treatment in persons who acquired their infections in Asia or the Pacific 
Islands due to high prevalence of resistance in these regions [79-81]. In 2002, the CDC no longer 
recommended fluoroquinolones for MSM and by 2006, they no long recommended 
fluoroquinolones for treatment of gonococcal infections [79]. The peak prevalence of 
fluoroquinolones resistant gonococci in 2002 was 52.2 %, by 2006 it had decreased 9.1 % [82]. 
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Unfortunately, this prevalence is still too high to reintroduce its use in first-line treatments, 
especially considering the ease at which resistance is acquired. 
Macrcolides have had a little more success than some of the other antimicrobials talked about so 
far. The macrolides erythromycin and azithromycin are still being used today for the treatment of 
N. gonorrhoeae infections. Erythromycin, as stated previously is now the only recommended 
prophylactic treatment for ophthalmia neonatorum. It has been reported that azithromycin is a 
better antimicrobial agent than erythromycin for gonorrhoeae as it is able to treat pharyngeal 
gonorrhoea, which are normally asymptomatic [83]. Hence, azithromycin is the preferred macrolide 
for treatment. Resistance to azithromycin has been reported in North America and Europe [84]. 
However, the use of azithromycin is still used in combination therapy [85]. Its continued use has 
resulted in high prevalence of resistant isolates in areas of China [86] and there have been resent 
outbreaks such those in Leeds, England of high-level resistant isolates [87, 88]. This outbreak in 
Leeds that occurred in September 2015 consisted of 18 heterosexuals cases. However, the high-
level azithromycin resistance has since been seen in the Midlands and in London. It is now thought 
that it is in MSM population [89]. 
Today, the class of antimicrobial most widely used to treat gonococcal infects are cephalosporins. 
The third generation cephalosporins are effective against PPNG as they are not prone to hydrolysis 
from the β-lactamase. This class of cephalosporins are often referred to as expanded-spectrum 
cephalosporins (ESC). This series of ESC carries a negligible risk of cross allergy in patients with 
penicillin allergies [90]. The most commonly ESCs used to treat gonococcal infections are 
ceftriaxone which is taken by injection and cefixime which is taken orally. Cefuroxime, which is an 
oral (or injectable) second generation cephalosporins, is also sometimes used in Europe but is a 
poor substitute [91]. Ceftriaxone is now the preferred ESC as lower rates of resistance have been 
seen. Since 2012, the European guidelines have recommended dual treatment of ceftriaxone 500 
mg (intramuscular injection) and azithromycin 2 g (oral) for treatment of uncomplicated Neisseria 
gonorrhoeae infections of the urethra, cervix, rectum and pharynx, when the antimicrobial 
sensitivity is unknown [92].  
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Figure 1.7 History of discovered and recommended antimicrobials and evolution of resistance in 
Neisseria gonorrhoeae [69]. Abbreviations used in figure SUL, sulfonamides; PEN, penicillin; SPT, 
spectinomycin; TET, tetracycline; CIP, ciprofloxacin; OFX, ofloxacin; CFM, cefixime; CRO, 
ceftriaxone; AZM, azithromycin; DOX, doxycycline.  
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1.1.8 Control measures of ophthalmia neonatorum 
Prevention of ophthalmia neonatorum can be controlled in three ways: selective treatment of 
expectant mothers via prenatal screening; blanket prenatal antimicrobial treatment of all expectant 
mothers; or postnatal application of prophylaxis to all neonates within the first few hours after 
birth. 
Postnatal prophylaxis can be in the form of an eye drop or eye ointment. Current recommended 
prophylaxis is 0.5 % erythromycin ophthalmic ointment. This is usually given in the first hour after 
birth. In the United Kingdom there has been no prophylaxis since the 1950s and currently prenatal 
screening via assessment of risk factors is used [20]. Risk factors include having had known contact 
with someone with gonorrhoea, having unprotected sex with a new partner(s), recent multiple 
sexual partners, living in an urban area, or having had a sexual partner from an urban area with a 
known high prevalence [93]. If the mother is deemed as being at risk then testing for STIs is 
recommended. However, the expectant mother still has the risk of becoming reinfected after 
treatment. It is therefore recommended that the mother be re-screened after 28 weeks or at the 
time of delivery [94]. 
The use of prophylactic treatment divides medical opinion. The United States Preventive Services 
Task Force (USPSTF) has graded the use of an ocular prophylaxis for prevention of ophthalmia 
neonatorum as “Grade A” which means that there is high certainty that the net benefit is substantial 
[95, 96]. They recommend that all newborns be given a prophylaxis within 24 hour after birth. 
However, meta-analysis of published data finds that the failure rate of prophylaxis treatment was 
too great to use in developed countries as the prevalence of disease was too low [15]. Prophylactic 
treatment is given in Canada where it is mandatory in some provinces and optional in others. The 
fact that it is mandatory in some provinces, such as Ontario, has been criticised by some health 
workers as parents that refuse prophylactic treatment are reported to the local children’s aid 
society [97]. Other concerns for the prophylactic treatment is that it could interrupt mother-infant 
bonding by blurring the vision of neonate [94]. During a shortage of erythromycin ointment in the 
United States in 2009, gentamicin ointment was used as prophylactic treatment but resulted in 
reports of severe ocular reactions [98, 99]. All these factors helps to undermine the use of 
prophylactic treatment in developed nations.  
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Table 1.1 Main virulence factors of Neisseria gonorrhoeae [55]. 
Virulence Factor Host Cell Interactions Interaction Results  
Pili 
  
Pilus PilC protein subunit 
binds 
to CD46* receptors that 
are present on most 
human cells [100] 
Calcium [101] release 
and cytoskeletal 
rearrangements that 
lead to elongation of 
microvilli which 
embrace the microbe, 
facilitating cell entry. 
Provides twitching 
motility function. 
Involved in DNA 
transformation. 
Undergoes phase 
variation. 
May play a role in 
resistance to granulocyte 
phagocytosis [102] 
Opacity-associated proteins 
(Opa; each strain can make at 
least 11 different types, but 
express no more than five at a 
time) 
Most interact with the 
CD66 
(CEACAM) family of 
receptors on epithelial 
cells and neutrophils. 
Mediates non-opsonic 
phagocytosis by 
neutrophils 
that is distinct from 
antibody- and 
complement-mediated 
phagocytosis [102, 
103] 
Undergo antigenic and 
phase variations. 
Sequesters pyruvate 
kinase while within host 
cells to acquire pyruvate 
for bacterial metabolic 
needs [103] 
Porin protein (most common 
outer membrane protein; exists 
as a trimer in the membrane) 
Translocates into the 
host cell membrane. 
Able to bind with 
C4b-binding protein. 
[104] 
Translocation permits a 
rapid Ca2+ influx into 
the host cell from the 
external environment 
[105]. 
Disrupts neutrophil 
degranulation, 
oxidative burst, and 
phagosome maturation 
[106, 107]. 
Down-regulation of 
complement 
activation. 
Can induce apoptosis in 
epithelial cells and 
neutrophils in vitro. [105] 
Located in the cell 
membrane in close 
proximity to lipo-
oligosaccharides and 
reduction modifiable 
proteins. Allows small 
molecules to pass 
through the bacterial 
outer cell membrane. 
Iron-scavenging system of 
proteins [108, 109] 
Scavenges iron from 
transferrin, 
lactoferrin, and 
hemoglobin 
Allows microbe to 
maintain metabolic 
processes in the face of 
the low free iron 
environment created 
by early innate 
immune responses. 
Gonococci do not 
produce any 
siderophores. 
Transferrin- and 
lactoferrin-binding 
proteins are required in 
order for gonococci to 
cause experimental 
urethritis [110]. 
IgA protease Cleaves IgA, at the hinge 
region. Cleaves host cell 
lysosome-associated 
membrane protein, 
which is involved in 
phagosome 
compartmentalization 
[111] 
May help to evade host 
IgA at the mucosal 
surface. 
Most important 
function may be to 
enhance intracellular 
survival within host cell 
phagosomes. 
 
Lipo-oligosaccharide (LOS; up to 
six variants expressed by a single 
strain) [112] 
LOS moieties mimic 
human 
glycosphingolipids; can 
bind 
to asialoglycoprotein 
receptor 
(ASGP-R). 
Induces cytokine 
production 
(TNF-α IL-1β, IL-6, IL-8) 
from urethral epithelial 
cells [113]. 
Can activate the classic 
complement pathway. 
Can mediate host 
defensin-enhanced 
adherence to 
epithelial cells [114] 
ASGP-R interaction 
mediates endocytosis 
(internalization of the 
microbe into epithelial 
cells). 
Consists of a lipid A 
moiety and a core 
polysaccharide; lacks the 
long polymeric sugars 
lipopolysaccharides. 
Predominately short LOS 
appear more sensitive to 
killing by human serum 
but also more able to 
invade eukaryotic cells. 
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Cell wall peptidoglycan (shed as 
membrane fragments during 
exponential growth 
 Activation of 
complement occurs. 
Modulation of 
mononuclear cell 
proliferation 
Cause damage to 
fallopian tube mucosal 
cells in organ culture 
[115]. 
Reduction modifiable protein 
(Rmp) 
Generates host 
antibodies against itself. 
Antibodies that bind to 
Rmp epitopes block the 
bactericidal effect of 
complement-fixing IgM 
antibodies that 
recognize LOS. 
Women with preexisting 
anti-Rmp antibodies 
appear more susceptible 
to infection than those 
without such antibodies 
[116]. 
 
Ribosomal protein L12 Binds to lutropin 
receptors in the upper 
female genital tract. 
Facilitates ascending 
infection in females. 
Ribosomal protein L12 
mimics the structure of 
human chorionic 
gonadotropin, which is 
the natural ligand for 
lutropin receptor [117, 
118]. 
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1.1.9 Virulence factors 
N. gonorrhoea has been studied for many years and some of its virulence factors have been 
identified and are listed in Table 1.1. As it is an obligate human pathogen it has developed complex 
systems for survival inside the human body. These range from complex avoidance of the immune 
system via antigen variation [103] to acquiring iron [108, 109].  
1.1.10 Attachment and internalisation 
N. gonorrhoeae is an intracellular pathogen. It possess a Type IV pili (Tfp) which is a retractable 
appendage known to mediate surface attachment [119]. The retractive force of the N. gonorrhoeae 
Tfp is estimated to be 50–100 piconewtons [120]. However, the pili usually form bundles of 8-10 
pili which are capable of retracting up to 1000 piconewtons sustainably [121]. The force generated 
by Tfp is one of the strongest microscale elements known to date, and is high enough to induce 
cytoskeletal rearrangements in the host cell [120, 121]. Tfp are made from filamentous polymers 
of the PilE protein with a diameter of 60-80 Å and several micrometers in length. The PilE expression 
locus (pilE), undergoes phase and antigenic variation by a range of different methods [122]. One of 
the most productive methods of antigenic variation of PilE is RecA-dependant recombination that 
replaces the pilE sequence with the sequence other silent pil loci (pilS) [123]. The amount of 
antigenic variation, which occurs at a rate of 4x10-3 events per cell per generation, can also result 
in a pilE variant defective in fibre formation leading to a non-piliated phenotype [124]. The Tfp also 
helps with microcolony formation [119]. This can occur on the surface of the host cell and the Tfp 
triggers what’s termed a cortical plaque. This is defined as rearrangements in the cortical 
cytoskeleton and the plasma membrane and helps cluster transmembrane signalling proteins, actin 
microfilaments and ezrin, which act as receptors for other attachment proteins on the gonococcus 
[125].  
Once N. gonorrhoeae has attached to the host cells it can then initiate more intimate binding with 
surface attachment proteins, as seen in Figure 1.8.A. One such class of proteins well described in 
the literature is the opacity-associated (Opa) proteins. E. coli expressing an Opa protein has been 
shown to attach and invade cultured human epithelial cells while the non-Opa expressing control 
was not [126]. N. gonorrhoeae possess approximately 11 Opa genes [127]. A bacterial population 
can contain cells expressing none, one or multiple Opa proteins, with varying levels of expression 
[128]. This series of proteins have different attachment targets on the host cell and the Opa can be 
classified by their targets such as OpaHS which bind to heperansulphate proteoglycan (HSPG), and 
OpaCEA, the most abundant group, which binds to the carcinoembryonic antigen-related cell 
adhesion molecule (CEACAM) protein family [129]. From this family, only CEACAM1, CEACAM3, CEA 
(or CEACAM5) and CEACAM6 have been shown to bind to neisserial Opa proteins [130]. OpaCEA-
CEACAM interactions can also have an added benefit of bypassing the exfoliation response of 
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epithelial cells which can be induced by infection [131]. Different host cells types express different 
CEACAM proteins, for example, CEACAM1, CEACAM5, CEACAM6 can be expressed by epithelial cells 
but CEACAM3 is normally found expressed in neutrophils [128]. The Opa proteins all have a similar 
structure, which contains eight antiparallel β strands which form a barrel, this structure sits in the 
outer membrane, and four extracellular loops extend out from the cell surface (see Figure 1.8.B) 
[132]. The loops contain variable regions which have specificities for certain host receptors [128].  
These variable regions are created by several mechanisms. The main mechanism is recombination 
between the different opa loci. As well as the recombination occurring within the bacteria, it can 
also occur between organisms [133]. 
It is clear that both the Tfp and Opa proteins are virulence factors as they are required for infection. 
Both are highly variable and that is one of the reasons why immunity is not possible with gonococcal 
infections [134]. Persons infected with gonorrhoea are not protected from reinfection, even when 
the reinfection introduces the same strain of bacteria back into the host. 
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Figure 1.8 How gonococci enter cells. (A) Simplistic image showing the stages used by N. 
gonorrhoeae to enter cells [103]. Type IV pili extending out from the surface of the bacteria allow 
them to anchor onto the host cells. Retraction of pili allows close interaction between the bacterial 
and host cell to occur with tight adherence being mediated by Opa proteins. These interactions 
cause a cytoskeletal change that internalises the gonococcus into the host cell. (B) Graphical 
representation of the typical Opa 3D structure [132]. The beta-barrel, in red, sits within the outer 
membrane of the bacteria, whilst the loops extend from the surface and are able to interact with 
host cells. 
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1.1.11 Efflux pumps 
N. gonorrhoeae processes four drug efflux pumps MtrC-MtrD-MtrE, FarA-Far-B-MtrE, MacA-MacB, 
and NorM [135]. Eflux systems are an important defence against antimicrobials as well as other 
toxins. The MtrC-MtrD-MtrE forms a tripartite multidrug efflux pump system that has been well 
studied. This efflux pump mediates the export of various structurally diverse hydrophobic 
antimicrobial agents and confers decreased susceptibility to penicillin, macrolides and tetracycline 
[136, 137]. It is similar to other resistance-nodulation-cell division (RND) -type pumps of Gram-
negative bacteria such as the MexA-MexB-OprM efflux pump of Pseudomonas aeruginosa [138]. Its 
name is derived from “multiple transferable resistance”. The pump is made from an inner 
membrane transporter (MtrD) [139], a membrane fusion protein (MtrC), and an outer membrane 
channel protein (MtrE) [140]. Transcription of mtrCDE is positively regulated by MtrA and negatively 
regulated by MtrR [141, 142]. Mutants deficient in MtrA have a decreased fitness and mutants 
deficient in MtrR have an increased fitness in mouse infection models [143]. However, the 
transcription regulator MtrR has many other roles in gene regulation within the gonococcus. MtrR 
also regulates other efflux systems and resistance mechanisms, see Figure 1.9. As well as this, it 
also regulates other “off-target” genes [144-147]. 
The fatty acid resistance (far) efflux pump (FarA-Far-B-MtrE ) is a member of the major facilitator 
(MF) family of efflux pumps and recognises long-chain fatty acids [148]. It confers a 32-fold 
decreased susceptibility to linoleic acid and oleic acid and an eight-fold decrease in palmitic acid 
susceptibility [148]. The efflux system shares the outer membrane channel protein, MtrE, with the 
Mtr efflux system. The FarR protein negatively regulates farAB transcription and is member of the 
MarR transcription regulator family [149, 150]. However, MtrR negatively regulates farR 
transcription, so MtrR therefore can indirectly activate farAB transcription [148, 151]. This 
association is shown in Figure 1.9.  
The MacA-MacB efflux system can confer decreased susceptibility to macrolides [152]. Substrates 
for the other efflux pump system, NorM, are various toxic compounds including several 
antimicrobial agents, (such as the fluoroquinolones, norfloxacin and ciprofloxacin), ethidium 
bromide, rhodamine 6G, acriflavine, crystal violet, berberine, doxorubicin, novobiocin, enoxacin, 
and tetraphenylphosphonium chloride [153]. 
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Figure 1.9 Proposed model of the regulatory system in N. gonorrhoeae [135]. The lines with bars 
indicate transcriptional repression and the lines with arrows indicate transcriptional activation. 
Factors that control mtrCDE expression directly or indirectly in gonococci are MtrR, MpeR, MisR-
MisS and MtrA. MpeR being a transcriptional repressor mtrF in the absence of iron and MisR-MisS 
being a two-component regulatory system. 
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1.2 Fatty acids and other novel solutions to antimicrobial 
resistance 
1.2.1 Antimicrobial agents discovery 
Antimicrobials are in no doubt lifesaving drugs and have revolutionised our healthcare system. They 
have not only made a massive difference to the way we treat infections but have made invasive 
operating procedures possible. They are commonly used to prevent infections as well as to treat 
current infection. When introduced in the 1940s, antibiotics made a massive change to public 
health. Infections, including N. gonorrhoeae infections, were thought to be diseases that would be 
condemned to history. Unfortunately, the bacteria fought back and developed methods of evading 
the action of certain antimicrobials. Starting in the 1940s many different classes of antimicrobial 
have been discovered with the so called “golden age” of antimicrobial discovery which went on to 
the late 1960s [154]. However, no new antimicrobial classes were discovered or have been 
developed in the following three decades [155]. Drugs currently in development are mostly 
derivatives of older classes’ already in use and therefore are prone to existing resistance 
mechanisms. 
The incentives for pharmaceutical companies in the present day to try to get new antimicrobial 
agents to market are too small. From a business perspective, it does not make financial sense to 
develop and market a drug that could potentially be obsolete in a matter of years due to resistance. 
In 2010, it was estimated that only 1.6 % of drugs in development by major pharmaceutical 
companies are antimicrobials [156]. The risk of resistance emerging and the cost to develop new 
antibiotics means that antimicrobial development is not appealing to pharmaceutical companies. 
Worse still, if they do develop an effective antimicrobial they could risk forced restrictions on its 
use in front-line medicine to prevent resistance emerging.  The initial cost to the company for basic 
drug development (drug discovery and preclinical development) typically costs $350m and takes a 
minimum of 3.5 years [157].  
Many antimicrobial agents are discovered by screening large libraries for growth-inhibitory effects 
[158]. It was hoped that the impact of the genomics era would aid antimicrobial discovery. 
Researchers believed that next generation sequencing (NGS) technologies combined with 
comparative genomics would reveal novel drug targets. However, despite large investments by 
pharmaceutical companies such GlaxoSmithKline who undertook a 7 year programme from 1995 
to 2001, no candidates have successfully progressed to clinical trials [159].  
Targets for antimicrobials would ideally not be present in the host and, like most of the successful 
antimicrobial classes to date, wouldn’t rely on a single target or a target that is encoded by only a 
single gene. It is imperative that single nucleotide polymorphisms do not lead to decreased 
susceptibility to the antimicrobial as this form of resistance is more easily acquired. If conventional 
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scientific development strategies are failing to produce new antimicrobial agents then maybe a 
more novel approach is required or perhaps revisiting some previously discovered agents or looking 
back at traditional remedies is required.  
1.2.2 Fatty acids 
Fatty acids are amphiphilic molecules. They are made up of a saturated or unsaturated carbon chain 
which is attached to a carboxylic acid. The carboxylic acid is hydrophilic while the carbon chain is 
hydrophobic. This gives the molecule its amphiphilic nature and means that it is a surfactant, able 
to act at the interface between polar and non-polar liquids and lower surface tension. The aqueous 
solubility of the molecule is determined by the length of the non-polar hydrophobic carbon chain. 
The longer the chain the less water soluble the fatty acid. The number of carbons in the chain are 
usually in multiples of two for naturally occurring fatty acids. However, fatty acids with an odd 
number of carbons in their fatty acids can be manufactured artificially. There are some contrasting 
opinions on the classification of the sizes of the chain. Generally, carbon chain length of ten or less 
are referred to as short-chain fatty acids, 12-16 are medium chain fatty acids and 18 or greater are 
known as long-chain fatty acids [160]. However, these length classifications may vary depending on 
the author’s preference. 
The carbon chain can also vary in complexity. Here and throughout this thesis we will only discuss 
unbranched fatty acids. Despite removing branched fatty acids, the level of complexity is still quite 
large. After carbon chain length, the next distinction of fatty acids is the number of saturated carbon 
bonds in the carbon chain. Fatty acids with no double bonded carbons in their carbon chains are 
known as saturated fatty acids. These are the simplest fatty acids. Fatty acids that do have double 
carbons in their carbon chain are known as unsaturated fatty acids. If only one double bond is 
present, then the term monounsaturated is sometimes used and fatty acids with more than one 
double bond can be termed polyunsaturated. The double bond(s) on the carbon chain can occur on 
any of the carbons but are commonly at certain positions. Chemists usually number the carbons 
starting from the main functional group of a molecule, see Figure 1.10.A. In the case of fatty acids 
this would be the carbon in the carboxyl group and then moving along the carbon chain until the 
final methyl end. However, another nomenclature system is favoured by some scientists where the 
carboxylic carbon end of the molecule is known as the alpha end and the methyl group end known 
as the omega end. This system is often favoured by some because the position of double bonds in 
relation to the omega end is more biologically relevant. For example, fatty acids with a double bond 
between the third and fourth carbons from omega end are known as omega three fatty acids. 
The double bond also creates another level of complexity as the bond could be in either cis or trans 
form, see Figure 1.10.B. The difference in physical properties between the two isomers is large. The 
trans form would make the molecule flatter, more like the straight carbon chain of an unsaturated 
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carbon chain. The cis form on the other hand would make a more “bent” molecule, see Figure 
1.10.B for an example. Polyunsaturated molecules with cis form double bonds therefore do not 
have straight carbon chains. This hinders the packing of molecules and can affect the melting 
temperature. An example of this is shown in Table 1.2. The cis form of double bond is more common 
in nature. Although the trans form can occur in nature, it is more commonly associated with man-
made processing for creating unsaturated fatty acid via hydrogenation.  
1.2.3 Lipid nomenclature systems 
Lipids normally have common names as well as systematic names (IUPAC standard). For example, 
the saturated 12 carbon chain fatty acid has the systematic name of dodecanoic acid but is 
commonly referred to as lauric acid. Man-made fatty acids with an odd number of carbons in their 
carbon chain do not have common names so are always referred to by their systematic name. The 
common naming system however, becomes more complex as the number, position, and types of 
double bonds change. For this reason, lipid numbers are often employed to simplify the naming 
process. This system consists of one number identifying the number of carbons in its chain followed 
a second number showing number of double bonds (separated by a colon). Therefore, lauric acid 
would have the lipid number, 12:0. Further to this, the position and type of double bond can also 
written after these numbers. Looking back at Table 1.2, oleic acid had the lipid number 18:1 cΔ9 as 
it has a cis form double bond on the ninth carbon and elaidic acid has the lipid number 18:1 tΔ9 as 
it had a trans form bond at the same position. This system is the most common so will be used from 
this point forward.  
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Figure 1.10 Structure of fatty acids. (A) Chemical structure of typical fatty acids, in this case lauric 
acid, a saturated medium chain fatty acid. The carbons are labelled with their carbon numbers and 
omega (ω) and alpha (α) ends are also labelled. (B) The differing structures of three 18 carbon chain 
length fatty acids. The first is steric acid which has a saturated carbon chain. The other two are 
cis/trans isomers with a double bond on the ninth carbon. Elaidic acid is a trans isomer with the 
carbon chains pointing out from opposite sides of the double bond creating a small kink in the 
molecule. Oleic acid is the cis isomer and has the carbon chains extending out on the same side of 
the molecule creating a large bend on the molecule.  Images in panel B were created using JSmol:  
an open-source Java viewer for chemical structures in 3D http://www.jmol.org/. 
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Table 1.2 Example how the number and form of a double bond in the carbon chain of a fatty acids 
affects the melting temperature [161]. 
Name Carbon chain Lipid 
number 
Melting 
temperature 
Stearic 
acid 
Unsaturated fatty acid 18:0 67-72 °C 
Oleic 
acid 
Monounsaturated, trans form double bond on 9th 
carbon 
18:1 tΔ9 42-44 °C 
Elaidic 
acid 
Monounsaturated, cis form double bond on 9th 
carbon 
18:1 cΔ9 13-14 °C 
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1.2.4 Antimicrobial effects of fatty acids 
The antimicrobial properties of fatty acids have been demonstrated scientifically for over 100 years 
[162]. Before this time, metal salts of fatty acids (soaps), had been known to have antibacterial 
properties. While scientists investigated the action of these soaps, the study of the antimicrobial 
properties of the fatty acids themselves was somewhat neglected in comparison. This continued 
with the discovery of antibiotics and then the “golden age” of antimicrobial discovery which went 
onto the late 1960s. Then, in 1972, Kabara and co-workers published the most comprehensive study 
of its time on the action of fatty acids on bacteria [163]. This study tested a range of Gram positive 
and Gram negative bacteria against saturated and unsaturated fatty acids as well as 
monoglycerides, other esters and amines. The trend of the antimicrobial effects of the different 
types of fatty acids mirrored that discovered for the soaps. The trend discovered was that lauric 
acid had the most potent antimicrobial properties of the saturated fatty acids and that linoleic (18:2  
cΔ9,12) and linolenic (18:3 cΔ9,12,15) were the most potent of the unsaturated fatty acids. 
However, the exact trend varied between studies and the action of the fatty acids could be different 
between bacterial species. The monoglycerides were also highlighted as enhancing antimicrobial 
properties. After this, publications of more defined studies were conducted focusing on a particular 
species or groups of organisms such as  Mycobacterium [164], enveloped viruses [165], C. 
trachomatis [166] , N. gonorrhoeae [167, 168], Candida albicans [169], Helicobacter pylori [170-
172], and Listeria monocytogenes [173] to name some examples. 
1.2.5 Mechanism of action of fatty acids and monoglycerides 
The mechanism of action of the antimicrobial properties of fatty acids and similar molecules is still 
unclear. However, a number possible targets have been identified [174], see Figure 1.11. Work 
done by Knapp and co-worker demonstrated that many morphological changes occurred upon the 
exposure of N. gonorrhoeae and Haemophilus influenzae to 10 mM arachidonic acid (20:4 
cΔ5,8,11,14) for one hour [175]. It was noted that there was separation of inner and outer 
membranes, loss of cell shape, and complete cell disorganisation and disruption. It is thought that 
this was due to the amphiphilic nature of fatty acids, that at high concentrations they act as a 
detergent and aid the solubilisation of the lipid in the membranes causing cell lysis. Work by Yoon 
and co-workers used quartz crystal microbalance-dissipation and fluorescence microscopy to 
examine the action of lauric acid on the destabilisation of the bacterial bilayers [176]. Their action 
on the outer cell membrane is thought to be the main target of the action of fatty acids. This would 
easily explain why fatty acids only inactivate enveloped viruses and not non-enveloped viruses 
[165]. 
The antibacterial action of fatty acids is seen to be bacteriostatic at lower concentrations and 
bactericidal at higher concentrations. Therefore, either the fatty acids have to interact with the cell 
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membrane or another intracellular targets to prevent cell division by inferring with essential cell 
processes. There are a number of theories to what these processes are that prevents cell division. 
Inhibition could potentially be due to fatty acids interacting with the cell membrane making it 
become more permeable and allow the escape of some of the cells’ contents without causing cell 
death. Miller and co-workers predicted that inhibition of the electron transport system was partly 
responsible for the growth inhibition observed by N. gonorrhoeae when exposed to various fatty 
acids [168]. Membrane-bound protein complexes involved in the electron transport chain could be 
inhibited by the presence of the fatty acids outside of the cell so cell entry may not be required. 
Likewise, fatty acids could interfere with other membrane-bound cellular processes such as 
nutrient uptake or enzyme inhibition [174]. Another possible mechanism of action, that would 
require entry to the cell, is the inhibition of fatty acid biosynthesis in the bacteria [177, 178]. 
Inhibition of fatty acid biosynthesis has long been a desired target of drug makers as it offers a 
target not used by existing antimicrobials so there is little chance of cross resistance [179]. 
1.2.6 Inhibition of antimicrobial properties 
Fatty acids and monoglycerides do not have bactericidal action against all bacterial species [180, 
181]. Generally speaking, more Gram positive species are prone to their action than are Gram 
negatives. As described above, the main target of the fatty acids is the cell membrane. Therefore, 
anything that prevents access to this target will inhibit their action. For Gram positives, it has been 
demonstrated that Streptococcus pneumoniae is more susceptible than Staphylococcus aureus, 
which is more susceptible than Bacillus subilis [163, 182]. This could be due to the differences within 
the peptidoglycan layer between these three bacterial species which may inhibit the action of the 
fatty acids. For example, the amount of teichoic acid present in this layer differs between these 
species [183]. 
Gram negatives are more likely to be resistant to effects of fatty acids with only species of Neisseria, 
Haemophilus, Moraxella, Helicobacter, and Campylobacter being shown to be susceptible [175, 
184]. This may be due to differences in the outer membrane of these bacteria. The protein content 
and lipopolysaccharide (LPS) structure can vary greatly between Gram negative species as well as 
the possible production of a capsule in some species. These may interact with the fatty acids 
preventing them from reaching their targets. 
However, some Gram negative bacterial species are susceptible. For example, we know that 
Neisseria and Haemophilus species are susceptible to a range of fatty acids and monoglycerides. 
These bacteria have notable differences to other Gram negative bacteria, for example members of 
the Enterobacteriaceae, which are intrinsically resistant to fatty acids. One difference in these two 
genera is that their LPS structures are different. They lack the repeating polysaccharide O-antigen 
found in other Gram negatives and instead have a highly variable and branched core 
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oligosaccharide region [185, 186]. They are so different that some researchers differentiate them 
by refereeing to them as lipo-oligosaccharides (LOS). As the O-antigen of other Gram negatives are 
made of a chain of hydrophilic sugars, the longer the chain the less lipophilic the outer membrane. 
In fact, bacteria expressing a shorter form of O-antigen are more permeable to hydrophobic 
antimicrobials [187]. 
Within the genus Neisseria, there are two pathogenic species: N. gonorrhoeae and N. meningitidis. 
These bacteria are very similar genetically but have different strategies for fatty acid resistance. 
Both have the FarA-Far-B-MtrE efflux system [188]. This is made up of the inner membrane bound 
FarA protein (Far being short for fatty acid resistance), the FarB protein which attaches to the FarA 
protein in the periplasmic space and the MtrE outer membrane protein [148, 151]. However, 
despite N. meningitidis having this efflux system, it also has additional resistance mechanisms due 
to its core oligosaccharide structure and hexa-acylation of its membrane anchor lipid A [189]. This 
highlights the importance of the role of the LPS in fatty acid resistance in Gram negative bacteria. 
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Figure 1.11. Mechanisms of bacterial inactivation by fatty acids [174]. The fatty acids could interact 
with the cell membrane causing cell lysis, affect bacterial energy production by disrupting the 
electron transport chain and/or interfering with oxidative phosphorylation, or they may hinder 
nutrient transport across the cell membrane. FFAs abbreviation in the figure stands for free fatty 
acids. 
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1.3 Anatomy of the eye and ophthalmic formulations 
1.3.1 Structure and function 
The eye is a complex organ. It converts light into electro-chemical signals that the brain can 
understand. The eye typically uses light wavelengths in the 400 to 700 nm range [190]. This light 
can be differentiated into around 2.3 million colours [191]. Human eyes are both forward facing 
giving us a good range of binocular vision. This gives us a good level of depth perception in front of 
us but restricts the overall visual range. For humans, sight is probably the most important of the 
five senses as we rely on it so heavily. The complexity of the eye has been driven through sight 
being a key advantage throughout evolution [192]. The structure of the eye is shown in Figure 
1.12.A. As sight is such a driver for evolution it has an array of defensive mechanisms to help protect 
it from physical injury or infectious diseases. In particular, the exposed parts of the eye (Figure 
1.12.B) are very important protective structures. 
The outer layers of the eye are the sclera and cornea. The sclera, commonly referred to as “the 
white of the eye” protects the inner workings of the eye and is mainly made up of a complex 
structure of collagen fibres [193]. The sclera covers the majority of the eyeball and unlike other 
mammals (including non-human primates) is not pigmented the same colour as the iris. The other 
outer part of the eye is the cornea. This is the highly specialised outer structure that is completely 
transparent. It contains no blood vessels but does contain many nerve endings. The cornea is 
actually responsible for two thirds of the refraction of the light. The rest is done by the lens. The 
other function of the cornea is to protect the eye. 
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Figure 1.12 Anatomy of the eye. (A) Photograph of an eyeball with visible features labelled. The 
cornea is completely transparent and therefore the iris and pupil below are visible. (B) Graphical 
representation of a cross section of an eyeball showing all the main structures. Image for panel A 
was downloaded from freely from Wikimedia Commons and panel B was freely downloaded from 
Clipartbest.com.  
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Figure 1.13 Histology of the cornea. (A) Haematoxylin and eosin stained section of a cornea with 
five distinct layers all labelled. (B) Haematoxylin and eosin stained epithelial layer, Bowman’s 
membrane and some of the stroma. The different morphology of the cells in the epithelial layer is 
clearly visible in this picture. These pictures were produced in this study, see chapter 2 for details. 
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1.3.2 The sclera and cornea 
The cornea is made of five layers (Figure 1.13.A); the epithelium, Bowman’s membrane, stroma, 
Descement’s membrane and endothelium. The corneal epithelium is made of layers of cells about 
six cells deep. Corneal epithelial cells are made in the corneal limbus; the region between the 
cornea and sclera (Figure 1.13.B). The cells continue to divide and move inward toward the centre 
of the cornea. The cells at the bottom of the epithelium are known as basal cells, cells in the middle 
are known as wing cells due to their flatten shape (relative to the basal cells) and cells at the top 
are known as squamous cells. The squamous cells appear almost completely flat with barely visible 
nuclei. On top of the squamous cells sits the tear film, which is an aqueous layer with a lipid coating 
to reduce evaporation of the tear film (Figure 1.14.B). Squamous cell slough off into the tear film 
but are quickly replaced. The epithelial layer is lipid rich and therefore hydrophobic. 
The Bowman’s membrane is a tough layer of interwoven Type I collagen fibres. This layer is more 
developed in higher mammals [195]. The stroma is the thickest part of the cornea at about 1 mm 
thick. It is made up of Type I collagen arranged in complex fibres. The fibres are made by corneal 
keratocyte cells that are sparsely spaced but interconnected. In contrast to the epithelial layer, the 
stroma is hydrophilic. The Descemet’s membrane is a thin layer composed mainly of type IV 
collagen fibres. The endothelia layer is made from a thin monolayer of corneal endothelia cells that 
transport fluid and solutes between the aqueous humor and stroma. 
1.3.3 Lacrimation and other defence mechanisms 
The eye is an immunologically privileged site which means the presence of leucocytes there is 
limited. This has the consequence that the eye is particularly vulnerable to infection, therefore 
relies on other powerful methods to prevent infection. The main defence against infection is 
lacrimation, commonly referred to as the production of tears. Figure 1.14.A shows the main parts 
of the eye that are responsible for producing tears and for the drainage of tears. The tear fluid itself 
is produced in the lacrimal gland. The composition of the tears can vary and tears can be generally 
being split into three categories: basal tears; reflex tears; and emotional tears. 
Basal tears are continually being produced and stop the eyes drying out. These tears remove 
potentially irritating particles, such as dust, and help to kill infectious agents. Reflex tears are 
produced when triggered by irritation to the eye. These are generally similar to basal tears but are 
released at a much greater flow rate to wash out any irritating particle or chemical. Emotional tears 
are triggered by a strong emotional response such as sadness, stress, happiness or physical pain. 
This tear type contains much higher levels of hormones. Infants cannot usually produce emotional 
tears until they are several months old [196]. 
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Figure 1.14 Lacrimal system of the eye. (A) Diagrammatic representation of the eye with tissues 
related to the lacrimal system taken from Lamellar Biomedical website 
http://lamellar.dnsblock4.com/wp-content/uploads/2015/01/Tear-film-sharp.jpg.  
(B) Diagrammatic representation of the different layers that make up tear film. This image is based 
an image created by User: FML and uploaded to WikiMedia Commons as Image:Sistema 
lacrimal.svg 
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The antimicrobial properties of tears have been well studied, see Figure 1.15 [197]. About 20-30 % 
of the protein content of basal tears is from of lysozyme [198]. Lysozyme attacks bacterial cell walls 
and is particularly effective at killing Gram positive bacteria [199]. Another 20-30 % of the protein 
content is made up from lactoferrin [198]. This sequesters iron from the tear fluid which would be 
essential to bacterial growth. Although this doesn’t kill bacteria, iron limitation is an effective part 
of the innate immune system, as it gives other antimicrobial systems a chance to act on the bacteria 
before they become overwhelmed. Secretory immunoglobulin A (sIgA) is the main immunoglobulin 
present in the tear fluid. It is secreted by plasma cells resident in the lacrimal gland and conjunctival 
associated lymphoid tissue [200]. sIgA is a poor activator of complement but acts as a neutralising 
antibody, blocking recognised bacterial, viral or fungal binding proteins so they can be flushed away 
from the eye by the lacrimation system. However, some pathogens such as N. gonorrhoeae can 
produce a IgA protease which cleave the secreted IgA present on body surfaces, such as the eye 
[201]. 
Tears are produced in the lachrymal glands. The basal rate of flow of the tears is 1 µl/min [202]. 
This liquid is then spread over the surface of the eye by blinking. Lipids are secreted by sebaceous 
glands and form an oily layer on top of the aqueous layer that helps to prevent evaporation of the 
tear fluid (see figure 1.14.B). The entire tear fluid volume (sometimes referred to as the precornel 
fluid) is 7 µl but the ocular surface is able to hold 20-30 µl before tearing [203]. This volume is likely 
to be smaller in children, infants and neonates. Most liquid dose formulations (commonly referred 
to as eye drops) have a droplet size of 25-70 µl [204]. This means that tearing is likely and loss of 
active substances in ocular formulations is common. Tear fluid is drained from the eye via the 
superior and inferior lacrimal canals that lead to the nasolacrimal canal. This process is sped up by 
blinking and by production of either reflex or emotional tears. Application of a liquid dose form 
would also increase the drainage rate with active compounds drained from the eye rapidly. 
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Figure 1.15 Known tear components that have antimicrobial properties and where they are 
produced [197]. (A) List of tear components and their mechanism of action. (B) Graphical 
representation of the antimicrobial components and where they are produced. 
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Figure 1.16 Ocular drug release. (A) Example of drug delivery levels to tear fluid (Cd), cornea (Cc) 
and aqueous humor (Ca) from a topical liquid dosage form [205]. (B) The difference between a 
solution, suspension and ointment for drug delivery to the aqueous humor [206]. (C) Difference in 
drug retention on the ocular surface of a liquid dosage form with two bioadhesives compared to 
saline [207]. 
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1.3.4 Types of ophthalmic dosage forms 
There are many types of delivery system options for ophthalmic formulations. The different delivery 
systems are usually chosen based on what will give the optimal drug delivery to the target site. 
However, other considerations are also taken into account such as ease of administration and 
whether the treatment results in blurred vision, as is the case with ointments applied to the eye. 
Figure 1.16.A. is a graph showing the time and concentration at which a drug reaches different parts 
of the eye. A pure liquid dosage form such as an eye drop will mix with the tear film instantly on 
contact but may be washed from the away from eye before it has enough time to start to migrate 
into the cornea in significant quantities to be effective. Therefore, a delivery system that is retained 
in the eye for an extended time maybe better suited. 
1.3.5 Traditional liquid dosage forms 
Due to factors mentioned above, liquid dosages forms don’t have a very long retention time on the 
ocular surface, see Figure 1.16.B. For drugs which need to penetrate into the eye this is a problem. 
However, if the purpose of the therapeutic agent is to kill bacteria on the ocular surface then this 
delivery system may be more suitable as long as the drug is fast acting. The drug candidate would 
need to have a good level of solubility in an aqueous solution as high levels of other solvents may 
not be tolerated. Suspensions could be used for poorly soluble drugs but this could potentially lead 
to dose uniformity problems in some cases. Thickening agents or viscosity enhancers may be added 
to decrease drainage rates and therefore potentially increasing the retention time of the active 
drug. Agents such as hydroxypropyl methylcellulose (HPMC), polyvinyl alcohol, povidone or dextran 
can be used for this purpose. Some viscosity enhancers double as bioadhesive agents which interact 
with the ocular surface (such as carboxymethylcellulose (CMC) and carbopol). This can increase 
retention time, see Figure 1.16.C. Ophthalmic liquid dosage forms always require a tonicity agent, 
antimicrobial preservative and preferably a buffering agent [208]. 
1.3.6 Phase-change liquid dosage forms 
These are dosage forms that are liquid upon administration but change to a semi-solid when 
exposed to the ocular surface; these can also be referred to as in situ hydrogels. This phase-shift 
can be triggered by temperature, pH or ionic strength. This is caused by crosslinking of polymers in 
the formulation and results in increased retention of the active drug. 
1.3.7 Semi-solid dosage forms 
The semi-solid dosage forms usually have the best retention times of any delivery system. The 
majority are based on blends of white/yellow petrolatum and liquid petrolatum (mineral oil). The 
addition of the liquid petrolatum would lower the softening point of the white/yellow petrolatum 
closer to the temperature of the ocular surface. Common ophthalmic ointments, such as 
chloramphenicol (1 % (w/w)), are produced in this way and are available over-the-counter in 
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pharmacies in the UK.  When treatment with an ointment is advised, it is often administered in 
adults just before sleep due to the side effect of blurred vision caused by the semi-solid formulation. 
As blurred vision is not of concern with neonates, where vision is not fully developed and where 
the eyes are closed for long periods. Therefore, ointments are often preferred in neonatal 
ophthalmic delivery systems. 
1.3.8 Ocular inserts 
A newer method of drug delivery is the application of ocular inserts. These can either be in soluble 
form where the insert slowly dissolves into the tear film over the period of up to 24 hours or an 
insoluble form where the inserts can release the active drug over a longer period. These delivery 
systems are not commonly used for antimicrobial drug delivery. 
1.4 Aims of this thesis and structure 
The aim of this thesis is to assess the suitability of using a fatty acid or fatty acid derivative as the 
active component in the development of an alternative prophylaxis and/or treatment for 
ophthalmia neonatorum. The rise in antimicrobial resistance may make current antibiotic based 
prophylaxis and treatments ineffective, while the use of other non-antibiotic drugs may cause an 
increase in the rate of chemical conjunctivitis. 
The main characteristics desired of such a formulation are that it is effective, safe, stable, easy to 
use, and cost effective. To address effectiveness, the active fatty acid must be able to kill N. 
gonorrhoeae cells quickly on the ocular surface. Also, the formulation must remain effective in the 
future so mechanisms of resistance should not already exist nor should they be easily acquired. The 
safety of any medicine used on neonates must be demonstrated. The drug and its formulation must 
not cause harm. Any damage to the cornea in neonates could have lasting effects. Furthermore, 
any adverse reaction would undermine use of the prophylaxis, as has been experienced with silver 
nitrate use. Also, the rate of adverse side effects of the treatment, such as chemical conjunctivitis, 
must be lower than the incidence rate of ophthalmia neonatorum. Formulations must be stable for 
a long shelf life. This ensures that the formulation can be stockpiled before use and will still retain 
its effectiveness. Consideration must also be given to how the formulation will be stored and used. 
The treatment should be formulated with the end user in mind, as well as where it will be used. 
Any mandatory medicine has to be cost effective. There were 695,233 live births in England and 
Wales in 2014 [209]. The lower the cost of the treatment, the greater the chance of uptake. 
This thesis will try to address all of these characteristics. First a suitable candidate must be 
identified. This suitability will be deemed as being able to kill gonococcal cells quickly but to also 
not be damaging to the ocular surface. This is addressed in Chapter 2. Pre-formulation testing and 
formulation is presented in Chapter 3. In this chapter an analytical technique that was developed 
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will be described. The physical and chemical properties of the candidates for drug formulation are 
reviewed. The formulation is described in this chapter to look at ease of use and cost effectiveness. 
Chapter 4 explores in vitro and ex vivo models to determine the effectiveness of the active 
candidate and possible formulations. Chapter 5 investigates whether any resistance to the 
candidate drugs exist and whether genetic mutations can lead to decreased susceptibility to the 
drug candidate. Chapter 6 looks at natural sources of fatty acids that have been shown to have good 
anti-gonococcal activity. These could offer a cheap alternative source of antimicrobial agents for 
treatment of ophthalmia neonatorum in under-developed areas of the world. 
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2.1 Introduction 
2.1.1 Drug candidate discovery 
As mentioned in Chapter 1, certain fatty acids and fatty acid derivatives have been identified by 
previous studies to be bactericidal to N. gonorrhoeae. Those studies although comprehensive, may 
be out of date as they don’t use recent isolates. Bacteria are continuously changing with their 
environment and antimicrobial resistance profiles of N. gonorrhoeae change within the space of a 
few years, especially if mechanisms of resistance easily acquired. Furthermore, it is important to 
repeat work by other researchers to ensure reproducibility and also to compare newly found 
antimicrobials against existing ones. For these reasons examination of previously tested fatty acids 
and fatty acid derivatives using recent gonococcal isolates as well as testing of more novel fatty acid 
derivative groups is important. Many antimicrobial agents are discovered by screening libraries for 
growth-inhibitory effects [158]. This is the starting approach that this study has also taken. 
However, the action of any drug in the ophthalmic formulation should be to kill gonococcal cells 
not just to inhibit growth. For this reason the bactericidal properties will also be needed to be 
measured. This will identify drug candidates that will go on to be further evaluated. 
2.1.2 Irritation assays 
Irritation potential of drug candidates or ophthalmic formulation can be assessed in a number of 
different ways. Currently, the gold standard test is the Draize test which involves the use of live 
New Zealand white rabbits [210]. However, in vitro testing is commonly used by pharmaceutical 
companies and mandatory use of the Draize test is no longer required by the European Union [211]. 
There are many available and are especially useful to initially screen chemicals and formulations to 
remove moderate to severe ocular irritants [212]. However, they can lack the sensitivity to identify 
mild to moderate irritants [213, 214]. It is therefore recommended that a battery of in vitro tests 
be used and not one single test alone [213, 215, 216]. 
This study uses three irritation assays to establish irritation potential. The first test is the bovine 
corneal opacity and permeability (BCOP) test. This is a model for damage to the cornea and involves 
the testing of substances on excised bovine eyes [217]. The test evaluates corneal swelling, 
wrinkling, opacity and fluorescein retention. Histopathological damage can also be assessed to 
grade damage to the corneal epithelia for enhanced discrimination of mild to moderate irritants 
[218]. The Hen's Egg Test – Chorioallantoic Membrane (HET-CAM) is a model of conjunctival 
irritation which has been used in this study [217, 219, 220]. Conjunctival hyperaemia is a common 
sign of ocular irritation and the vascular CAM of a hen’s egg is therefore an ideal model. The 
capillaries located just under the epithelium of the CAM will have a rapid response to any substance 
that causes damage to the vascular system. The third test is the red blood cell (RBC) lysis assay 
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which is a more general test that determines whether the substances is capable of lysing cells 
membranes [221]. This test has been reported to offer a higher level of sensitivity [222]. These tests 
combined will give a good level of certainty of the irritation potential of any drug candidate. 
2.1.3 Aims of this chapter 
The main aim of this chapter is to identify fatty acids and/or fatty acid derivatives which are suitable 
for further development into ophthalmic formulation in terms of anti-gonococcal properties and 
also ocular safety. The anti-gonococcal properties will be tested in terms growth inhibition first and 
then killing abilities. Candidates with the fast killing properties will be selected further. The ocular 
safety of the candidates will be evaluated via the use of three in vitro models. Finally, the killing 
action of the candidates will also be measured in simulated tear fluid to assess their ability to act in 
the eye. 
2.2 Materials and methods 
2.2.1 Bacterial strains and culture conditions 
GC agar was used to grow all Neisseria isolates. This was produced by adding 18 g/L GC base (15 g/L 
Special peptone, 1 g/L corn starch, 5 g/L sodium chloride, 4 g/L dipotassium hydrogen phosphate, 
1 g/L, potassium dihydrogen phosphate, and 10 g/L agar) (Oxoid Limited, Hampshire, UK) to 
deionised water and sterilising by autoclaving at 121 °C for 15 minutes. Once cooled to 
approximately 50-60 °C, Kellogg supplements (final concentrations: 12.3 µM Fe(NO3)3, 22.2 mM D-
glucose, 0.68 mM L-glutamine and 0.43 µM thiamine pyrophosphate) were added and poured into 
either 55 or 90 mm sterile petri-dishes [101]. Isolates were often maintained in GC broth (15 g/L 
protease peptone, 4 g/L potassium phosphate dibasic (K2HPO4), 1 g potassium phosphate 
monobasic (KH2PO4), and 5 g/L NaCl) which had been sterilised by autoclaving as above [223]. 
However, gonococcal isolates were always grown on solid agar medium. Growth conditions were 
37 °C, 5% CO2 which was maintained by a laboratory CO2 laboratory incubator. Trays of water 
containing copper sulphate were placed in the incubator to increase humidity to prevent agar plates 
drying out.  
After receiving isolates for the first time, a swab was used to inoculate GC agar plates. A continues 
streak was done over an entire 90 mm agar plate and incubated for 24 hours at 37 °C, 5% CO2. Cells 
were then scraped off the surface of the plate and placed into GC broth containing 15 % (v/v) 
glycerol. Aliquots were then stored at -80 °C freezer for long term storage. To revive a culture, 
stocks were briefly taken out the -80 °C freezer, a sterile cotton wool swab used to take cells off the 
surface of stock and then returned to the freezer before the stock had defrosted. The swabs were 
used to inoculate GC plates and these were incubated at 37 °C, 5% CO2. Growth was checked to 
ensure no contamination present. Plates containing bacterial growth that differed from the 
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characteristic gonococcal growth (see Figure 1.3.B) where discarded. Cultures could be maintained 
by passage every 24 hours on GC agar but no cultures were maintained any further than four 
passages from the glycerol stock. This was done to maintain genotype and phenotypic 
characteristics of the isolate.  
The well characterised N. gonorrhoeae strain NCCP11945 was used in the screening stage of this 
experiment [224]. Eight isolates that were obtained from PHE from various European locations 
were used in the log reduction assays (designated HPA 1-8). All isolates were first cultured for 24 
hours prior to any testing by plating on GC agar and incubating at 37 °C, 5% CO2. 
2.2.2 Fatty acid and fatty acid derivatives 
A full list of all the fatty acid and fatty acid derivatives used in this study is in Table 2.1. The tested 
compounds include saturated and unsaturated fatty acids, monoglycerides, dicarboxylic acids, and 
fatty acid sodium salts. All compounds investigated were resuspended at a concentration of 100 
mM in ethanol unless stated, these were stored at -20 °C. All chemicals were obtained from Sigma-
Aldrich (Poole, Dorset, UK). 
2.2.3 Screening of the fatty acids/ fatty acid derivatives for bactericidal 
action 
A diagrammatical representation of the screening stage can be found in Figure 2.1. GC plates were 
prepared with a concentration 1 mM of the test compounds. This was done by adding a 1/100th 
volume of the 100 mM stock to the molten agar with Kellogg supplements (see 2.2.1) before 
pouring. For this stage of screening, 55 mm petri dishes were used. N. gonorrhoeae isolate 
NCCP11945 was grown overnight on GC agar at 37 °C with 5 % CO2 and cells scrapped into GC broth 
medium. It was previously determined that an optical density (OD) at 520 nm of between 0.25 and 
0.3 was equivalent to approximately 107 gonococcal cells. Therefore, suspensions were made to 
that value and a sample was also diluted 1/1,000, therefore producing a 104 CFU/ml suspension. 
An aliquot of 100 µl of the undiluted cell suspension and the dilution were then plated on separate 
plates containing the different test candidates and spread using an L shaped spreader. This would 
challenge the candidates with approximately 106 and 103 cells per plate.  The plates were incubated 
for 48 hours at 37 °C with 5 % CO2. Any test candidates that had inhibited growth of the bacteria 
were selected for the next stage of selection. 
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Table 2.1 A list of fatty acids and fatty acid derivatives with their chemical formulae used in this 
study. 
Chemical Class Candidate Formula 
Saturated Fatty Acids 
Caprylic  (8:0) CH3(CH2)5COOH 
Capric acid (10:0) CH3(CH2)8COOH 
Undecanoic acid (11:0) CH3(CH2)9COOH 
Lauric acid (12:0) CH3(CH2)10COOH 
Tridecanoic acid (13:0) CH3(CH2)11COOH 
Myristic acid (14:0) CH3(CH2)12COOH 
Pentadecylic acid (15:0) CH3(CH2)13COOH 
Palmitic acid (16:0) CH3(CH2)14COOH 
Heptadecylic acid (17:0) CH3(CH2)15COOH 
Stearic acid (18:0) CH3(CH2)16COOH 
Mono-Unsaturated Fatty 
Acids 
Myristoleic acid (14:1  cΔ9) CH3(CH2)3CH=CH(CH2)7COOH 
Palmitoleic acid (16:1 cΔ9) CH3(CH2)5CH=CH(CH2)7COOH 
Oleic acid (18:1 cΔ9) CH3(CH2)7CH=CH(CH2)7COOH 
Elaidic acid (18:1 tΔ9) CH3(CH2)7CH=CH(CH2)7COOH 
Petroselinic acid (18:1 cΔ6) CH3(CH2)10CH=CH(CH2)3COOH 
trans-Vaccenic acid (18:1 tΔ11) CH3(CH2)5CH=CH(CH2)9COOH 
cis-Vaccenic acid (18:1 cΔ11) CH3(CH2)5CH=CH(CH2)9COOH 
Erucic acid (22:1 cΔ13) CH3(CH2)7CH=CH(CH2)11COOH 
Poly-Unsaturated Fatty 
Acids 
Sorbic acid (6:2 tΔ2,4) CH3CH=CHCH=CHCOOH 
Linoleic acid (8:2  cΔ9,12) CH3(CH2)4CH=CHCH2CH=CH(CH2)7COOH 
Linolenic acid (18:3 cΔ9,12,15) CH3(CH2CH=CH)3(CH2)7COOH 
Arachidonic Acid (20:4  cΔ 5,8,11,14) CH3(CH2)4(CH=CHCH2)4CH2CH2COOH 
Monoglycerides 
Monocaprylin (8:0MG) H3C(CH2)6COOCH2CH(OH)CH2OH 
Monocaprin (10:0MG) H3C(CH2)8COOCH2CH(OH)CH2OH 
Monolaurin (12:0MG) H3C(CH2)10COOCH2CH(OH)CH2OH 
Monomyristin (14:0MG) H3C(CH2)12COOCH2CH(OH)CH2OH 
Dicarboxylic Acids 
Succinic acid HOOCCH2CH2COOH 
Adipic acid HOOC-(CH2)4-COOH 
Pimelic acid HOOC-(CH2)5-COOH 
Suberic acid HOOC-(CH2)6-COOH 
Azelaic acid HOOC-(CH2)7-COOH 
Sebacic acid HOOC-(CH2)8-COOH 
Ricinoleic acid Ricinoleic acid CH3(CH2)5CH(OH)CH2CH=CH(CH2)7COOH 
Isopropyl myristate CH3(CH2)12COOCH(CH3)2 
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Esters Isopropyl palmitate CH3(CH2)14COOCH(CH3)2 
Fatty Acid Sodium Salt 
Sodium dodecanoate CH3(CH2)10COONa 
Sodium myristate CH3(CH2)12COONa 
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Figure 2.1 Diagrammatical representation of fatty acid/ fatty acid derivative drug candidate 
selection process. This phase of the selection process focused on selection based on anti-
gonococcal properties of the tested substances. The first stage (screening) identified whether the 
candidates inhibited growth. Ones that did inhibit growth were then tested for fast killing 
(bactericidal) properties by log reduction experiments. 
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2.2.4 Measurement of bactericidal action of the fatty acids 
Log reductions were done using a modified method of Bergsson and co-works [167]. A 
diagrammatical representation this process can be found in Figure 2.1. Briefly, cells were suspended 
in GC broth to an optical density of between 0.25-0.3 at 520 nm which is approximately equivalent 
to 107 cells per millilitre. Five hundred microliters of the suspension was then added to 5 µl of the 
100 mM stocks to give a final concentration of 1 mM. A negative control was also done to calculate 
the reduction in bacterial titre by adding 500 µl to 5 µl ethanol. The tubes were then mixed at room 
temperature for two minutes and immediately diluted in a 10 fold dilution series down to 10-4. The 
dilutions were plated in duplicate by spreading 10 µl on a quarter of a GC agar plate and 100 µl of 
the neat solution was also plated over a whole plate, again in duplicate. Plates were incubated at 
37 °C, 5% CO2 for 48 hours. All experiments were repeated on separate days to ensure that results 
were reproducible. A reduction in viable cell count by more than 4 log10 was deemed to be 
bactericidal and was selected for further investigation. Bactericidal compounds were then tested 
at concentrations of 0.75, 0.5 and 0.25 mM (0.125 mM was also used in some potent compounds) 
to find the minimum bactericidal concentration (MBC). These MBC calculation experiments were 
done using eight clinical gonococcal strains as well as the NCCP 11945 isolate that was used for the 
screening stage. 
2.2.5 Bovine corneal opacity and permeability test 
Bovine eyes were collected from a slaughter house (ABP, Guildford, Surrey, UK) and were 
transported in cold saline for testing at the laboratory. Each eye was first examined for signs of 
damage before use. Plastic weighing boats were used to hold individual eyes in a closed shaking 
water bath at 37°C, 90 rpm. The eyes were incubated in the water bath for 10 minutes and then a 
rubber 8 mm O-ring was carefully placed on the centre of the cornea. One drop of saline was added 
to the test area inside the O-ring and incubated for 5 minutes. The saline was then removed and 
the test substance added for 30 seconds. Bactericidal compounds were tested at a concentration 
of 1 mM in saline. Overall concentration of ethanol from carry-over from the stock was therefore 1 
%. A negative control of saline with 1 % ethanol, an irritant control of 100% acetone and a strong 
irritant control of 0.5 M sodium hydroxide were all tested in each experiment. The test area of the 
cornea was then washed with 10 ml saline and the eyes were incubated for 10 minutes in the water 
bath. 
Corneal damage to the test area was the assessed by fluorescein examination by adding a few drops 
of 2 % sodium fluorescein and washing with 10 ml saline. The eyes were examined under a cobalt 
blue filter and pathological scoring based on opacity, epithelial integrity and epithelial detachment 
was done in accordance with previous publications (see Table 2.2) [217]. Each of the seven 
Chapter 2 – Identification of possible drug candidates 
55 
 
candidates were tested in triplicate, each test was performed on a separate day from a different 
batch of eyeballs. 
2.2.6 BCOP - Cornea Histology 
After BCOP experiments, the corneas were excised from the eyeballs. These were trimmed, put into 
histological cassettes and placed in neutral buffered formalin (Sigma-Aldrich) for 24 hours. The 
formalin was removed and replaced with 70% industrial methylated spirit (IMS) and stored for a 
minimum of 48 hours until the samples were ready to test. The samples were put into a Thermo-
Fisher Scientific (Loughborough, Leicestershire, UK) Shandon-Citadel 1000 automatic tissue 
processor where they were processed as stated in Figure 2.2.A The samples were embedded in 
paraffin in 37 X 24 X 9 mm stainless steel moulds (Thermo-Fisher Scientific) using a Histostar 
embedding centre (Thermo-Fisher Scientific) and stored at 4 °C overnight. Excess wax was removed 
using a scalpel and the block placed on a Leica Biosystems (Milton Keynes, Buckinghamshire, UK) 
rotary microtome (model RM2255) and sections taken at a thickness of 5-7 µm. The sections were 
mounted on polysine coated microscope slides (Thermo-Fisher Scientific) and incubated at 40 °C 
overnight. After this, the slides were stained with Haematoxylin and Eosin (H&E) using standard 
protocols outlined in Figure 2.2.B. After soaking in Histoclear II (National Diagnostics, Atlanta, 
Georgia, USA) for 15 minutes after staining, a coverslip was mounted on the slides using DPX 
mountant (BDH Chemicals, VWR International, Lutterworth, Leicestershire, UK) and the slides dried 
at 40 °C for 24 hours. The slides were examined using a Nikon Eclipse i80 (Nikon UK Limited, 
Kingston-Upon-Thames, Surrey, UK) light microscope and images captured using NIS-Elements BR 
3.0 SP7 (Nikon UK Limited) software. 
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Figure 2.2 Conditions for automated tissue processing and H&E staining. (A) Conditions for the 
automated tissue processor which was run overnight. The paraffin baths (stages 11 and 12) were 
done at 65 °C. (B) Order and length of incubation of slides for H&E staining. Staining was done glass 
staining dishes in batches of up to twelve. Abbreviations used: IMS, Industrial Methylated Spirit. 
 
  
Chapter 2 – Identification of possible drug candidates 
57 
 
 
 
 
Table 2.2 Scoring table of bovine cornea opacity permeability test. 
Opacity Score Epithelial 
integrity 
Score Epithelial 
detachment 
Score Cumulative 
score 
Score 
None 0 None 0 No gross 
abnormalities 
0 ≤0.5 None 
Slight 1 Diffuse 
and weak 
0.5 Wrinkling of 
corneal 
surface 
2 0.6-1.9 Slight 
Marked 2 Confluent 
and weak 
1 Loosening of 
epithelium 
3 2.0-4.0 Moderate 
Severe 3 Confluent 
and 
intense 
1.5 Epithelium 
absent 
4 >4 Severe 
Opaque 4 
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2.2.7 Hen's Egg Test – Chorioallantoic Membrane (HET-CAM) 
The HET-CAM was performed as Alany and co-workers [219]. Fertilised White Leghorn eggs were 
purchased from Henry Stewart & Co. Ltd (Fakenham, Norfolk, UK) and delivered to Kingston 
University. If the eggs were not being used immediately then they were stored at 10-15 °C but for 
no longer than one week. All eggs were checked for damage and any which were overly misshaped 
were discarded. Eggs were cleaned with 70 % IMS and incubated at 37.5 °C ± 1°C with 60-70 % 
relative humidity. Conditions were monitored by an Ebro (Ingolstadt, Germany) EBI20-TH1-se 
temperature and humidity data-logger. The eggs were turned three times a day to prevent shell 
membranes adhering to the shell. 
After four days of incubation the eggs were again cleaned. A growth chamber was made by placing 
cling film over a white PVC tube with a 10 cm diameter and a depth of 10 cm. The cling film was 
pushed half way into the tube so it would be able to hold the contents of the egg. The cling film was 
secured to the holder with a circular PVC clip which had the same diameter as the holder but only 
had a depth of 1 cm. The eggs were broken open carefully and poured into the growth chambers 
(see Figure 2.3). A sterile glass 120 mm petri-dish half was then placed over the chamber. Any eggs 
that didn’t have a viable chorioallantoic membrane or that had a broken yolk sac were discarded. 
All viable eggs in chambers were returned to the incubator. 
At day nine, the CAMs were tested. This was done by applying 200 µl of the testing material and 
recording results at 30, 120, and 300 seconds. At each of these time-points the effect of the 
substance on the CAM was evaluated for signs of hyperaemia, haemorrhaging and coagulation 
(examples are shown in Figure 2.4) and assessed using a scoring system as shown in Table 2.3 [217]. 
Photographs were also taken before exposure and at each time-point. The negative control used in 
this experiment was saline solution. Positive controls were 0.1 M NaOH, acetone, and propylene 
glycol. 
2.2.8 Red Blood Cell (RBC) lysis assay 
RBC lysis assay testing was done following European Union Reference Laboratory for Alternatives 
to Animal Testing (EURL-ECVAM) guidelines [225]. A sterile 60 ml pot (Sterilin Ltd, Newport, Gwent, 
UK) containing 10 ml citrate anticoagulation buffer (110 mmol/L citrate (66 mmol/L sodium citrate, 
44 mmol/L citric acid)) was couriered to a slaughter house (ABP, Guildford). The pot was filled up 
to 100 ml with fresh bovine blood and mixed well. The pot was transported back to Kingston 
University and RBCs were isolated the same day. The blood was diluted in four volumes to ten in 
PBS with 10 mM glucose (PBSG). This was centrifuged at 1,500 x g for 10 minutes. The supernatant 
(serum and white “buffy coat”) were discarded and RBCs resuspended by adding PBSG. A total of 
five washes were completed. Finally, the pellet was resuspended in PBSG. A sample of 500 µl was 
diluted in 5 ml distilled water and the OD measured at 541 nm. Extra PBSG was added to the RBCs 
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until a sample gave an OD value of 0.5 using the Equation 2.1. This would give a 2 % suspension of 
RBCs which could then be stored at 4 °C and used within two weeks.  
Equation 2.1 
 
𝑂𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑂𝐷 × 𝑜𝑟𝑖𝑔𝑖𝑛𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑏𝑢𝑓𝑓𝑒𝑟 𝑎𝑑𝑑𝑒𝑑
𝐷𝑒𝑠𝑖𝑟𝑒𝑑 𝑂𝐷
= 𝐷𝑒𝑠𝑖𝑟𝑒𝑑 𝑓𝑖𝑛𝑎𝑙 𝑣𝑜𝑙𝑢𝑚𝑒 𝑜𝑓 𝑏𝑢𝑓𝑓𝑒𝑟 
 
The fatty acids stocks were made up in dimethyl sulfoxide (DMSO) at a concentration of 13,333 
mg/L. Before accurate testing, a range-finding experiment was conducted to know the approximate 
testing concentration range. The stocks were diluted one in ten with PBS and then diluted in a ten-
fold dilution series to 0.01 mg/L with PBSG with 10 % DMSO. Tests were set up by incubating 750 
µl of the test concentration with 250 µl of the 2 % RBC suspension at room temperature for one 
hour with shaking at 125 rpm. Controls used were a complete lysis control (deionised water) and a 
fragility control (PBSG + 10 % DMSO). Samples were centrifuged at 10,000 x g for 2 minutes. An 
aliquot of 750 µl of the supernatant was taken, placed in a plastic cuvette and absorbance at 451 
nm measured. The testing range lay between the lowest dilution to cause haemolysis and the 
dilution below. 
Once the testing range had been identified, at least five concentrations within the range were 
tested as above but this time testing was done in triplicate. The OD451nm of the mean fragility control 
was subtracted from the means of all samples and percentage haemolysis estimated for each 
sample by comparison of the complete lysis control. By plotting these values the concentration at 
which lysis of 50 % of the RBC occurs (H50) could be estimated. 
2.2.9 Testing in simulated tear fluid 
A simulated tear fluid based on published work was made up as Table 2.4 [226]. The stock solution 
were combined before use and diluted to working concentration by the addition of deionised 
water. The simulated tear fluid was filter sterilised through a 0.22 µm filter (Nalgene, Rochester, 
New York, USA) before use. The fatty acid candidates were tested in the simulated tear fluid to 
demonstrate that they were still able to kill the bacteria in this environment. Log reductions were 
tested as 2.2.4 with one exception; after adjusting the bacterial suspension to OD520nm of 0.25-0.3, 
the cell suspension was centrifuged at 14,000 x G for 3 minutes, culture medium removed and 
bacteria resuspended in the simulated tear fluid. This was then added to the concentrated fatty 
acid candidates as 2.2.4 
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Figure 2.3 HET-CAM method. (A) The cleaned eggs in the first few days of the experiment. The 
crosses on the eggs make it easier to tell if the eggs have been turned. (B) Example of a HET-CAM 
holder, clip and top (glass perti-dish lid). (C) The holder after the egg has been added with the cling 
film holding the egg. (D) The egg inside the holder at either day 3 or 4. At this stage of the 
experiment the heart can be seen beating 
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Figure 2.4 Examples of different reactions of the HET-CAM test. (A) A normal CAM before exposure. 
(B) Typical hyperaemia reaction. This is the increase of blood flow to different areas caused by 
vasodilation. The blood vessels are clearly being affected by the presence of the testing substance. 
(C) Haemorrhaging is where the blood vessels fail to contain the blood and it leaks into the tissue. 
(D) CAM exhibits haemorrhaging but here the blood starts to coagulate (clot) forming darker spots. 
Images are from this study. 
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Table 2.3 Scoring scheme for the HET-CAM with the classification of the cumulative score. 
Effect 
Score 
0.5 min 2 min 5 min 
Hyperaemia 5 3 1 
Haemorrhage 7 5 3 
Clotting/coagulation 9 7 5 
    
Cumulative Score Interpretation 
0-0.9 None 
1.0-4.9 Slight 
5.0-8.9 Moderate 
9.0-21.0 Severe 
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Table 2.4. Components and concentrations of the simulated tear fluid. 
Stock Name Tear Component 
Sigma 
code 
Final 
Concentration 
(g/L) 
Stock 
concentration 
A - Proteins 1 
Lysozyme, human, rice recombinant L1667 1.9 
10 X 
Lactoferrin, human, rice recombinant L1294 1.8 
α1-Acid Glycoprotein from bovine 
plasma 
G3643 0.5 
B - Proteins 2 
Albumin from human serum A9511 0.2 
10 X 
Mucin from bovine submaxillary 
glands 
M3895 0.15 
γ-Globulins from human blood G4386 0.1 
C - Lipids 
Cholesteryl linoleate C0289 0.024 
10 X 
Linalyl acetate W263605 0.02 
Glyceryl trioleate T7140 0.016 
Cholesterol C8667 0.0016 
D - Salts and 
buffer agents 
Sodium chloride  S5886 6.626 
2 X 
Potassium cholride P9541 1.716 
Sodium bicarbonate S6014 1.376 
Lactic acid 252476 0.27 
Calcium cholride, dihydrate C3306 0.147 
Sodium diydrogen phosphate, 
monohydrate 
S9638 0.1 
MOPS M3183 4.18 
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2.3 Results 
2.3.1 Screening of the fatty acids/ fatty acid derivatives 
In total thirty-seven fatty acids/ fatty acid derivatives were tested in the screening process. With 
the compounds added directly to the solid agar media to a concentration of 1 mM, 20 (54 %) of the 
compounds completely inhibited growth of the test gonococcal strain (NCCP11945). The full list of 
results are listed in Table 2.5. For the saturated fatty acids, only medium chain (11-15) fatty acids 
were inhibitory. For monounsaturated fatty acids medium to long (14-18) were inhibitory. 
However, only oleic acid and elaidic acid were inhibitory from the 18 carbon chain length 
monounsaturated fatty acids which may suggest that the position and/or type of double bond are 
important. Poly-unsaturated fatty acids with a chain length of 18 and 20 were inhibitory. All 
monoglycerides were inhibitory. None of the dicarboxylic acids were inhibitory and in fact the 
bacteria grew very well in their presence. This indicates that the hydrophobic carbon chain plays a 
vital role in the inhibitory properties of the fatty acids. None of the propyl esters were inhibitory 
but the tested saturated fatty acid sodium salts were. 
2.3.2 Measurement of bactericidal action of the fatty acids 
Log reductions were completed using a concentration of 1 mM on the twenty compounds that had 
passed the screening. Only seven of these compounds were classed as being bactericidal at this 
concentration. The seven compounds were lauric acid, tridecanoic acid, myristoleic acid, 
palmitoleic acid, linolenic acid, monocaprin and sodium dodecanoate. Results of the log reductions 
can be found in Table 2.5. The candidates were further tested at lower concentrations against a 
total of nine gonococcal isolates, these results can be found in Figure 2.5 and Figure 2.6. The mean 
MBCs were estimated using the log reductions averaged over all nine isolates tested and are given 
in Table 2.5. The results indicate that myristoleic acid, palmitoleic acid, linolenic acid, monocaprin 
(all had MBC of 0.5) performed slightly better than lauric acid, tridecanoic acid, and sodium 
dodecanoate (MBC of 0.75). However, this is may not be the case. Figure 2.7 displays the log 
reduction graphs for the seven candidates, with the bars representing the mean log reduction and 
the error bars the standard deviation over the nine isolates investigated. Any candidate that caused 
complete killing of all bacterial cells in the cell suspension would be given a log reduction score of 
six (scores of seven could not be given due to measurement limitation of the experiment) so 
therefore if one concentration caused total killing of all isolates testing no error bars would be 
present (as all log reduction values would be 6.0). Lauric acid, myristoleic acid, monocaprin, and 
sodium dodecanoate when tested at a concentration of 1 mM killed all gonococcal cells for all 
isolates. However, palmitoleic acid, linolenic acid, and tridecanoic acid did not. Two isolates (namely 
HPA 3 and HPA 4) in particular had some level of tolerance to palmitoleic acid and linolenic acid and 
were not completely inhibited by a 1 mM concentration of these compounds. Log reductions were 
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completed in triplicate with new batches of stock fatty acid of these fatty acids on these isolates to 
confirm this result. The results are shown in Figure 2.8. 
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Table 2.5 Results of all stages of the investigation of anti-gonococcal properties of fatty acids and 
derivatives tested. 
Chemical Class Organic Acid Growth 
inhibition 
Log 
reduction 
at 1 mM 
MBC 
Saturated Fatty Acids Caprylic/Octanoic acid 8:0 No     
Capric Acid/ Decanoic acid 10:0 No     
Undecanoic acid 11:0 Yes No - 0.2   
Lauric acid 12:0 Yes Yes >6 0.75 mM 
Tridecanoic acid 13:0 Yes Yes >6 0.75 mM 
Myristic acid 14:0 Yes No - 1.5   
Pentadecylic acid 15:0 Yes No - 0.5   
Palmitic acid 16:0 No     
Heptadecylic acid 17:0 No     
Stearic acid 18:0 No     
Mono-unsaturated Fatty 
Acids 
Myristoleic acid 14:1  cΔ9 Yes Yes - >6 0.5 mM 
Palmitoleic acid 16:1 cΔ9 Yes Yes - >6 0.5 mM 
Oleic acid 18:1 cΔ9 Yes No - 1.0   
Elaidic acid 18:1 tΔ9 Yes No - 0.5   
Petroselinic acid 18:1 cΔ6 No     
trans-Vaccenic acid 18:1 tΔ11 No     
cis-Vaccenic acid 18:1 cΔ11 No     
Erucic acid 22:1 cΔ13 Yes No - 0.0   
Poly-Unsaturated Fatty 
Acids 
Sorbic acid 6:2 tΔ2,4 No     
Linoleic acid 18:2  cΔ9,12 Yes No - 1.6   
Linolenic acid 18:3 cΔ9,12,15 Yes Yes - >6 0.5 mM 
Arachidonic Acid 20:4  cΔ 5,8,11,14 Yes NT   
Monoglycerides 1-Octanoyl-rac-Glycerol (C8MG) Yes No - 0.0   
Monocaprin (C10MG) Yes Yes - >6 0.5 mM 
Monolaurin (C12MG) Yes No - 3.4   
Monomyristin (C14MG) Yes No - 0.6   
Dicarboxylic Acids Succinic acid No     
Adipic acid No     
Pimelic acid  No     
Suberic acid  No     
Azelaic acid  No     
Sebacic acid No     
Ricinoleic acid Ricinoleic acid Yes No - 3.5   
Esters Isopropyl myristate No     
Isopropyl palmitate No     
Fatty Acid Sodium Salt Sodium dodecanoate Yes Yes - >6 0.75 mM 
Sodium myristate Yes No - 0.5   
  
 
Figure 2.5 Individual log reduction results of the nine N. gonorrhoeae isolates when tested against 
the unsaturated carbon-chain drug candidates. (A) Myristoleic acid log reductions. (B) Palmitoleic 
acid log reductions. (C) Linolenic acid log reductions. The error bars represent the standard 
deviation over the duplicate experiments. Note that HPA-2 and HPA-3 had decreased susceptibility 
to palmitoleic acid and linolenic acid.    
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Figure 2.6 Individual log reduction results of the nine N. gonorrhoeae isolates when tested against 
the saturated carbon-chain drug candidates. (A) Lauric acid log reductions. (B) Tridecanoic acid log 
reductions. (C) Monocaprin log reductions. (D) Sodium dodecanoate log reductions. The error bars 
represent the standard deviation over the duplicate experiments.  
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Figure 2.7 Summary of log reduction assays conducted in culture medium. The results shown are 
mean log reductions with standard deviations for each of the seven candidates assayed against nine 
different gonococcal isolates. (A) Results for the unsaturated carbon chain fatty acids. (B) Results 
for the saturated-carbon chain fatty acids and fatty acid derivatives. The maximum value for the log 
reduction was six, so samples at this value effectively killed all bacteria in the sample. The error 
bars for some samples cover over 2 log10, this demonstrates the variation of susceptibility between 
isolates. 
  
Chapter 2 – Identification of possible drug candidates 
70 
 
 
 
 
 
 
 
 
 
Figure 2.8 Summary of repeated log reduction assays of linolenic acid. Comparison of linolenic acid 
log reductions of two clinical isolates tested in triplicate against mean of all other gonococcal 
isolates (n=7). Error bars represent positive Standard Deviation. The susceptibility to linolenic acid 
appeared to be highly variable as demonstrated by size of the error bars of isolate HPA-4. The 
reason for this variation is unknown but may be due to the state of the bacterial suspension before 
testing. 
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2.3.3 BCOP test 
The corneas primary function is to protect eye. This means that it is in fact impermeable to many 
substances. The stroma in particular will not allow lipids to permeate through the cornea. The 
fluorescein dye as well does not permeate the cornea making it ideal to assess corneal damage as 
any increase in permeability is due to tissue damage of the outer layers of the cornea. 
Each of the seven drug candidates were tested on three separate occasions. Photographs of the 
post-exposure eye balls, fluorescein staining and histology of the cornea are shown in Figure 2.9 to 
Figure 2.18. The mean cumulative score of each of the compounds and the controls are shown in 
Figure 2.19. As expected, the sodium hydroxide and acetone controls caused significant tissue 
damage to the cornea. The sodium hydroxide control caused visible opacity of the cornea that could 
be viewed even before fluorescein staining. Post-staining showed that the fluorescein was able to 
penetrate the cornea indicating extensive corneal tissue damage. The acetone control caused less 
marked opacity which was only visible pre-staining via close examination.  
The eyeballs which were exposed to the seven candidates on the other hand were similar to the 
negative control. These had no visible opacity and had little fluorescein permeability. However, 
tridecanoic acid, linolenic acid, monocaprin and sodium dodecanoate did give a small amount of 
fluorescein staining around where the rubber application ring was placed. With tridecanoic acid, 
and sodium dodecanoate this only occurred in one of the three experiments but twice for linolenic 
acid and monocaprin. This damage could have been caused when removing the application ring and 
the mean BCOP cumulative score of these four candidates was still lower than 0.5 which means 
they are classed as non-irritant. 
2.3.4 Histological examination of bovine corneas 
The bovine corneas from all tested eyeballs were removed and prepared for histological 
examination by H&E staining. Histological examination of the sodium hydroxide and acetone 
samples were also completed to show tissue damage caused by strong and moderate irritant. These 
two controls had different cytopathic effects (see Figure 2.9 to Figure 2.18). The sodium hydroxide 
caused a breakdown in the epithelial layer integrity with the layer become thinner, more condensed 
with more intensive haematoxylin staining. Cellular structures were also hard to make out in 
comparison to the negative control. The epithelial layer had also detached from the stroma in 
places and was completely absent in other places. 
The sodium hydroxide control also caused stromal swelling with an observed increased thickness 
in comparison with non-treated sections of the cornea and in relation to negative controls. 
However, this was only an observation and not proven statistically as stroma thickness varies 
greatly between animals. In contrast the acetone control did not cause epithelial layer detachment. 
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The main cytopathic effect of exposure to the acetone to the epithelial cell types was cytoplasmic 
vasuolation predominantly in basal and wing cells. There was none of these cytopathic effects seen 
in any of the slides of the seven tested candidates. The test samples appear identical to the negative 
controls. 
2.3.5 HET-CAM 
 The candidates were applied to CAMs and left for 5 minutes. The samples were all tested at a 
concentration of 1 mg/L. This would give a concentration range from 3.6 mM for linolenic acid to 5 
mM for lauric acid. As all candidates were totally bactericidal at a concentration of 1 mM, the testing 
concentration would demonstrate the safety of the candidates. Concentrations higher than this 
could not be used as the candidates would not be soluble at higher concentrations and even 
dispersal of the candidate would not be achieved. 
Photographs of the CAM before exposure and at each time point for all candidates are given 
Appendix 1.1-1.11 but a summary of pictures are given in Figure 2.20. The cumulative scores of all 
the controls and test candidates are given in Figure 2.21. Sodium hydroxide produced the most 
notable effect upon the CAM with hyperaemia and haemorrhaging seen within the first 30 seconds. 
The acetone also caused hyperaemia and haemorrhaging in the first 30 seconds but not to the same 
extent as the sodium hydroxide and did not cause any coagulation. Sodium hydroxide caused 
coagulation but only after the two minute time-point. Propylene glycol was a good control as it only 
caused tissue damage at the 2 minute time-point onward. None of the candidates caused any visible 
tissue damage to the CAM over the five minute exposure time.  
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Figure 2.9 Bovine corneal opacity and permeability test results for 0.5 M sodium hydroxide. (A) 
Photograph of the eyeball after the exposure. The cornea appears completely opaque. (B) 
Photograph of the eye after fluorescein staining under a cobalt blue filter light. The fluorescein has 
completely penetrated into the cornea indicating extensive damage. (C and D) Photomicrographs 
of H&E stained section of exposure site. The bars in the bottom left hand corner of each panel are 
a 100 µm bar. The corneal epithelial layer has become thinner and has detached from the stroma 
in places. 
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Figure 2.10 Bovine corneal opacity and permeability test results for acetone. (A) Photograph of the 
eye ball after the exposure. The cornea appears slightly opaque. (B) Photograph of the eye after 
fluorescein staining under a cobalt blue filter light. The fluorescein has penetrated into the cornea 
indicating loss of integrity. (C and D) Photomicrographs of H&E stained section of exposure site. The 
bars in the bottom left hand corner of each panel are a 100 µm bar. Cell of corneal epithelial layer 
now have vacuoles present.  
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Figure 2.11 . Bovine corneal opacity and permeability test results for saline. (A) Photograph of the 
eye ball after the exposure. The cornea appears normal. (B) Photograph of the eye after fluorescein 
staining under a cobalt blue filter light. The fluorescein has been washed off and couldn’t penetrate 
the cornea. (C and D) Photomicrographs of H&E stained section of exposure site. The bars in the 
bottom left hand corner of each panel are a 100 µm bar. Cell of corneal epithelial layer look normal. 
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Figure 2.12 Bovine corneal opacity and permeability test results for lauric acid. (A) Photograph of 
the eye ball after the exposure. The cornea appears normal. (B) Photograph of the eye after 
fluorescein staining under a cobalt blue filter light. The fluorescein has been washed off and 
couldn’t penetrate the cornea. (C and D) Photomicrographs of H&E stained section of exposure site. 
The bars in the bottom left hand corner of each panel are a 100 µm bar. Cell of corneal epithelial 
layer look normal.  
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Figure 2.13 Bovine corneal opacity and permeability test results for tridecanoic acid. (A) Photograph 
of the eye ball after the exposure. The cornea appears normal. (B) Photograph of the eye after 
fluorescein staining under a cobalt blue filter light. The fluorescein has been washed off and 
couldn’t penetrate the cornea. (C and D) Photomicrographs of H&E stained section of exposure site. 
The bars in the bottom left hand corner of each panel are a 100 µm bar. Cell of corneal epithelial 
layer look normal. 
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Figure 2.14 Bovine corneal opacity and permeability test results for myristoleic acid (14:1). (A) 
Photograph of the eye ball after the exposure. The cornea appears normal. (B) Photograph of the 
eye after fluorescein staining under a cobalt blue filter light. The fluorescein has been washed off 
and couldn’t penetrate the cornea. (C and D) Photomicrographs of H&E stained section of exposure 
site. The bars in the bottom left hand corner of each panel are a 100 µm bar. Cell of corneal 
epithelial layer look normal.  
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Figure 2.15 Bovine corneal opacity and permeability test results for palmitoleic acid (16:1). (A) 
Photograph of the eye ball after the exposure. The cornea appears normal. (B) Photograph of the 
eye after fluorescein staining under a cobalt blue filter light. The fluorescein has been washed off 
and couldn’t penetrate the cornea. (C and D) Photomicrographs of H&E stained section of exposure 
site. The bars in the bottom left hand corner of each panel are a 100 µm bar. Cell of corneal 
epithelial layer look normal.  
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Figure 2.16 Bovine corneal opacity and permeability test results for linolenic acid (18:3). (A) 
Photograph of the eye ball after the exposure. The cornea appears normal. (B) Photograph of the 
eye after fluorescein staining under a cobalt blue filter light. The fluorescein has been washed off 
and couldn’t penetrate the cornea. (C and D) Photomicrographs of H&E stained section of exposure 
site. The bars in the bottom left hand corner of each panel are a 100 µm bar. Cell of corneal 
epithelial layer look normal.  
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Figure 2.17 Bovine corneal opacity and permeability test results for monocaprin (10:0MG). (A) 
Photograph of the eye ball after the exposure. The cornea appears normal. (B) Photograph of the 
eye after fluorescein staining under a cobalt blue filter light. The fluorescein has been washed off 
and couldn’t penetrate the cornea. (C and D) Photomicrographs of H&E stained section of exposure 
site. The bars in the bottom left hand corner of each panel are a 100 µm bar. Cell of corneal 
epithelial layer look normal.  
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Figure 2.18 Bovine corneal opacity and permeability test results for sodium dodecanoate (12:0Na). 
(A) Photograph of the eye ball after the exposure. The cornea appears normal. (B) Photograph of 
the eye after fluorescein staining under a cobalt blue filter light. The fluorescein has been washed 
off and couldn’t penetrate the cornea. (C and D) Photomicrographs of H&E stained section of 
exposure site. The bars in the bottom left hand corner of each panel are a 100 µm bar. Cell of 
corneal epithelial layer look normal.  
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Figure 2.19 Summary of the cumulative BCOP scores of the seven selected candidates and the 
controls. Error bars represent standard deviation (n=3). Abbreviations are; lauric acid (12:0), 
tridecanoic acid (13:0), myristoleic acid (14:1), palmitoleic acid (16:1), linolenic acid (18:3), 
monocaprin (12:0MG), and sodium dodecanoate (12:0Na). 
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Figure 2.20 Example photographs from HET-CAM. Photographs on the left were taken before 
exposure and the ones on the right were taken of the same spot five minutes after exposure. The 
top three pictures are positive controls are cause hyperaemia and haemorrhaging at the site of 
application. The tested candidates (bottom picture is an example) did not cause a reaction. 
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Figure 2.21 HET-CAM results. A graph of the cumulative scores of controls and test substances from 
the HET-CAM. The positive controls caused visible damage to the CAM but the negative control and 
samples did not. All samples were tested in triplicate. Abbreviations are; lauric acid (12:0), 
tridecanoic acid (13:0), myristoleic acid (14:1), palmitoleic acid (16:1), linolenic acid (18:3), 
monocaprin (10:0MG), and sodium dodecanoate (12:0Na). 
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Figure 2.22 Comparison of red blood cell lysis assay results against minimum bactericidal 
concentration of the drug candidates. H50 values are defined by the concentration range to lyse 50 
% of the red blood cells. Two candidates had MBC greater than their H50 results (16:1 and 18:3), all 
others had H50 greater than their MBCs. Abbreviations are; lauric acid (12:0), tridecanoic acid (13:0), 
myristoleic acid (14:1), palmitoleic acid (16:1), linolenic acid (18:3), monocaprin (12:0MG), and 
sodium dodecanoate (12:0Na). 
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Figure 2.23 Log reductions in simulated tear fluid with or without calcium. Calcium ions (CaCl2, 1 
mM) present in the simulated tear fluid inactivated the antimicrobial effects of lauric acid, 
tridecanoic acid, and sodium dodecanoate. The calcium ions also effected palmitoleic acid and 
linolenic acid but to a lesser extent. Myristoleic acid and monocaprin were unaffected. 
Abbreviations are; lauric acid (12:0), tridecanoic acid (13:0), myristoleic acid (14:1), palmitoleic acid 
(16:1), linolenic acid (18:3), monocaprin (10:0MG), and sodium dodecanoate (12:0Na). Error bars 
represent one standard deviation based on two separate experiments. 
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2.3.6 RBC lysis assay 
The RBC lysis assay gave considerably different results to the HET-CAM and BCOP. The RBC lysis 
assay results are shown in Figure 2.22. The larger unsaturated fatty acids, palmitoleic acid and 
linolenic acid, required the lowest concentrations to cause haemolysis in 50 % of the RBCs. The best 
performer was tridecanoic acid which didn’t cause any haemolysis even at the highest 
concentration tested. Surprisingly, the twelve carbon-chain unsaturated sodium salt gave very 
similar results to that of lauric acid. Also presented in Figure 2.22 are the MBC values of each of the 
candidates. This allows the comparison of the anti-bacterial properties of the candidate to possible 
ocular irritation effects. It is clear that tridecanoic acid, myristoleic acid and monocaprin performed 
the best with H50 values over their MBC values. 
2.3.7 Log reductions of selected fatty acids in simulated tear fluid 
The anti-gonococcal properties of the seven selected fatty acids were tested in the simulated tear 
fluid. The addition of 1 mM of lauric acid, tridecanoic acid, or sodium dodecanoate gave no 
reduction in cell number after exposure, a complete reversal from when they were tested in culture 
medium (see Figure 2.23). Palmitoleic acid and linolenic acid were also affected but to a lesser 
extent. Upon addition of some the candidates, lauric acid, tridecanoic acid, or sodium dodecanoate 
in particular, it was observed that the clear simulated tear fluid would turn cloudy. This cloudiness 
was obviously the fatty acids precipitating out of solution when added to the simulated tear fluid. 
After some research calcium ions were identified as the possible cause.  The simulated tear fluid 
contains a concentration of 1 mM CaCl2. A batch of simulated tear fluid was made omitting calcium 
chloride and the anti-gonococcal properties were completely restored (Figure 2.23). All candidates 
caused complete killing in the simulated tear fluid without calcium chloride but only myristoleic 
acid and monocaprin caused complete killing in the full simulated tear fluid. 
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2.4 Discussion 
2.4.1 Selection of fatty acid candidates 
During the course of this study, thirty-seven fatty acid or fatty acid derivatives have been screened 
for anti-gonococcal properties. From this, seven were selected for further analysis. These 
candidates were lauric acid, tridecanoic acid, myristoleic acid, palmitoleic acid, linolenic acid, 
monocaprin and sodium dodecanoate. All these candidates demonstrated they possess powerful, 
fast-acting bactericidal activity against N. gonorrhoeae. However, further log reductions on 
European clinical isolates showed that two of these isolates were not completely inactivated by 1 
mM palmitoleic acid (16:1) or linolenic acid (18:3). This may suggest that these two isolates (HPA 3 
and HPA 4) have protection mechanisms against these two fatty acids. The exact mechanism for 
this increased tolerance to these fatty acids is not known and was not investigated further. 
However, as the farAB-encoded efflux pump of N. gonorrhoeae mediates resistance certain long 
chain fatty acids such as linoleic acid (18:2) and palmitic acid (16:0), the increased tolerance maybe 
linked to this efflux system [148]. The log reduction for these isolates against linolenic acid was still 
between 3 and 4 log10 so they still have good activity against N. gonorrhoeae. Also, the two isolates 
were still susceptible to other fatty acids. 
2.4.2 Irritation assays 
The seven candidates were tested in three irritation assays, all candidates were classed as non-
irritants by HET-CAM and BCOP. However, for the RBC lysis assay, the H50 value of palmitoleic acid 
and linolenic acid was lower than their MBC. These two values are not directly comparable as the 
methods they use are very different. The log reductions (used to measure the MBC) uses an 
incubation time of two minutes while the RBC lysis assays H50 value incubates the drug candidate 
with the RBCs for one hour. If a liquid dosage form is used in formulation then the drug may only 
be in contact with the ocular surface for a few minutes so the one hour incubation time of the RBC 
lysis assay is not representative. The RBC lysis assay was performed in accordance to EURL ECVAM 
guidelines. However, EURL ECVAM recommends two different protocols for performing the assay 
[225, 227]. The protocol used in this study uses an incubation time of 1 hour at room temperature 
with shaking while another protocol uses an incubation time of 10 minutes at room temperature 
with shaking. The protocol selected for this study was preferred as it gave more experiment detail 
on use of a vehicle (DMSO was used in these experiments) to aid the solubility of candidates. Some 
researchers have chosen to use this protocol but reduce the incubation time [214]. However, as 
these two fatty acids that performed poorly in the RBC lysis assay also had some form of tolerance 
in some gonococcal isolates, they were excluded from further consideration. 
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2.4.3 Testing in simulated tear fluid 
Testing in simulated tear fluid revealed a problem with the use of the saturated fatty acids 
candidates (lauric acid, tridecanoic acid, and sodium dodecanoate). These fatty acids were 
completely ineffective in the presence of calcium ions. On further research, these metal ions would 
cause dimerization of fatty acid molecules forming a highly hydrophobic molecule that would 
precipitate out of solution. This would appear to make them completely ineffective against 
gonococcal cells. The inhibition of the antimicrobial effects of fatty acids by calcium ions has also 
been report previously but could be limited by lowering the pH [164, 181]. Lowering the pH could 
be used in a liquid dosage form but would not be suitable for any formulation that would have 
extended contact time with the ocular surface. Why mainly saturated carbon-chain fatty acids were 
affected is unknown. The effect on unsaturated carbon chain fatty acids is curious, the worst 
affected was linolenic acid while myristoleic acid was not affected at all. At first glance there 
appears to be some correlation between the carbon chain length of the unsaturated fatty acids and 
its effectiveness in the presence of calcium ions with longer chains worse affected than short chains. 
As monocaprin has no carboxylic acid, this candidate was not affected by the presence of the 
calcium. 
It is possible that a chelating agent such as ethylenediaminetetraacetic acid (EDTA) or the more 
calcium specific ethylene-glycol tetraacetic acid (EGTA) could reverse the effect of the calcium. 
EDTA is not an uncommon excipient in ophthalmic formulations but its concentration is limited to 
0.1 % (equivalent to 3.4 mM). Further testing would be required to determine whether this 
concentration is sufficient to reverse the effects of the calcium present in tear fluid. Also, 
consideration must be given to what other effects the chelating agent would have; would it 
increased irritation or affect the eyes natural defences against bacterial infection? These points 
would have to be addressed if they were to be included in any formulation. 
2.4.4 Selection of drug candidates for further analysis 
Initially seven candidates that were selected based on antibacterial properties. However, it soon 
became clear that palmitoleic acid and linolenic acid should be withdrawn from further selection. 
These both performed poorly in the RBC lysis assay and did not cause total killing in some isolates. 
Also linolenic acid, having three unsaturated bonds in its carbon chain is more prone to oxidation 
reactions than other candidates and is therefore less stable. During testing the stock for this fatty 
acid was stored at -20 °C and was regularly replaced. The activity in simulated tear fluid has also 
raised problems with some candidates. All candidates apart from monocaprin and myristoleic acid 
were affected by the presence of calcium. As there are candidates that are unaffected by the 
calcium it would be easier to examine these candidates rather than trying to remove the free 
calcium ions from the tear fluid. 
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This means that only two candidates remain: myristoleic acid and monocaprin. Out of these two 
remaining candidates, two main factors were considered for their inclusion into a formulation. 
These were: cost and amount of literature on bactericidal activity. The cost of myristoleic acid is 
£511 per gram [228]. The cost of monocaprin is £57.70 per gram [229]. Monocaprin has already 
been reported to have strong anti-gonococcal properties but myristoleic acid has never been tested 
[167]. However, myristoleic acid was found to be ineffective against C. trachomatis, while 
monocaprin has again been shown to be bactericidal [166]. This means that monocaprin would 
have the advantage that it is active against other causes of ophthalmia neonatorum. Monocaprin 
has also reportedly been used to make hydrogel based formulations and has been proposed for the 
treatment of cold sores and as protection against sexually transmitted infections [230-232]. 
Monocaprin based hydrogels have been used in a mouse model for protection against herpes 
simplex-2 virus infection [231]. In that study no irritation was observed of the vaginal mucosa on 
application of the hydrogel.  
The mode of action of the monocaprin and myristoleic acid is unknown but it has been suggested 
to be cell membrane disruption (see 1.2.5) [165, 167, 174]. This may help to explain why the 
candidates caused lysis of RBCs. However, some candidates had MBCs far below their H50 result. 
This demonstrates that there exists some level of selective toxicity in these candidates. This is a 
valid target for inhibition or cidal activity against bacteria but is not the best [233]. For example, 
polymyxin B is an antimicrobial that targets the cell membrane of bacteria that is very effective 
against Gram negative bacteria (in particularly Pseudomonas aeruginosa) [234, 235]. It is usually 
used as a drug of last resort; this is because of the similarities between the bacterial and eukaryotic 
cell membranes. However, this mode of action would theoretically also have the added advantage 
that is less likely that the bacteria could develop resistance in comparison to antimicrobials that act 
on single targets inside the cell. One possible way it could develop resistance is if modification to 
existing efflux systems (e.g. mtrCDE or farAB encoded systems) enabled the transport out of the 
cell [148, 236]. Despite N. gonorrhoeae strain NCCP11945 possessing these efflux systems, in this 
case it was unable to transport the fatty acid outside the cell quick enough to prevent membrane 
lysis. However, use of these efflux pumps will be investigated further in Chapter 5. 
2.4.5 Further work 
To fully establish whether either monocaprin and/or myristoleic acid can be used in a formulation 
of an ophthalmic formulation to prevent ophthalmia neonatorum, the safety has to be evaluated. 
Three irritation assays have been competed in this study but an in vivo test will have to be 
conducted to be sure that no irritation occurs. There are no doubts that these two candidates have 
powerful antimicrobial properties that will not be inactivated by tear fluid but their effectiveness 
on the surface of the eye or in an ointment needs to be fully evaluated. However, this study has 
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demonstrated that there are fatty acid candidates with the potential to be developed into 
alternative prophylaxis options to help prevent ophthalmia neonatorum. 
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3.1 Introduction 
3.1.1 Preformaulation studies 
Preformulation studies are fundamental to drug development [237]. Once a drug has been 
discovered then preformulation is the next step in development. This can comprise of literature 
searches on use of that particular drug candidate or similar compounds in relation to: degradation 
processes, any published cases of adverse effects relevant to the drug, bioavailability, 
pharmacokinetics and formulation of similar compound [238]. As well as these literature searches, 
experiments can also be done to initially assess the physical and chemical properties of the drug 
candidate such as: 
I. Solubility – solubility in different solvents, dissociation constant (pKa), salt formation, 
partition or distribution coefficient (log P or log D) and pH solubility profile. 
II. Permeability – permeability of the drug candidate to ensure that the drug can be delivered 
to the target site. 
III. Physical properties – Solid state properties like solid form and melting temperature. 
IV. Stability – Stability of drug candidate in pure form or with other excipients, pH stability 
profile and photo-stability are studied. 
These properties will aid formulation of the drug into a form which ensures it can be delivered to 
the point of action in an active form with no toxic effects or that harmful products have not been 
built up over the storage life of the drug-form.  
First consideration must be given to site of action. Our aim is to kill the bacteria on the ocular 
surface before they can infect the eye. The ophthalmic formulation would be given in the first 
hour(s) of life. It therefore must reach all the areas of the eye where the bacteria are present at 
that time. If the bacteria mix with the tear fluid this would mean that they are present everywhere 
where the tear fluid can reach. That would mainly be the corneal surface, conjunctiva and would 
also include tear drainage ducts such as the inferior lacrimal punctum. Any formulation must cover 
these areas for long enough for the active drug to kill any of the gonococcal cells present. During 
the time of birth to the time of applying the prophylaxis the gonococcal cells may have invaded the 
first layer of epithelial cells of the cornea. The ability of the active drug to treat these cells will be 
fully addressed by in vitro models in Chapter 4. So, in the case of our study, the drug is applied 
directly to the ocular surface and has to kill bacteria on this surface, it has to mix with the tear fluid 
to kill all the bacteria in the tear fluid and be able to reach all the areas in contact with the tear 
fluid. For this reason, delivery of sufficient active drug to the target site is not so much of a problem 
as to say a drug that has to reach the vitreous humour as the drug doesn’t have to permeate 
through complex tissue structures such as the stroma. 
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3.1.2 Physical and chemical properties of monocaprin 
Monocaprin is a monoglyceride (sometimes referred to as monoacylglycerols) which are made up 
of a single fatty acid attached to a glycerol molecule by an ester bond (see Figure 3.1.A). In the case 
of monocarpin, this fatty acid has a saturated carbon chain with a length of ten carbons. The 
empirical formula of monocaprin is C13H26O4 and it has a molecular weight of 246.34 g/mol. Other 
synonyms for monocaprin include 1-decanoyl-rac-glycerol and glycerol monocaprate. The synonym 
1-decanoyl-rac-glycerol describes more accurately that the monocaprin used in this study has the 
fatty acid chain on the first carbon of the glycerol molecule as opposed to the second. 2-decanoyl-
rac-glycerol was not tested in this study as it was not readily available from a supplier. Studies of 
monolaurin have demonstrated that there was little observed difference in bactericidal activity 
against Streptococcus pyogenes between the two isomers [239]. 
Just like free fatty acids, monoglycerides have both hydrophobic and hydrophilic regions with the 
fatty acid tail being highly hydrophobic and the ester bond and two hydroxyl groups on the glycerol 
molecule being hydrophilic (see Figure 3.1.A). Monoglycerides are more water soluble than their 
constituent free fatty acids alone. This also means that monoglycides have a higher hydrophilic-
lipophilic balance (HLB). Figure 3.1.B shows a table which contains the values (calculated via Davies’ 
method [240]) of each of the original seven drug candidates from Chapter 2. With the exception of 
sodium dodecanoate, monocaprin has the highest HBL value. This suggests that it is more water 
soluble than most of the other original candidates. This could potentially be an advantage when 
formulating an eye drop or other aqueous based ophthalmic formulation.  
Monocaprin is a waxy solid powder at room temperature. It has a melting temperature of around 
51-55 °C [241]. It is poorly water soluble but highly soluble in ethanol [241]. As seen in Chapter 2, 
monoglycerides are not prone to inactivation by calcium or magnesium ions like fatty acids. 
However, the ester bond could be attacked by a strong base (such as sodium hydroxide) with the 
hydroxide anion cleaving the ester bond forming glycerol and a fatty acid metal salt as products. 
This process is called saponification and is used in industry to make soap [242]. As well as bases, 
esters bonds are also prone to hydrolysis. The rate that this occurs in water is very slow (via non-
enzymatic hydrolysis). However, the process can be sped up with either the use of lipase enzymes 
or even a weak acid. This process would split the monoglyceride back into its fatty acid and glycerol 
constituents.  
3.1.3 Analytical methods for detection and quantification of monocaprin 
An analytical method for detection and quantification of a drug candidate is an important part 
preformulation. It can be used to obtain information of the chemical properties of the candidate 
such as saturation solubility, Log P and Log D. It can also aid in estimating drug permeability through 
biological barriers, measure chemical breakdown in stability trails [243] and ensure drug uniformity 
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of dosage units [244]. As well as the active drug, methods of quantification of the drugs possible 
breakdown produces for possible drug impurities are required [245]. 
There are three published analytical methods for the direct detection of monocaprin. All of these 
methods have the advantage over other indirect methods what they don’t require prior 
derivatisation before analysis. These methods have been summarised in Error! Reference source 
not found.. Two of these methods [230, 246] have already been used for development of 
pharmaceutical products. The saturated fatty acid carbon chain means that the molecule would 
have poor UV absorbance at anything but the lowest UV wavelengths. For this reason Chu and co-
workers [247] developed a high performance liquid chromatography (HPLC) method based on mass 
spectrometry detection. Their method is claimed to be able to detect monoglycerides down to 1–
30 ppm.  
3.1.4 Monocaprin in pharmaceuticals 
Pharmaceutical products containing monocaprin have been proposed previously. The first 
proposed product developed was a hydrogel to protect against sexually transmitted infections 
[230-232, 248]. This formulation used monocaprin at a concentration of 20 mM (approximately 
equivalent to 0.5 % w/w). The authors originally tested various co-solvents and polymer mixes. 
From the solvents, Glycofurol 75 (tetraglycol) produced the best anti-microbial effects. The two 
blends of polymers used were either NaCMC and PVP (2 % (w/w) and 1 % (w/w)) or carbomer and 
HPMC (0.5 % (w/w) and 1 % (w/w)). From these polymers, the carbomer and HPMC mix gave the 
fastest release profile [230]. The fee status of the patent for this formulation is classified as lapsed 
which suggests that the patent is no longer valid [248]. 
The second pharmaceutical products is a virucidal cream which has been proposed to be a 
treatment for cold sores [246, 249]. The oil in water emulation also uses monocaprin at a final 
concentration 20 mM. The aqueous phase contains 5 % propane-1,2-diol and 1 % Polysorbate 20 
with the monocaprin and this is mixed with the oil phase to create an oil in water emulsion. 
Formulations with oil phases comprising 2.5, 5, 7.5 or 10 % (v/v) were tested in conjunction with 
varying amount the polymer carbomer. The smaller volumes of oil phases gave better release of 
the monocaprin with 2.5 % carbomer performing the best with greater than 40 % release within 50 
minutes. Also, 0.33 % carbomer gave a more rapid drug release profile than 0.5 %. 
Monocaprin, as well as other fatty acids and monoglycerides, has also been suggested for the use 
of disinfecting contact lenses [250]. Details of concentrations and other excipients are not described 
but the patent does suggest that Tween® 80 could be used in the finalised formulation. No contact 
lens solution products containing monocaprin have ever come to market and the patent status is 
lapsed. 
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Use of monocaprin to kill Helicobacter have been described in the literature [170-172, 251]. A 
couple of patents also covers their use in pharmaceutical products. The earliest of the patents is 
very non-descript and gives very little detail [252]. This patent lapsed in 2011. The second patent 
gives more detail and combines the active fatty acid or monoglyceride with a proton pump inhibitor, 
solubilising agent, density modifier and a viscosity enhancer [253]. The preferred solubilising agent 
is a non-ionic surfactant (Tween® 20 or 80 suggested), named possible viscosity enhancers include 
CMC and HPMC and peppermint oil is the preferred density modifier. 
3.1.5 Potential for ophthalmic formulations 
There are two simple formulation options that could be proposed first. A liquid dosage form and a 
semi-solid dosage form. Currently, the recommended prophylaxis is in the form of a semi-solid 
ointment [31]. Therefore this dosage form maybe preferred by hospitals using the current 
prophylaxis. The application process between the use of eye drops and ointment on newborns is 
similar as both are applied under the lower eyelid [254, 255]. Therefore, a change in the dosage 
form shouldn’t cause too much disruption. In terms infection control, single-use applicators maybe 
preferred by healthcare workers. Both dosage forms would be compatible with this form of 
packaging. Single-use containers are not required to contain extra antimicrobials but still must meet 
sterility requirements and pass testing for leakages and presence of metal particles [256]. This 
means that both dosage forms would be suitable to use as an ophthalmia neonatal prophylaxis and 
both should be investigated.  
3.1.6 Ophthalmic semi-solid dosage form 
The use of semi-solid dosage forms is common in anti-inflammatory and antimicrobial ophthalmic 
products [257]. The base of the semi-solid ointment is primarily petrolatum [258]. As stated in 
Chapter 1, it has many advantages over liquid dosage forms, mainly that it is retained in the eye for 
a much longer period improving ocular drug levels [259]. White Petrolatum USP is usually preferred 
for ophthalmic formulation but even within this type the grade of Petrolatum can vary significantly 
in terms of colour, clarity and hardness [258]. The addition of mineral oil, surfactants and/or 
preservatives can often lower the viscosity and change other physical properties. Due to the lack of 
water, microbial contamination would be less likely but still possible [260]. The ointment base is a 
non-aqueous environment, so lack of aqueous solubility would not be a problem. Furthermore, 
drug breakdown by non-enzymatic hydrolysis would not be an issue. This dosage form needs to be 
explored further as a possible formation option. 
3.1.7 Use texture profile analysis in semi-solid dosage form development 
Texture profile analysis is a test of the physical properties of a product. The product could be a food 
substances, such as, for example, ice creams [261], cheeses [262] or bread product [263, 264]. 
Although texture profile analysis is mainly done in the food industry, it has also been used in the 
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development of pharmaceutical products. For example, testing varying concentration of polymers 
in polymeric semi-solid dosage forms [265, 266]. In the testing of pharmaceutical semi-solid dosage 
forms, the main texture properties examined are cohesiveness, adhesiveness, and hardness [267]. 
These can be estimated by texture profile analysis where the force taken to insert and withdraw a 
probe a set distance into the semi-solid is measured. An example of typical output data produced 
in such an experiment is give in Figure 3.2. The maximum force to enter the semi-solid (positive 
peak 1 height), is used to measure the hardness. The total force used to enter the semi-solid 
(positive peak 1 area), is a measure of the cohesiveness and the total force used to withdraw from 
the semi-solid (negative peak 1 area) used to measure adhesiveness. The testing procedure is 
usually repeated after a rest of a few seconds and a second positive and negative peak produced 
as further properties can be measured by the comparing the differences between the initial and 
repeated test cycles.  
As mentioned above, the physical properties of ointments varies depend upon the type of White 
Petrolatum used and what other excipients are used in the ointment base. It should be possible to 
imitate the physical properties of an unknown ointment by comparing its texture profile analysis 
against a panel of known blends of excipients. These blends could be fine-tuned to replicate the 
cohesiveness, adhesiveness, and hardness of the unknown ointment. 
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Figure 3.1 Hydrophilic lipophilic balance of monocaprin. (A) Breakdown of Davies' hydrophilic 
lipophilic balance values for monocaprin with calculations of overall value. (B) Table of Davies’ 
hydrophilic lipophilic values of monocaprin and all of the other first original seven drug candidates. 
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Table 3.1. High performance liquid chromatography methods for detection and quantification of monocaprin 
 Chu et al. [247] Kristmundsdoättir el al. [230] Thorgeirsdóttir et al. [246] 
Equipment Thermo Accela 1250 system Thermo Separation Products Spectra 
Series P200 with SP4400 autosampler 
Thermo Separation Products Spectra 
Series P200 with SP4400 autosampler 
Column Two Waters Atlantis C18 columns, 
3 µm particle size, 2.1 mm × 150 
mm (run in series) 
Waters µBondapak C18, 10 µm particle 
size, 3.9 × 300 mm column 
Cosmosil C18, 5 µm particle size, 4.6 
mm, 150 mm column 
Detection TSQ Quantum Access MAX mass 
spectrometer 
Spectra Series UV150 detector, 218 nm Spectra Series UV150 detector, 208 nm 
Injection volume 25 µl Not stated Not stated 
Mobile phase Gradient consisting of: (A) water, 
(B) 1 mM ammonium-formate in 
methanol, and (C) 
isopropanol:n-hexane 1:1. 
Isocratic: (A) acetonitrile, (B) water, 
and (C) tetrahydrofuran (57:42:1) 
Isocratic: (A) acetonitrile and (B) water 
(58 : 42) 
Flow rate Variable, 0.25-0.4 ml/min 1.25 ml/min 1.5 ml/min 
Retention time N/A 2.1 min 4.00 min 
Notes Lower limit of 
quantification 1–30 ppm for 
monoglycerides 
Used in development and evaluation of 
moncaprin based hydrogel 
Used in development and evaluation of 
virucidal cream for treatment of cold 
sores 
Pros and cons Pros: highly sensitive 
Cons: requires mass spectrometry 
which can be expensive and more 
difficult to optimise 
Pros: rapid method 
Cons: low sensitive 
Pros: rapid and simple method 
Cons: low sensitive 
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Figure 3.2 Typical texture analysis profile of a single testing cycle of an ophthalmic semi-solid dosage 
form.   
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3.1.8 Ophthalmic liquid dosage forms 
Liquid dosage forms are normally aqueous based but novel oil based liquid dosage forms have been 
described [268, 269]. It is likely that monocaprin will have poor aqueous solubility. More than 40 % 
of new chemical entities developed by the pharmaceutical industry are classed as practically 
insoluble [270]. This can pose a major challenge when formulating products such as ophthalmic 
liquid dosage forms. However, solubility can be improved with the addition certain excipients [271].  
One solution is to add a co-solvent that is miscible with water which can increase solubility of the 
drug [272]. The drug will have to have a high solubility in the co-solvent for it to significantly improve 
solubility in the overall mixture. Use of co-solvents can increase the solubility by several thousand 
times compared to the aqueous solubility of the drug in water alone [273]. The amount of co-
solvent is important, the higher the concentration of co-solvent then the higher the solubility of the 
drug. However, the co-solvent could be an irritant at higher concentrations so guidelines should be 
checked regarding acceptable levels and irritation assays (such as in Chapter 2) should be conducted 
on the finalised formulation. 
3.1.9 Aiding drug solubility in liquid dosage forms 
It is likely that monocaprin will have poor aqueous solubility. More than 40 % of new chemical 
entities developed by the pharmaceutical industry are classed as practically insoluble [270]. This 
can pose a major challenge when formulating products such as ophthalmic liquid dosage forms. 
However, solubility can be improved with the addition of certain excipients [271].  One solution is 
to add a co-solvent that is miscible with water which can increase solubility of the drug [272]. The 
drug will have to have a high solubility in the co-solvent for it significantly improve solubility in the 
overall mixture. Use of co-solvents can increase the solubility by several thousand times compared 
to the aqueous solubility of the drug in water alone [273]. The amount of co-solvent is important, 
the higher the concentration of co-solvent then the higher the solubility of the drug. However, the 
co-solvent could be an irritant at higher concentrations so guidelines should be checked regarding 
acceptable levels and irritation assay (such as in Chapter 2) should be conducted on the finalised 
formulation. 
Micellar solubilisation is term used when a surfactants is used aid drug solubility by forming 
micelles. At low concentrations in an aqueous solution, a surfactant will accumulate at the air-liquid 
interface and lower the surface tension [274]. Once the interface is saturated, any extra surfactant 
will be forced into the bulk of the aqueous phase. This continues until a certain concentration is 
reached where the surfactant molecules form a single layered sphere with hydrophilic regions on 
the outside and the hydrophobic regions pointing inward. This concentration is known as the critical 
micelle concentration. The micelle can then entrap the insoluble drug either inside the micelle or if 
the drug also has amphiphilic properties it can be contained in the surfactant monolayer.  
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Conventional surfactants which are commonly used include polysorbates (Tween 20 and Tween 
80), polyoxyethylated castor oil (Kolliphor EL), lauroyl macroglycerides and mono and di-fatty acid 
ester of low molecular weight [270]. More recently, higher molecular weight surfactants made from 
polymers such as polyethylene glycol (PEG), polyvinylpyrrolidone (PVP),  or Poloxamers (such as 
Pluronic F127 and Pluronic P85) have been used [275, 276]. These have lower critical micelle 
concentration values and are more thermally and kinetically stable [275].  
3.1.10 Viscosity enhancing agents in liquid dosage forms 
In Chapter 1, we discussed briefly about viscosity enhancers used in ophthalmic formulations. In 
this chapter, we will be using two particular types of viscosity enhancers; CMC and HPMC. The role 
of the viscosity enhancer is to increase the viscosity of the formulation to prolong the residence 
time on the ocular surface. However, although highly viscous formulations have better residence 
times, they may increase blinking, lacrimation, hinder drug release and generally be less tolerated 
[277]. This is why it is important to get the viscosity of the formulation right so the drug is released 
at a therapeutic level and maintain this level for long enough to be completely effective. 
Both CMC and HPMC are long chain polymers derived from cellulose. With CMC, carboxymethyl 
groups replace the hydroxyl groups on carbons 2, 3 and 6 of the glucopyranose sugars. In the case 
of HPMC, 2-hydroxypropyl (isopropanol) groups replace these same hydroxyl groups. This is shown 
in Figure 3.3. With CMC, the carboxyl group is often converted to a sodium salt to further increase 
aqueous solubility (NaCMC). The polymer chain length of both polymers can be varied, with longer 
chains used to create stiffer gels. As the polymers are cellulose based they are prone to hydrolysis 
by cellulases that could be produced from a number of sources including bacteria [278]. Both 
polymers have excellent safety records. CMC (E number E466) is commonly used in foods and 
pharmaceutical products such as toothpastes and ophthalmic preparations [279]. Similarly, HPMC 
(E number E464) is also found in foods and pharmaceutical products such as cosmetics as well as in 
paints and adhesives [279].  
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Figure 3.3 Graphical representation of chemical structure of cellulose based polymers CMC and 
HPMC. 
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3.1.11 Aim of this chapter 
In the last chapter, we discovered one drug candidate, which was the monoglyceride monocaprin, 
had fast acting antigoncoccal properties and was deemed by in vitro testing methods, to have low 
ocular irritation potential. There are two main aims of this chapter: the first is further testing of the 
physical and chemical properties of monocaprin to determine its suitability in an ocular formulation 
(preformulation studies) and the second is to develop potential ophthalmic formulations. 
3.2 Materials and methods 
3.2.1 Chemical and reagents 
Monoglycerides: monocaprin, monolaurin and monomyristin were obtained from Tokyo Chemicals 
Industry UK ltd (Oxford, UK). All solvents used in HPLC and solubility testes such as acetonitrile, 
dimethylacetamide (DMAc), ethanol, methanol, propane-1,2-diol and butane-1,3-diol were HPLC 
grade reagents (BDH Chemicals, VWR International). 
For the formulation work, Vaseline (Sigma-Aldrich) was used as petroleum jelly and light (0.84 
g/mL at 25 °C) mineral oil (Sigma-Aldrich) used for to make the ointment base. The polymers for 
the thickened eye drops used carboxymethylcellulose sodium salt (Sigma-Aldrich), medium 
viscosity (400-800 cP, 2 % in H2O at 25 °C) (Sigma-Aldrich) and (Hydroxypropyl)methyl cellulose with 
an average polymer molecular weight of 90,000 (15,000 cP, 2 wt. % in H2O at 20 °C) (Sigma-Aldrich). 
The Polysorbate 20 (BDH Chemicals, VWR International) was used as the surfactant. 
3.2.2 Ultra violet spectrophotometry 
A solution of 1 mg/mg monocaprin was made up in acetonitrile. An aliquot of 2 ml was transferred 
into a quartz UV cuvette and placed in a Varian Cary 100 Scan (Agilent Technologies LDA UK Limited, 
Stockport, Cheshire, UK) UV spectrophotometer. A scan of absorbance in the range of 200-400 nm 
was completed for the sample using acetonitrile as a blank. Data was acquired using Varian Cary 
WinUV Version 3.00 software (Agilent Technologies LDA UK Limited).  
After the initial scan, individual readings at a set absorbance were done on a concentration range 
of monocaprin at 1000, 750, 500, 250, 125 and 62.5 µg/ml. All dilutions were done in acetonitrile. 
The data was inputted into Graphpad 6 software and a regression line produced.  
3.2.3 High performance liquid chromatography 
The HPLC method of Thorgeirsdottir et al. was used as the basis for method development [246]. A 
Perkin Elmer 200 series HPLC system with a series 225 auto-sampler and series 200EP diode array 
detector (UV/VIS) was used in all experiments. Data was acquired using Perkin Elmer TotalChrom 
Workstation (version 6.3.1). A 4.6 X 250 mm C18 column packed with 5 µm Kinetex solid core 
particles (Phenomenex, Macclesfield, Cheshire, UK) was used to analyse samples. An isocratic 
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mobile phase of 80:20 (v/v) of acetonitrile/water was used at a flow rate of 1 ml/min. Samples were 
injected at a volume of 50 µl. Monocaprin was detected by UV absorption at 208 nm. 
3.2.4 Validation 
A stock of 2 mg/ml monocaprin was made in acetonitrile. This was diluted in acetonitrile to 
monocaprin concentrations of 1000, 750, 500, 250, 125 and 62.5 µg/ml. Five injection of each of 
these standards was made on the optimised method followed by five injection of acetonitrile 
(blank).  
For the intra-day and inter-day testing, monocaprin concentrations of 750, 250, 125 and 62.5 µg/ml 
were tested. Three injections of a 1000 µg/ml monocaprin (standard) followed by a blank and then 
a sequence of the test samples with each being tested in triplicate and a standard and blank being 
run after every six injections. 
3.2.5 Limits of detections and quantification 
The limits of detection (LoD) and quantification (LoQ) were determined by a signal-to-noise 
approach. A signal-to-noise ratio of 3:1 was used to determine the LoD and 10:1 used for LoQ [280]. 
3.2.6 Saturation solubility 
Solubility was determined by shaking flask method [281]. Common solvents tested were: 
acetonitrile, ethanol, methanol and water. Solvents that are commonly used in pharmaceuticals 
products and appearing British Pharmacopoeia were also selected: butane-1,3-diol, DMAc, 
propane-1,2-diol and tetraglycol. A given amount of monocaprin known to be above the saturation 
point of the solvent was added to a 100 ml conical flask containing either 5 or 10 ml of the specified 
solvent (5 ml was used for solvents capable to dissolving large amounts of monocaprin). Flasks were 
placed on a shaker at room temperature and shaken for 16-18 hours at 100 rpm. Flasks were left 
at room temperature without shaking for a further five hours. The solutions were passed through 
a 0.22 µm disposable syringe filter (Nalgene) to remove any undissolved monocaprin. Samples that 
required dilution were done so in acetonitrile so that a concentration was within the HPLC 
validation zone was obtained. Monocaprin was quantified using HPLC. Experiments were done in 
duplicate.  
3.2.7 Texture analysis 
Blends of light mineral oil and white petroleum were made by adding 1, 2, 3, 4 or 5 parts light 
mineral oil to 10 parts white petroleum blends. The light mineral oil was mixed into the white 
petroleum on a black pill tile and sheered together using two 30 cm spatulas until an even 
consistency was obtained. To compare these to commercially available ophthalmic ointments, 1 % 
(w/w) chloramphenicol ophthalmic ointment (GoldenEye, Typharm Limited, Norwich, Norfolk, 
UK) was used. 
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Semi-solid samples for texture analysis were first put into 10 ml wide-necked glass vials and packed 
into the bottom of the vial ensuring no air bubbles were present. The vials were placed on a Stable 
Microsystems TA.XTplus Texture Analyser testing stage and clamped into position. The testing 
probe was positioned just above the surface of the sample and two testing cycles automatically run 
one after the other. Each sample was tested five times, after each reading the sample was removed 
and the sample surface flattened before testing again. Stable Microsystems Exponent Lite (version 
6.1.4.0) software was used to obtain data and to combine each of the five replicate into 
representative plots. 
3.2.8 Production of ophthalmic ointments 
Monocaprin was warmed on a heat-block in a centrifuge tube to 55 °C until melted. This was mixed 
with the light mineral oil (warmed to 37 °C to prevent precipitation of monocaprin) and added to 
the required amount of white petroleum on a black pill tile. The mineral oil was mixed and then 
sheered into the white petroleum using two 30 cm spatulas until an even consistency was obtained 
and the drug was evenly distributed throughout the ointment. Ointments were stored in 60 ml 
plastic pots (Sterilin Ltd) at room temperature until required. 
3.2.9 Production of CMC polymer based thickened eye drops 
A monocaprin stock of 100 g/L in propan-1,2-diol was made. The required amount of CMC powder 
was added to half the required final volume of sterile deionised water (for example, if 100 g 
formulation wanted, then 50 ml of water added) in a sterile conical flask and placed on an orbital 
shaker at 200 rpm overnight at room temperature. A double concentrate of Polysorbate 20 was 
made up in sterile deionised water. The monocaprin stock was then added at double the required 
overall concentration and extra propan-1,2-diol was added (if required) to bring the concentration 
up to 10 %. After briefly mixing this solution, the double concentrate of the polymer was added to 
the double concentrate of Polysorbate 20, monocaprin and propan-1,2-diol to the required weight. 
This thickened solution was mixed at room temperature on a Labnet Mini LabRoller (Edison, NJ, 
United States) with a 5 X 50 ml tube rotisserie. 
3.2.10 Production of HPMC polymer based thickened eye drops 
HPMC based formulations were produced using the same method as CMC based formulation apart 
from the preparation of the polymer. To produce the polymer gel, the required about of HPMC 
powder was added to the required amount of sterile deionised water heated to 90 °C. The double 
concentrate polymer was shaken on an orbital shaker at room temperature at 200 rpm until cooled. 
The polymer was then placed at 4 °C for an hour and the added to the double concentrate of 
Polysorbate 20, monocaprin and propan-1,2-diol as above. 
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3.2.11 Assessing growth inhibition properties of formulations via growth 
inhibition tests 
N. gonorrhoeae strain NCCP11945 was cultured as in Chapter 2 overnight on a GC plate at 37 °C, 5 
% CO2. A cell suspension in PBS equal in the opacity to a 0.5 McFarland standard was made. A sterile 
cotton-wool swab was dipped into the bacterial suspension and excess liquid removed by pressing 
it against the side of the glass universal tube. Three continuous streaks were made on a GC plate, 
each one starting at the top of the plate continuing down the plate to the bottom and then plates 
were turned plate 90 ° before starting the next streak. After allowing a few minutes for the plates 
to dry, a sterilised number 5 cork borer was used to make a well in the agar with a diameter of 8 
mm. Approximately 150 µl of the testing substance was placed in the well. For testing of ointments, 
the semi-solid material was used to fill the well until full. Plates were incubated at 37 °C, 5 % CO2 
for 16-18 hours. The diameter of the inhibition zones were measured if present. 
3.2.12 Assessing bactericidal properties of formulations via log reductions 
Log reductions as in Chapter 2 were used with slight modification. A double concentration of 
bacteria suspension (2 X 107) was used as compared to in Chapter 2, and only 250 µl was added 
(instead of 495 µl) to 0.25 g of the testing formulation. All formulations were tested for the standard 
2 minutes and ointments were additionally tested at 1 hour exposure as well. For the negative 
control, formulations minus the monocaprin were used. All plate counts were and calculations were 
done as in Chapter 2. 
3.3 Results 
3.3.1 Ultra violet - Spectrophotometric scan and calibration curve 
As expected, monocaprin poorly absorbed UV light at anything but the lowest wavelengths (See 
Figure 3.4.A). Due to this, the wavelength 208 nm was chosen for further testing as it has previously 
been used to detected monocaprin in a HPLC method. Regression analysis of the calibration curve 
of the standard concentrations tested at 208 nm revealed a straight line relationship (R2 = 0.9992) 
(Figure 3.4.B). 
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Figure 3.4 Ultra violet absorbance properties of monocaprin. (A) Ultra violet spectrophotometric 
scan of 1 mg/ml monocaprin in acetonitrile from 200-400 nm. (B) Ultra violet calibration curve of 
monocaprin in acetonitrile at 208 nm. 
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3.3.2 High performance liquid chromatography - method development 
Some modifications had to be made from the published method of Thorgeirsdottir and co-workers 
[246]. The peaks produced with the published method were wide and would give poor resolution 
at lower concentrations. It was decided to switch to a column based on solid core particles (still 5 
µm in diameter) instead of fully porous. This increased the resolution of technique (see Figure 3.5.A 
for an example of chromatogram). The column length was also extended from 150 mm to 250 mm 
to further increase the resolution over the original method. These changes increased the retention 
of the monocaprin with the stationary phase. Therefore, the concentration of acetonitrile in the 
mobile phase was increased to 80 % to reduce the retention time. The final retention time of 
monocaprin using this method was approximately 3.4 minutes. 
3.3.3 High performance liquid chromatography - calibration curve 
The estimated concentrations of the samples run in the HPLC calibration curve are shown in Table 
3.2. Example chromatograms and the regression analysis are shown in Figure 3.5.A and 3..B 
respectively. The test performed well in terms regression analysis with a R2 value of 0.9997. 
However, the relative standard deviations for lower concentrations were slightly high (Table 3.2). 
The relative standard deviations (RSD) for the 62.5 and 125 µg/ml monocaprin solutions were 5.9 
% and 2.9 % respectively. However, the mean estimated concentrations are 62.6 µg/ml (100.2 %) 
and 124.5 µg/ml (99.6 %) respectively. This would indicate the method is accurate but not precise 
at these lower concentrations. At concentrations of 500 µg/ml and above, the RSD was 1 or less 
demonstrating that the test had a good level of repeatability at higher concentrations. Figure 3.5.A 
shows an overlay of the chromatograms of the concentrations of the tested concentrations. The 
baseline readings are not completely flat which could be due a consequence of the low wavelength 
used for detection.  
3.3.4 Precision and accuracy 
To test the precision and accuracy of the HPLC method, test samples were tested in three different 
run in the same day (intra-day) and in three runs on separate days (inter-day). The results of the 
intra-day and inter-day testing are given in  
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Table 3.3. One immediate observation of the data was that the majority of the readings gave a small 
overestimate of the concentration. This could be due to a small inaccuracy with the validation. 
Despite this, the method still gave accurate results. Overall, for the tested samples in the intra-day 
testing, the mean recovery was 102.4 % with a RSD of 2.7 %, and for the inter-day testing the mean 
recovery was 102.5 % with a RSD of 3.0 %.  
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Figure 3.5 Results of high performance liquid chromatography validation of monocaprin. (A) 
Overlaid chromatograms from HPLC validation of monocaprin tested at different concentrations. 
(B) Calibration curve of the different concentration of monocaprin and area under the curve of their 
resulting chromatogram peak. 
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Table 3.2 Estimated concentrations of HPLC validation samples. 
Sample Estimated Concentration (µg/ml)  
Regression 
Coefficient 
 
Slope 
 
Intercept 62.5 125 250 500 750 1000 
Replicate 1 61.11 123.08 248.60 507.25 756.44 1001.38 0.9999 1.0065 -1.2028 
Replicate 2 65.36 129.14 255.84 494.25 763.11 985.91 0.9995 0.9888 6.0198 
Replicate 3 70.10 123.31 255.97 500.97 753.38 996.64 0.9999 0.9937 4.9647 
Replicate 4 67.42 131.28 247.67 504.72 765.63 1007.79 0.9998 1.0084 2.404 
Replicate 5 62.21 128.47 252.96 498.44 760.21 1003.83 0.9999 1.0051 0.8189 
Mean 62.6 124.5 249.6 498.5 757.2 996.5 0.9999 1.0005 -0.0044 
S.D. 3.7 3.6 3.9 5.1 4.9 8.4       
RSD (%) 5.9 2.9 1.6 1.0 0.7 0.8     
Accuracy (%) 100.2 99.6 99.8 99.7 101.0 99.7     
 
* 
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Table 3.3 Summary of inter and intra day testing results of a selection of standards of monocaprin. 
Standards 
Intra-day testing (n=3) Inter-day testing (n=3+3+3) 
Mean 
estimate 
(µg/ml) 
S.D. 
(µg/ml) 
RSD 
(%) 
Accuracy 
(%) 
Mean 
estimate 
(µg/ml) 
S.D. 
(µg/ml) 
RSD 
(%) 
Accuracy 
(%) 
750 761.2 18.5 2.5 101.5 751.0 8.5 1.1 100.1 
250 255.5 5.6 2.2 102.2  257.3 6.4 2.6 102.9 
125 127.7 1.0 0.8 102.1 130.3 3.0 2.4 104.2 
62.5 65.0  3.3 5.2 103.9 64.2 3.8 6.0 102.7 
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3.3.5 Limits of detection and quantification  
The International Council for Harmonisation of Technical Requirements for Pharmaceuticals for 
Human Use (ICH) guidelines only give a brief outline of how to set the LoD and LoQ as there are a 
few methods that can be used [280]. The optimised method has already demonstrated that it has 
a good level of repeatability, precision, and accuracy. However, the baseline of chromatograms is 
slightly noisy. Due to this, it was decided that the LoD and LoQ should be estimated taking this into 
account and a signal-to-noise ratio based method should be used.  
The LoD and LoQ of the optimised method was determined to be 13.4 and 40.6 µg/ml respectively 
from analysis of the calibration curve. These limits have values outside our calibration range which 
is encouraging. 
3.3.6 Testing of other monoglycerides and possible breakdown products  
Other monoglycerides as well as monocaprin were tested using the optimised HPLC method. This 
was done to make sure that the test could detect any possible impurities, contamination or 
incorrect labelling of samples. Examples of chromatograms are shown in Figure 3.6.A. Monolaurin 
(12:0MG), a saturated twelve carbon chain length monoglyceride and monomyristin a saturated 
fourteen carbon chain length monoglyceride were tested. The retention times of the 
monoglycerides increased with carbon chain length as would be expected. The retention of 
monocaprin was approximately 3.38 min with monolaurin having a 1.27 min longer retention time 
at approximately 4.65 min. The difference in retention time between monolaurin and monomyristin 
was 2.66 min with monomyristin having a retention time of 7.31 min. Therefore, the difference 
between the 12 and 14 carbon length is double that of the difference between the 10 and 12 carbon 
length monoglycerides. More testing would be required to confirm if this trend of double retention 
time differences continues. 
One of the possible breakdown pathways is hydrolysis. Breakdown of monocaprin by hydrolysis 
would lead to the formation of capric acid and glycerol. Therefore, these were run on the HPLC 
method to be sure that the method could detect this possible breakdown route. The resulting 
chromatograms from the testing of these products are shown in Figure 3.6.B. Testing of capric acid 
resulted in a peak at 4.28 mins. The increase in retention time over monocaprin would be expected 
due to the loss of the ester bond and two hydroxyl groups resulting in greater net hydrophobicity 
of the molecule despite the gain of the hydrophilic carboxylic acid group. 
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Figure 3.6 Overlaid single representative HPLC chromatograms (UV detection at 208 nm) of 
monocaprin and closely related chemicals. (A) Comparison of monocaprin (3.38 min) to other 
monoglycerides; monolaurin (4.65 min) and monomyristin (7.31 min). (B) Comparison of 
monocaprin (3.38 min) to capric acid (4.28 min). Chromatogram for glycerol also displayed (light 
blue line) but didn’t result in any peaks. Capric acid and glycerol would be products from the 
potential breakdown of monocaprin by hydrolysis.  
  
Chapter 3 – Preformulation and formulation studies 
117 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.4 Experiment solubility of monocaprin in selected solvents at 20 °C. 
Solvent 
Experimental 
saturation solubility 
(g/L) 
SD (g/L) 
Acetonitrile 99.6 2.3 
Butane-1,3-diol 184.71 0.6 
DMAc 693.53 22.0 
Ethanol 331.4 9.3 
Methanol 432.4 5.2 
Propane-1,2-diol 303.38 1.7 
Tetraglycol 439.00 19.1 
Water 0.26 0.008 
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3.3.7 Monocaprin solvent solubility 
Results of the solubility of monocaprin in the tested solvents are displayed in Table 3.4. Monocaprin 
was highly soluble in the two alcohol based solvents tested (ethanol and methanol). Experiment 
results confirm that monocaprin is insoluble in water with an estimate of solubility of 0.26 g/L.  
3.3.8 Texture analysis of commercially available ointments 
The commercially available 1 % (w/w) chloramphenicol ophthalmic ointment was tested against 
different blends of light mineral oil and white petroleum. This was done to reverse-engineer an 
ointment based from an existing ophthalmic ointment. The results of the texture analysis are 
displayed in Table 3.5. Also, the data is graphically represented in Figure 3.7. From this data, it 
estimates that it should be possible to replicate the texture properties of the ophthalmic ointment 
with a blend of two parts light mineral oil to ten parts white petroleum. The initial measure of parts 
for light mineral oil was by volume and the measure of parts for white petroleum was by weight. 
As light mineral oil has a density of 0.84 g/cm3, this means that this mixture is equivalent to 
approximately 15 % by weight light mineral oil and 85 % by weight white petroleum. 
Unfortunately, the texture analysis graph for chloramphenicol in Figure 3.7.B doesn’t completely 
match that to the blends of the light mineral oil and white petroleum. The negative peak height 
doesn’t match the values given by the known standard. However, this blend of excipients does 
match the chloramphenicol ophthalmic ointment in terms the physical properties of hardness 
(positive peak 1 height), cohesiveness (positive peak 1 area) and adhesiveness (negative peak 1 
area). The reason for this is unknown but may be because of the contribution of the 
chloramphenicol on the texture properties of the ointment.  Despite this, 15 % by weight light 
mineral oil and 85 % by weight white petroleum was clearly the closest match to the ointment 
especially in terms of hardness.  
3.3.9 Development of ointment based ophthalmic ointments 
The 15 % by weight light mineral oil and 85 % by weight white petroleum was used as the ointment 
base. The monocaprin was incorporated into the base using standard ointment manufacturing 
procedures (also outlined in the methods section). The monocaprin concentrations chosen to be 
used in the formulations were 0.068 %, 0.125 %, 0.188 %, and 0.25 % by weight. The monocaprin 
was evenly distributed within the ointment with no sign of clumping upon storage.  
3.3.10 Initial development of CMC and HPMC polymer based liquid dosage 
forms 
The development of the liquid dosage forms was much more complex than with the ointment. As 
seen in previous results in this chapter, monocaprin has poor aqueous solubility. Therefore, co-
solvents had to be used to aid solubility. The concentrations of monocaprin chosen for the 
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formulations were 0.068 %, 0.125 %, 0.188 %, and 0.25 % by weight to be comparable to the 
ointment. However, to aid solubility of the drug, monocaprin was first dissolved in propane-1,2-diol 
and Polysorbate 20 was also added to the formulation. Initially 0.1 % (v/v) Polysorbate 20 was 
added to these monocaprin concentrations. Figure 3.8 shows photographs of these formulations 
and demonstrates the action of the Polysorbate 20 on the solubility of the monocaprin. At a 
concentration of 0.1 % Polysorbate 20, the monocaprin was completely in solution in the HPMC 
polymer based formulation. This however, was not the case in the CMC based formulation at the 
same concentration of surfactant and drug. The reason for the decreased solubility of monocaprin 
in CMC based formulations is unknown. Without the Polysorate 20, the monocaprin in both the 
CMC and HPMC polymer based formulations was not solubilised. Interestingly, the visual form of 
the precipitate in the two polymer type based formulations were different with the CMC based 
formulations having clumps of monocaprin and the HPMC precipitate forming a cloudy precipitate 
at the top of the vessel just below the meniscus (as shown in Figure 3.8). However, with the 
Polysorbate 20, all the tested concentrations of monocaprin in both polymer types formed a stable 
cloudy suspension.  
3.3.11 Antimicrobial testing of ointments and CMC and HPMC polymer 
based liquid dosage forms 
The antimicrobial testing was done by growth inhibition testing (bacteriostatic) and also by 
performing log reductions (bactericidal). The growth inhibitions for liquid dosage forms based 
formulations was slightly more complex than the ointments. This was because the excipients alone 
(formulations with no drug added) caused some inhibition of growth. It was possible that 
Polysorbate 20 was inhibiting the GC growth. Therefore, all the liquid dosage forms; no drug, 0.068 
%, 0.125 %, 0.188 %, and 0.25 % monocaprin for both polymer types were tested with and without 
the added 0.1 % Polysorbate 20. The only difference in the results between the formulations with 
or without Polsorbate 20 was for the negative control where the no-drug control would cause a 
mean 13 mm zone inhibition compared to no zone for formulations without Polysorbate 20. This 
indicates that the Polysorbate 20 has some bacteriostatic properties but these are hidden when the 
more powerful bacteriostatic agent monocaprin has been included in the formulation.  
Graphical representations of the growth inhibition testing are displayed in Figure 3.9. It is clear that 
the ointment gave the smallest zones of inhibition. This is not surprising as the diffusion rate of the 
monocaprin from the well would be much slower than that from the liquid dosage forms due to the 
difference in viscosity. Furthermore, the base of the ointment is very hydrophobic so it would be 
more difficult for the monocaprin to travel from this matrix into a more aqueous based matrix. For 
the liquid dosage forms, the HPMC based formulations performed slightly better than CMC based 
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formulations. However, the viscosity of the CMC based formulations was slightly greater than that 
of the HPMC formulations. 
The log reductions were done for the ointments at 0 %, 0.068 %, 0.125 %, 0.188 %, and 0.25 % 
monocaprin concentrations. There was no reduction in bacterial count after the standard two 
minute exposure time despite rigorous mixing. However, this would not be a fair test for the 
ointment as it intended to release the drug over an extended period. Therefore, the bacterial counts 
were also done on the ointments after an hour of exposure. There was again no reduction in 
bacterial counts. Any extension of this exposure time would have an intrinsic effect on the bacteria 
as they would have been starved of nutrients and optimal temperature conditions for a prolonged 
period.  
The log reduction results of the liquid dosage forms was interesting. Initial testing demonstrated 
that there was no difference between the log reductions of the two polymer types. However, it was 
clear that there was difference in Polysorbate 20 concentration. Polysorbate 20 concentrations of 
0 %, 0.1 %, 0.2 %, 0.5 %, 1 %, and 2 % were tested with or without drug. The results of these for the 
HPMC based formulations are given in the graph in Figure 3.10. All tested formulations without 
monocaprin didn’t cause any killing of GC cell even at a concentration of 3 % Polysorbate 20 
indicating that the action of the Polysorbate 20 is bacteriostatic only not bactericidal. Surprisingly, 
the higher the concentration of Polysorbate 20 the lower the anti-gonococal properties of the 
monocaprin. This inhibition of the monocaprin by the surfactant appears to be concentration 
dependant – the greater the monocaprin concentration in the formulations the more Polysorbate 
20 required to inhibit its action. If a log reduction value of four or great was deemed bactericidal, 
then the maximum concentration of Polysorbate 20 of 0.2 % should be used for 0.062 and 0.125 % 
monocaprin formulations; 0.5 % for 0.188 % monocaprin formulations; and 2 % for 0.25 % 
monocaprin formulations. 
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Table 3.5 Amounts of force (mN) required for TA.XTplus Texture Analyser to complete testing cycle 
of ophthalmic chloramphenicol ointment in comparison to blends of light mineral oil and white 
petroleum. 
Parts 
Mineral 
Oil 
Parts 
Petroleum 
Jelly 
Positive Peak 
Height 1 
Positive Peak 
Height 2 
Negative Peak 
Height 1 
Negative Peak 
Height 2 
Mean* S.D.* Mean S.D. Mean S.D. Mean S.D. 
0 10 329.82 25.72 307.06 20.08 -217.79 21.1 -200.81 21.1 
1 10 259.62 30.28 246.33 23.47 -189.54 24.32 -174.62 20.53 
2 10 184.14 16.59 171.65 15.64 -128.21 13.41 -120.78 10.41 
3 10 151.62 4.83 146.24 4.56 -111.30 4.41 -107.18 4.43 
4 10 137.93 9.5 133.13 9.32 -97.24 11.91 -94.72 9.96 
5 10 123.68 9.39 120.20 7.3 -87.68 8.30 -85.02 7.06 
Chloramphenicol 
ointment 
184.89 5.69 170.55 5.22 -112.98 3.10 -110.15 5.22 
          
Parts 
Mineral 
Oil 
Parts 
Petroleum 
Jelly 
Positive Peak 
Area 1 
Positive Peak 
Area 2 
Negative Peak 
Area 1 
Negative Peak 
Area 2 
Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
0 10 537.52 80.05 433.05 75.11 -425.79 73.81 -486.84 104.87 
1 10 495.76 88.31 388.08 63.78 -397.03 60.64 -463.41 85.60 
2 10 331.86 21.62 256.85 23.76 -265.12 23.35 -311.37 14.30 
3 10 293.10 9.92 241.85 13.99 -236.21 12.50 -304.14 34.28 
4 10 273.70 22.83 227.53 19.84 -209.17 22.35 -305.78 27.88 
5 10 247.46 25.09 200.17 15.89 -190.54 17.25 -264.90 23.78 
Chloramphenicol 
ointment 
321.23 11.93 257.59 10.02 -259.66 8.78 -369.56 19.63 
* Means and standard deviations are based on five separate readings. 
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Figure 3.7 Texture analysis of ointments. (A) Comparison of texture of different light mineral oil and 
white petroleum blends (1-5:10). (B) Comparison of chloramphenicol ophthalmic ointment to the 
blends of different light mineral oil and white petroleum. The chloramphenicol ophthalmic 
ointment closely resembles the 2:10 light mineral oil and white petroleum blend profile. Graphs 
represent a mean of five tests on the each sample. 
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Figure 3.8 Comparison of the effects of polymer and addition of Polysorbate 20 on the solubility of 
monocaprin. For the CMC polymer based formulations, if the monocaprin at concentrations were 
above 0.125 % without Polysorbate 20 would form clumps (marked by red asterisk). With the 
addition of 0.1 % Polysorbate 20, the monocaprin would not be fully soluble but would at least 
evenly distributed. For HPMC based formulations, without the addition of Polysorbate 20, the 
monocaprin would form a fine precipitate just under the meniscus of the formulation at 
concentrations of 0.125 % and above (red hash). 
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Figure 3.9 Growth inhibition zones of all formulations. (A) Growth inhibition zones of the ointments, 
(B) Growth inhibition zones of the CMC based formulations. (C) Growth inhibition zones of the 
HPMC based formulations. Each ring represents a 2 mm zone of inhibition; the diameter of the well 
is 8 mm. Numerical zone sizes are displayed as mean results with standard deviation over two 
repeated experiments. 
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Figure 3.10 Effect of Polysorbate 20 concentration on the anti-gonococcal properties of 
monocaprin. Formulations without monocaprin were not bactericidal even at a concentration of 2 
% Polysorbate. All formulations were strongly bactericidal at low concentrations (> 0.2) or without 
Polsorbate 20. At higher concentrations of Polysorbate 20, antibacterial properties were diminished 
and at 2% only 0.25 % monocaprin was effective. Results are displayed means of two separate 
experiments, error bars represent standard deviation. The large standard deviation for 0.068 % 
monocaprin without Polysorbate 20 is a result of in one experiment causing complete killing (LR = 
6) and in the other causing no killing (LR = 0). The reason why it may not have been bacteriacidal 
could be due to the monocaprin precipitating out of the formulation. 
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3.4 Discussion 
The chemical properties of monocaprin have been explored both via literature and by experimental 
research. As expected, monocaprin has poor aqueous solubility which did hinder formulation. 
However, monocaprins solubility in other solvents highlight that a co-solvent based formulation 
could work. Propane-1,2-diol was in the end selected for later development of the liquid dosage 
form due to common use in ophthalmic formulations over some of the other solvents. The 
development of an analytical method aided formulation and could be used in future. The lower 
detection limit of the method was relatively high for a HPLC method which was due to the low UV 
absorbance of the monocaprin. Mass spectrometry could be used as Chu and co-workers [247] and 
this would vastly decrease the lower detection limit but extensive validation of the method would 
be required. The method validated here was sufficiently sensitive for the purposes of this study. 
The semi-solid dosage form developed in this study was based on an ointment. The ointment base 
of the formulation used a blend of petrolatum and mineral oil to replicate the physical properties 
of an existing ophthalmic ointment already commercially available. The formulation of the 
ointment after this was straightforward with incorporation of the monocaprin into the ointment 
base.  
The formulation of the liquid dosage form was based on use of a co-solvent and a surfactant to aid 
aqueous solubility. The power of the surfactant to aid solubility was much greater than that of the 
solvents with very small amounts drastically aiding the aqueous solubility of the monocaprin. Like 
the ointment four concentrations (0.068 %, 0.125 %, 0.188 %, and 0.25 %) were selected going 
forward as potential formulation. 
The performance of the two dosage forms were compared in terms of their action against 
gonococcal cells. The growth inhibition test which measures bacteriostatic activity demonstrated 
that both formulation had strong bacteriostatic properties. However, when the bactericidal activity 
was tested via log reductions only the liquid dosage forms were bactericidal. This could mean that 
the ointment, when applied to the eye may not be able to kill gonococcal cells in the tear fluid. It 
appears that release of the monocaprin from the ointment base is insufficient to reach a level where 
it would actively kill the bacterial cells. In comparison, the thicken eye drop formulation which 
blended with the simulated tear fluid during log reduction assay, killed all the gonococcal cells 
present. At this point it would have been beneficial to compare the action of the monocaprin 
ointments to that of other antimicrobial ointments. The action of erythromycin is mostly 
bacteriostatic and this is already used to successfully prevent development of ophthalmia 
neonatorum [282]. Therefore, the use of the monocaprin ophthalmic ointment cannot be 
discounted completely. 
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The surfactant used in the formulation of the thicken eye drop was Polysorbate 20. This surfactant 
is highly soluble in water and is a strong solubilising agent. The results from this study show that 
the Polysorbate 20 had a strong effect on the level of solubility of the monocaprin. However, the 
Polysorbate 20 also had a negative on the bactericidal properties of the monocaprin. This has also 
been reported in another study [283]. Without any surfactant present, the monocaprin would 
precipitate into clumps at concentrations past the maximum solubilising capability of the matrix. 
This would render the formulation ineffective as the drug is not evenly distributed throughout the 
formulation. Fortunately, it has been discovered that if only a small amount of surfactant were 
added, even if the maximum solubilising capability of matrix was still not enough to completely 
solubilise all of the monocaprin, a stable suspension would be formed. Therefore, the drug would 
be evenly distributed throughout the formulation without being completely solubilised. The 
stability of this suspension can also be enhanced with the use of the viscosity enhancers such as 
that we have used in this study (CMC and HPMC). As long as the surfactant is kept at a high enough 
level to completely solubilise the monocaprin or to create a stable suspension but is not high 
enough to inhibit the action of the surfactant then it can be included in the formulation. The only 
alternative to the use of co-solvents and surfactants which has not been tried is the use of a 
complexing agent [270]. A complexing agent such as cyclodextrin can aid the solubility of 
hydrophobic drugs by complexing with them [284]. The drug would interact with hydrophobic 
regions on the inside of the ring structure of the cyclodexin while the hydrophilic groups on the 
outside of the ring structure would aid the solubility of complex. The reason why this option was 
not explored was due to cost of the complexing agent. Cost of the treatment has to be as low as 
possible due to the number treatments that would be required. Also, complexing in this manner 
may also have an effect on the antimicrobial properties of the monocaprin in a similar way to the 
Polysorbate 20. 
This study focused on the use of two commonly used ophthalmic viscosity enhancing polymers; 
CMC and HPMC. Both are widely used in ophthalmic preparations and have good safety records. 
HPMC is thickening agent which would also act as ophthalmic lubricant [285, 286]. The benefit of 
having a thickening agent in the formulation is to control the release of the drug. The thicker the 
polymer matrix the greater the ocular residence time of the drug. This would stop the natural 
removal of the drug before it has had a chance to take effect. However, as monocaprin is a more 
concentration dependant drug rather than a time-dependant drug, if the release of the drug is to 
slow then there will a minimal effect from the drug. Data from the first chapter demonstrates that 
the drug must be delivered in an active form at a concentration of 0.5 mM or above to be 
bactericidal. Anywhere below this level and the drug would not be bactericidal and would be 
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removed too rapidly via the natural draining mechanisms of the eye to remain at MIC level or above 
for any length of time. 
What could be tested is a measure of drug release? Franz diffusion cell experiments can be used to 
estimate drug release rates by measuring the diffusion rates from the semisolid to a receptor 
compartment through a synthetic membrane [287]. Franz diffusion cell experiments were 
attempted in this study but no meaningful drug release was detected probably due to the 
monocaprin forming micelles with the Polysorbate 20 and thus not being able to pass though 
dialysis pores used in the experiment (data not shown). Franz diffusion cells are popular to study 
diffusion of transdermal drug delivery systems through membranes [288, 289]. So their relevance 
to estimate rate of release from a formulation to tear fluid and ocular surface is questionable. 
During the development of the monocaprin based cream for treatment of cold sores referenced in 
the introduction of this chapter, a membrane-less diffusion cell was used [246]. The exact method 
used in that study is not given but other studies do give details for the use of membrane-less in 
drug release studies [290-292].   
There were two observed benefits of the use of HPMC over the CMC. The first was the slight 
increase in the solubility of the monocaprin in HPLMC formulations in comparison to the CMC based 
formulations.  The second is the increased stability that was observed in the formulation over long-
term storage (data not shown). Upon storage the thickened eye drop solution would decrease in 
viscosity after a few months. This was presumably due to breakdown of the polymers over time. 
The reason why this affected the CMC based formulations only is unknown but must be due 
enzymatic breakdown. The rate of enzymatic breakdown would likely be increased by the presence 
of the Polysorbate as non-ionic surfactant have been well documented to increase the rate of 
reactions of cellulases [293, 294].  
At the beginning of the chapter the aims were stated and this work has gone some way to achieve 
those aims. Working formulations have been developed but questions still remain unanswered such 
as which concentration of monocaprin should the final formulation contain? Working in the 
laboratory killing purified gonococcal cells in simulated tear fluid has been demonstrated that a 
monocaprin concentration greater than 0.5 mM will be sufficient to kill all gonococcal cell present. 
Whether this concentration is sufficient or not will be addressed in the next chapter. For now the 
thickened eye drop formulations will be used going further as many questions remain about how 
effective the ointment based formulation will be. In vitro testing suggest that the monocaprin is not 
released quick enough to be effective. Whether this testing reflects how effective it would be in 
vivo remains to be seen and no ending of in vitro testing could possibly completely answer this 
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question. It would therefore need some sort of animal testing or clinical trial to fully answer that 
question. 
More work could also be done to further develop the thickened eye-drop formulation. The 
comparisons of the polymers was arbitrary as no standardisation between the viscosities of the two 
polymer types was done. This would better compare the two polymers in terms of drug release but 
at this point use of HPMC is preferable to CMC for the reasons already mentioned above. Study of 
the drug release should also be conducted using a membrane-less diffusion cell method. This would 
give more confidence that the drug candidate is being released at the correct levels before the 
formulation has been removed from the eye by natural processes. 
Questions still remain about stability. Testing of 9 month old formulations after storage at room 
temperature in the dark show that thicken eye drop formulations are still as effective as newly 
made formulations and HPLC testing cannot detect any decrease in monocaprin or presence of any 
breakdown products (data not shown). However, full analysis in accordance with ICH guidelines 
should be done to fully assess the stability of the formulations. These tests should be done on the 
finished formulation as well as a repeat of the irritation testing to demonstrate that the formulation 
as a whole does not cause irritation not just the active components. 
Overall we have potential formulations to test in other models to prove their effectiveness. A 
thicken eye drop based formulation has been selected over the ointment based formulation. In the 
development of the thicken eye drop formulation the use HPMC as a thickening agent is preferred. 
The use of Polysorbate 20 must be balanced with the amount of monocaprin used in the 
formulation. In the formulation containing 0.068 and 0125 % monocaprin, 0.2 % Polysorbate 20 
must be used and in 0.188 and 0.25 % monocaprin formulations, 0.5 % Polysorbate 20 must be 
used. Despite the lack aqueous solubility of the monocaprin, the application of the thickened eye 
drop formulation is at this point the must suited formulation option given the properties of the 
killing action of the monocaprin. 
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4.1 Introduction 
At this point we have demonstrated that we have identified a highly effective drug candidate for 
the prevention of ophthalmia neonatorum. We have developed potential formulations which 
prevent growth and kill gonococcal cells. These have to be further tested to establish whether they 
are suitable for their intended purpose. The treatment being developed in this thesis is a post-
exposure prophylaxis. It is deemed as post-exposure as passage through the birth canal can be 
classed as an event which significantly increases the risk of developing a particular disease, in this 
case ophthalmia neonatorum. This prophylaxis would normally be given within the first one hour 
of life. For this reason it would be logical to test the formulations ability to prevent the progression 
of infection after the bacteria have had a chance to initially infect tissues. The performance of any 
formulation can tested with clinical trials but there are experiments involving the use of in vitro 
models which can try to replicate what is otherwise achieved in vivo. 
4.1.1 Cell culture based models of gonococcal infection 
One way to test the effectiveness of the prophylaxis would be in a cell culture based model. The 
host cells would be exposed to the bacteria, then after a defined time, the drug could be added to 
test its ability to prevent progression of the infection. This is particularly important in the case of 
gonococcal infection as N. gonorrhoeae is an intracellular pathogen. Once the bacteria has been 
internalised, it may be protected from the action of the drug. In that case, use of this drug in the 
formulation would not prevent the development of ophthalmia neonatorum. This is why this type 
of model can help answer such questions which the antimicrobial testing done so far has not.  
There are many studies that have used cell culture infection models. Most of the studies focus on 
gonococcal attachment and internalisation to host cells. Use of cell culture based methods to study 
gonococcal infection became popular in the 1990’s. Some of the pioneering work at that time was 
conducted at the University of Amsterdam. Researches originally used Chang “conjunctiva 
epithelial” cells (a known HeLa contaminated cell line [295]), HeLa cells (cervical cancer cell line) 
and HEC-1B cells (human uterus epithelial cell line) as host cells [296, 297]. Following work by this 
research group also used primary human cornea epithelial cells [298, 299]. The work conducted in 
these studies focused on cell entry, particularly the use of the gonococcal type IV pilus and Opa 
protein family [296]. Staining of the host cells and the gonococci at this time was done by using 
crystal violet and then immunogold-silver tag monoclonal antibodies used to help differentiate 
between bacteria and host [300]. 
One area of research conducted at the University of Virginia has focused more on gonococcal 
invasion of polymorphonuclear leukocytes [301-305]. Studies there have developed methods and 
techniques to aid infection such as selection of pili expressing variants and specialised fluorescence 
Chapter 4 – Models of ocular gonococcal infections 
132 
 
microscopy methods [306]. Fluorescent labelling of gonococcal cells and host cells have made major 
advancements in the study of cell culture based infections and the study of host-pathogen 
interactions.  
A number of studies have also been conducted at the Oregon Health and Science University which 
has published articles on gonococcal infection of epithelial cells (Chang and A431 (epidermal) cell 
lines) [102, 307-311]. Their work focuses on the role of the gonococcal pili and Opa protein family 
to aid attachment of the bacterial cell to the cell culture. All of these publications, plus the work of 
others, have helped to almost standardise infection procedures. However, certain variables still 
differ due to the preferences of the researcher and experimental aim. For example, the multiplicity 
of infection (MoI), which is the bacteria to host cell ratio differs between studies. The value is 
usually between 10 and 100. An infection time of 3 hours is commonly used but this does depend 
on the aim of the study [297, 301].  
4.1.2 Ex vivo tissue based models of infection 
There is only a single scientific article describing the infection of any excised or explanted ocular 
tissue with N. gonorrhoeae [312]. This publication describes the infection of human corneas with 
N. gonorrhoeae. The experiment used electron microscopy to describe the stages of infection and 
pathological effect on the tissue during the infection. It notes that attachment to the cornea surface 
was only achieved by piliated cells and that internalised gonococci cells were observed after just 
one hour. The article was published in 1988 and a lot of technologies and techniques with explanted 
tissue have since moved on but it does demonstrate the viability of the experiment. Other, more 
recent, scientific articles have been published on ocular tissue models involving different species of 
bacteria. One such publication on the subject describes the infection of explanted bovine 
conjunctiva samples with L. monocytogenes [313]. After the explantation of the bovine conjunctiva 
samples, they were infected with 107 L. monocytogenes cells, a MoI of approximately 100. The 
infection time used in the experiments was 20 hours after which any non-internalised cells were 
killed by gentamycin treatment. Internalised cells were recovered for CFU counts by homogenising 
the tissue in PBS with stainless steel beads.  
Moving away from bacteria models, a review of the literature does show that excised corneas have 
been used as models of infection with herpes viruses, firstly using herpes simplex virus type 1 (HSV-
1) on rabbit and human excised corneas [314]. The method describing the infection process was 
published in great detail by the authors and a video demonstrating the technique is available along 
with written instruction. The authors have since published three scientific articles using the 
technique [315-317] as well as it being used by other researchers [318]. The application of the 
technique to has also been used successfully with canine herpes virus type 1 (CHV-1) [319]. The 
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corneas were removed from the eyeball, explanted in cell culture medium and could be maintained 
for over one week. The corneas were infected with HSV-1 or CHV-1, incubated for an hour and virus 
removed. The tissue could then be tested directly or further incubated depending on the aim of the 
experiment.  
4.2 Materials and methods 
4.2.1 Host cells and cultivation 
Primary human corneal epithelial cells (pHCEC) (Gibco, Thermo Fisher Scientific Inc) were selected 
to be host cells for infection. Tissue culture flasks or plates used to grow these cells were first coated 
with recombinant human type-1 collagen. Coating was done using a Coating Matrix Kit (Gibco). 
Between 60-70 µl of Dilution Medium from this kit was used per cm2 of vessel surface, this was 
added directly to the flask/plate, for example: 5 ml for 75 cm2 flask (T75) and 1.7 ml for 25 cm2 flask 
(T25). The Coating Matrix was added at a volume 1/100th of the volume of the Dilution Medium. 
This was then mixed briefly and then incubated at room temperature for at least 30 minutes. After 
this time, the coating solution was removed and plates or flasks used immediately or stored at 4 °C 
for a maximum of two weeks. 
When initially reviving cells from the supplier or using in-house liquid-nitrogen stocks, cryovials 
were first dipped into a waterbath at 37 °C for two minutes. The contents were removed using a 
sterile transfer pipette and put into 20 ml pre-warmed keratinocyte serum free medium (KSFM) 
(Gibco) in a 50 ml centrifuge tube. Antimicrobial treatment was only used on the first passage when 
Antibiotic-Antimycotic (Gibco) (100 units/mL of penicillin, 100 µg/mL of streptomycin and 0.25 
µg/mL of Fungizone Antimycotic) was used. The cells were moved into a pre-coated T75 flask and 
incubated at 37 °C, 5 % CO2. The medium was changed every 2-3 days and cells checked under an 
inverted microscope (model AE31, Motic, Wetzlar, Germany).   
When cells had become 80 % confluent, the medium was removed and cells washed with 7 ml 
trypsin solution (Gibco, 5.3 mM KCl, 0.44 mM KH2PO4, 4.2 mM NaHCO3, 137.9 mM NaCl, 0.34 mM 
Na2HPO4, 5.6 mM D-glucose, 0.48 mM EDTA, phenol red 25 µM and 21 µM (0.5 g/L) trypsin). After 
washing, a further 2 ml of the pre-warmed trypsin solution was added and incubated at room 
temperature for up to 15 minutes until all cells had un-adhered from the flask. Progress was 
monitored using an inverted microscope. After this, 8 ml trypsin neutraliser (KSFM plus 10 % fetal 
bovine serum (FBS) (Gibco)) was added and the flask was rocked for a few seconds. The cells were 
transferred to 15 ml centrifuge tubes and a 20 µl sample taken for a cell count (see 4.2.3) before 
centrifuging at 125 x G for 10 minutes. The supernatant was discarded and cells resuspended in 
pre-warmed KSFM. A subcultivation ratio of 1:3 was recommended for this cell type but may have 
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been altered due to the results of the cell count, a value close to 5000 cells/cm2 was required to 
seed a new vessel. Precoated T75 flasks were seeded with 20 ml of cells. 
4.2.2 Preparing liquid nitrogen frozen stocks 
As primary cells only have a limited life expectancy, freezer stocks had to be made. This was only 
done after the original first passage after receiving the cells from the suppliers. The cells were 
grown in a T75 and trypsinised as above. After centrifuging and removing the supernatant, the cells 
were resuspended in 8 ml freezing medium (85% KSFM, 10% FBS and 5% DMSO). This was then 
aliquotted into 1 ml volumes in 1.2 ml cryovials, put in a Mr Frosty freezing container (Nalgene) 
containing 2-propanol and moved carefully to a -80 °C freezer and frozen overnight. The samples 
were placed in liquid nitrogen vapour phase until required.  
4.2.3 Cell counts  
Cell counts were performed after trypsinising cells to ensure that flasks/plates were seeded with 
sufficient cells to ensure growth. For this, a 20 µl aliquot of cells was added to 20 µl 0.4 % trypan 
blue solution (Sigma-Aldrich) and briefly mixed. A cleaned Bright-Line™ haemocytometer slide 
(Hausser Scientific, Horsham, PA, USA) was prepared with a coverslip over the counting surface and 
10 µl of the sample put into each sampling port of the slide. After a minute to allow for the sample 
to completely cover the counting surface, the haemocytometer was examined under an inverted 
microscope. Four four-by-four squares, each in the corners of the counting surface were counted. 
Cells on the top and left side lines were counted and cells on the bottom and right side lines were 
not counted, see Figure 4.1. Both live (clear) and dead (blue) cells were counted. Viable cell density 
and health estimates were estimated as equation: 
 
Equation 4.1 
𝑪𝒆𝒍𝒍 𝒅𝒆𝒏𝒔𝒊𝒕𝒚 (𝒄𝒆𝒍𝒍𝒔. 𝒎𝒍−𝟏)
= 𝑫𝒊𝒍𝒖𝒕𝒊𝒐𝒏𝒇𝒂𝒄𝒕𝒐𝒓 × 𝒎𝒆𝒂𝒏 𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝒄𝒆𝒍𝒍𝒔 𝒊𝒏 𝒐𝒏𝒆 𝒔𝒒𝒖𝒂𝒓𝒆 × 𝟏𝟎, 𝟎𝟎𝟎  
 
4.2.4 Preparing 24-well plates for infection 
Twenty-four well plates were used for the infection experiments. For each infection experiment, 
four wells would be set up for each sample. Two of these would be utilised for microscopy and two 
for bacterial cell counts. Wells for microscopy had to contain 13 mm round glass coverslips 
(Thermo-Fisher Scientific) so they could be easily mounted on glass slides. These were omitted from 
the cell count plates. The plates were collagen coated as above. T75 flasks were prepared as above 
to 80 % confluency and then trypsinised. However, after centrifugation the cells were resuspended 
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in 24 ml of medium per T75 flask of cells. The resuspended cells were then aliquoted 500 µl into 
each well on the plate. This would mean that one T75 flask would provide enough cells for two 24-
well plates. The plates were then incubated at 37 °C, 5 % CO2 and inspected the next day. Cells were 
either infected 24 or 48 hrs after trypsinising once the cells reached at least 80 % confluence. 
4.2.5 Infecting pHCEC 
Gonococcal strain NCCP11945 was selected for the infection. The bacteria were plated on to a GC 
agar plate at an approximate concentration of 103 CFU/ml by using methods described in Chapter 
2. The plates were incubated at 37 °C, 5 % CO2 for 24 hours. This produced a plate of individual 
gonococcal colonies which were observed using a dissecting microscope. Piliated (P+) and Opa 
expressing colonies (Opa+) were then selected by colony appearance [320]. These colonies were 
placed in GC liquid medium with 15 % glycerol and frozen at -80 °C until required. To produce the 
inoculum for infecting the pHCEC, GC plates were inoculated with the P+, Opa+ freezer stocker the 
day before infection and incubated at 37 °C, 5 % CO2 overnight. P+, Opa+ cells were again selected 
and washing into GC broth and OD520nm adjusted to between 0.25 and 0.50 (equivalent to 
approximately 107 CFU/ml). A MoI of 10 was used for the infection meaning that 50 µl of the 
bacterial suspension was added to positive control and sample wells. The course of the infection 
was run for three hours after which all wells were washed five times in sterile 0.1 M PBS and 
processed as below. 
4.2.6 Controls and samples tested 
For each experiment a range of controls were used, these are displayed in Table 4.1. A Non-
Infection Control was used to show the morphology of healthy cells, Non-Infected Treated Control 
was used to observe the effect of the drug on the HCECs. The Infection Control samples were used 
as positive control; this would be used in log reductions to measure the effect of the drug and also 
to be sure that the florescence microscopy had worked. The Gentamycin Control was used for the 
microscopy so a comparison between the action of gentamycin and monocaprin could be made. 
Monocaprin was tested at various concentrations: 1; 0.5; 0.25; and 0.125 mM. These 
concentrations were added to the wells just before the addition of the bacteria at time zero (T0) 
but also at 90 minutes post infection (T90). This tested whether the monocaprin would be able to 
clear the infection even if it was administered an hour or so after birth.  
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Table 4.1 Controls used in gonococcal infection of human cornea epithelial cells experiments. 
Control Contents 
Non-Infected Control HCEC only 
Non-infected Treated 
Control 
HCEC plus 1 mM monocaprin 
Infection Control HCEC infected with GC (MoI = 100), no 10:0MG 
Gentamycin Control HCEC infected with GC (MoI = 100), treated with 50 µg/ml gentamycin 
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Figure 4.1 Graphical representation of cell counting using a haemocytometer slide. The cells within 
the four marked squares were counted. Cells touching the top or left lines (marked in red) were 
counted while cells touching the lower or right lines (marked in blue) were not counted. 
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4.2.7 Processing of florescence microscopy samples post-infection 
The wells used for microscopy all contained 13 mm round glass coverslips. After the washing in 0.1 
M PBS, the cells were fixed in 4 % paraformaldehyde for 20 minutes at room temperature. 
Paraformaldehyde was removed and wells washed once in PBS. The samples were blocked in 300 
µl 5 % bovine serum albumin (BSA) in PBS and incubated for 30 minutes at room temperature. The 
wells were washed, each with 1 ml PBS four times. To each well, 200 µl rabbit polycolonal IgG anti-
gonococcal antibody (Abcam plc., Cambridge, UK) at a dilution of 1/400 in 0.2% BSA in PBS was 
added and plates incubated at 4 °C overnight. The wells were washed again and 200 µl of goat 
polycolonal IgG anti-Rabbit-IgG conjugated to Alexa Fluor 555 (Abcam plc.) at a dilution of 1/500 
and phalloidin-Fluor 488 at a dilution of 1/1000 in 0.2 % BSA in PBS was added. The plates were 
incubated at room temperature for 1 hour in the dark and then wells washed again. The glass 
coverslips were carefully removed, dipped in deionised water and mounted cells facing down on a 
spot of Fluoroshield Mounting Medium with 4',6-diamidino-2-phenylindole (DAPI) (Abcam plc.) on 
a glass slide and allowed to set at room temperature for five minutes. The edges were then sealed 
using nail varnish and, once dried, viewed under a Nikon Eclipse i80 (Nikon UK Limited) fluorescence 
microscope and images captured under standard DAPI, FITC and TRITC filters using NIS-Elements 
BR 3.0 SP7 (Nikon UK Limited) software. The images were later merged using ImageJ [321].  
4.2.8 Log reduction experiments of attached and internalised gonococci 
After the infection and washing in PBS to remove non-attached cells, the HCEC were lysed by adding 
100 µl pre-warmed 1 % (w/v) saponin (Sigma-Aldrich) and incubating at 37 °C for ten minutes. After 
lysis, 900 µl of GC broth was added and samples diluted ten-fold another three times. Each dilution 
was plated in duplicate, dropping 10 µl of the dilution on a GC plate and spreading over a quarter 
of the plate using a loop. Plates were then incubated at 37 °C, 5 % CO2 for 48 hours. CFU counts 
were estimated by averaging all four replicates (duplicate plating for duplicate wells for each 
sample). The CFUs of the drug exposed wells were compared to the CFU counts of the Infection 
Controls to estimate the log reduction caused by the action of the monocaprin. Comparisons of the 
log reductions at different drug administration times at given concentrations was analysed in an 
unpaired t test using GraphPad Prism (version 6.01). 
4.2.9 Gentamycin protection assays 
After the infection and washing in PBS to remove non-attached cells, 100 µl 10 mg/ml gentamycin 
(Gibco) in KSFM was added to all wells and incubated at 37 °C for two hours. After the removal of 
the gentamycin and washing twice in 1 ml 0.1 M sterile PBS, cells were lysed and treated as the 
above (method for the attached and internalised cells), apart from 100 µl of the dilutions were 
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plated over a whole GC plate instead of only 10 µl over a quarter of a plate. This was done as cell 
numbers of the “internalised only” were much lower than those of the “attached and internalised”.  
4.2.10 Live dead staining 
Live/dead staining was done using LIVE/DEAD® BacLight™ Bacterial Viability Kit for microscopy (Life 
Technologies) according to manufacturer’s instructions. After the course of infection the wells were 
washed five times, as before, but washes were done with sterile 0.85 % NaCl (approx. 1 ml per 
wash) to remove non-adhered bacterial cells.  
Staining solution was made by adding an equal amount of Component A (1.67 mM SYTO 9 + 1.67 
mM propidium iodide) to Component B (1.67 mM SYTO 9 + 18.3mM Propidium iodide); this was 
then diluted 1/333 in saline solution and 0.5 ml added to each well. The plate was incubated at 
room temperature in the dark for 15 minutes and then washed once in 0.85 % saline solution. Glass 
cover slips were carefully removed and mounted cell side down on a drop of BacLight mounting oil 
(provided with kit). The slides were then examined in the following 30 minutes. Due to the limited 
time frame, only the infection control was compared to the 1 mM treated sample. Slides were 
visualised on a Nikon Eclipse i80 (Nikon UK Limited). Due to the narrow band emission filter on this 
microscope, images were taken of samples on standard FITC and TRITC filters using NIS-Elements 
BR 3.0 SP7 (Nikon UK Limited) software and then merged later using ImageJ.  
4.2.11 Preparation of corneas for ex vivo infection 
The method used in this study for the preparation of the corneas and the infection was based on a 
method used of infecting corneas with Herpes Simplex virus [314, 316, 319]. Bovine eyes were 
collected from a local slaughter house (ABP, Guildford, Surrey, UK) and were transported in cold 
PBS plus Antibiotic-Antimycotic solution (Gibco). Once back in the laboratory, each eye was first 
examined for signs of damage before use. The eyeballs were then placed in a sterile 90 mm petri-
dish and a sharp scalpel used to make an incision just outside the edge of the cornea. A pair of 
scissors inserted into the incision and the cornea removed with a small amount of excess sclera 
with it. The sclera was trimmed back to 3-4 mm from the edge of the cornea if required. The lens 
was carefully peeled away from the back of the cornea using two forceps. The corneas were rinsed 
in PBS plus Antibiotic-Antimycotic solution, again in PBS without antibiotics and placed on a sterile 
spot-plate epithelial layer facing down. 
A scaffold medium was made that would maintain the shape of the cornea while also providing 
sufficient nutrients to maintain the cornea. To produce this medium, 0.2 g agarose was added to 
20 ml Minimum Essential Media (MEM) (Gibco) and heated in a microwave just until it started to 
boil. This was mixed well and left to cool to approximately 55 °C before use. The medium was added 
to the corneas until they were filled (between 1.5 and 2 ml) and allowed set at room temperature 
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for a couple of minutes. The corneas were moved to sterile 6-well cell culture plates, this time with 
the epithelial side up. MEM plus non-essential amino acids (Gibco) medium with 50 µg/ml 
gentamycin was added to the wells containing cornea, enough to sufficiently to cover the whole of 
the cornea (approximately 5 ml). The plates were incubated at 37 °C, 5 % CO2. The corneas would be 
stable for up to one week but infections were all done within 24 hours. 
4.2.12 Infecting the corneas 
N. gonorrhoeae strain NCCP11945 was cultured as in Chapter 2 overnight on a GC plate at 37 °C, 5 
% CO2. Cells were then scraped off the plate into GC broth and OD520nm adjusted to between 0.25 
and 0.50 (equivalent to approximately 107 CFU/ml). To the centre of a sterile 55 mm petri-dish, a 
100 µl spot of the bacterial suspension was added. The corneas were place epithelial side down on 
to the spot. Care was taken so that the bacteria suspension did not come into contact with any 
other part of the corneal button. A negative control made with a cornea incubated with 100 µl 
uninoculated GC medium was also done. The samples were then incubated for 1 hour at 37 °C, 5 % 
CO2. 
After the incubation the corneas were removed from the 6 well plates, washed five times by 
pipetting 1 ml of sterile PBS on to the contact points of the cornea and then the whole corneal 
button was dipped into sterile PBS five times taking care so that the scaffold medium did not 
become dislodged from the back of the cornea. The corneas were placed scaffold medium down 
on a new sterile 55 mm petri-dish and 500 µl of the thicken eye-drop formulations added. A 
summary of the formulations tested is given in Table 4.2. The formulations were left on the cornea 
for two minutes after which they were washed by dipping them in sterile PBS ten times.  
Two methods were used to evaluate the effects of the formulations on infected corneas. Both of 
these methods are summarised in Figure 4.3. The first method was based on CFU counts on 
surviving gonococcal cells. To help recover the gonococcal cells, the corneal buttons were incubated 
epithelial layer down on a 100 µl spot of pre-warmed 1 % saponin in PBS in 6-well plates at 37 °C 
for 10 minutes. A clean scalpel blade was passed over the epithelial layer and then the saponin was 
used to wash the epithelial layer of any loose cells. The 100 µl of saponin was recovered and diluted 
in GC broth and then diluted one in ten again in GC broth. CFU counts were done by plating 
duplicate samples of 100 µl over a whole GC plate for both dilutions. The plates were incubated at 
37 °C, 5 % CO2 for 48 hours. 
The second testing method was a qualitative method. After the corneal button had been washed 
after formulation treatment, they were then pressed against a GC plate and then left for 30 
seconds. The samples were then discarded and the plates were incubated for 48 hours.   
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Figure 4.2 Explanted bovine cornea infection model. Photographs of the different stages of 
infection experiment starting from the excision of the bovine corneas. Once the corneas were 
removed they were infected and then treated with the test formulation. 
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Figure 4.3 Methods of assessing the effectiveness of the treatment. The first method uses a saponin 
treatment to release attached and internalised cells which were then counted by CFU. The second 
method was more qualitative. A “print” of the cornea was made on a GC which was then incubated 
for 48 hours. The amount of growth on the plate represents the level of gonococcal contamination 
on the cornea.   
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Table 4.2 Summary of formulations tested in the ex vivo cornea infection study 
Formulation 
Name 
Amount of 
monocaprin 
Polymer used Polysorbate 20 
amount 
No drug control 0 % HPMC , 1.25 % 0.5 % 
0.068 % C10MG 0.068 % HPMC , 1.25 % 0.2 % 
0.125 % C10MG 0.125 % HPMC , 1.25 % 0.2 % 
0.188 % C10MG 0.188 % HPMC , 1.25 % 0.5 % 
0.250 % C10MG 0.250 % HPMC , 1.25 % 0.5 % 
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4.3 Results and discussion 
4.3.1 Development of cell culture based model 
Primary HCEC were used as host cells in the infection model. A continuous cell line (ATCC HCE-2 
[50.B1] (ATCC® CRL-11135™)) was also successfully infected but its growth rate was much slower 
than that of the primary cells (data not shown). Also, these cells required pre-coating with 
fibronectin which is known to have an affinity with gonococcal cells [296]. The pHCECs were 
infected in three separate experiments and analysis by log reduction and fluorescence microscopy 
was done after each one. 
4.3.2 CFU counts of attached and internalised gonococci 
The drug candidate was tested in two fold dilution series from 1 mM to 0.125 mM. The drug was 
also challenged at two different time-points, at the time of the inoculation and 90 minutes after. 
After the course of the infection experiment, CFU counts of the drug candidate treated wells were 
compared to that of the Infection Control to estimate the killing effect of the drug by calculating 
the log reductions. A summary of the results are displayed in Figure 4.4. and the raw data is given 
in Tables 4.3 to 4.9. The log reduction results obtained are similar to the log reduction results 
obtained in Chapter 2 (Figure 2.7) when the monocaprin was tested on bacterial cell suspensions. 
This suggests that action of the drug candidate is concentration dependant rather than time 
dependant as the action of the drug when exposed for 3 hours appears to have no greater effect 
than the original 2 minutes log reduction experiments that were conducted in Chapter 2. However, 
as the experiments in this chapter and Chapter 2 are fundamentally different, a direct comparison 
should be conducted to prove this trend. 
There is a clear difference between the log reduction results of the drug when added at the same 
time as the bacteria or 90 minutes after. When the drug is added at a concentration of 1 mM there 
is no difference in log reduction between the two different times at which the drug candidate was 
added. At that concentration, the drug candidate caused complete killing in both insistences. 
Conversely, at a concentration 0.125 mM the drug was completely ineffective, so again there was 
no difference between the administration time-points T0 and T90. However, the log reductions at 
0.25 and 0.5 mM between the two drug administration times do appear to be different with the 
administration of the drug at T0 being more effective. In the case the drug concentration at 0.25 
mM, this difference was found to be statistically significant (p = 0.0422), while the results from the 
0.5 mM concentration were not statistically significant (p = 0.0545).  However, the latter’s P value 
is indeed close to the 95 % confidence cut-off of 0.05 and only appears to be outside this value due 
to its larger standard deviation. When the drug candidate was added at a concentration of 0.5 mM, 
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the mean log reduction values were 2.9 and 4.3 for the administration of the drug after 90 minutes 
and administration at the same time as the bacteria, respectively. 
The number of bacterial cells recovered after performing the gentamycin sensitivity assay (to 
determine internalised cell numbers) was very low. In fact, one of the experiments failed to recover 
any bacteria at all from any sample (Experiment 2, Tables 4.5.and 4.6), while the other experiments 
resulted in a number colonies so low that they weren’t statistically significant to count. Only the No 
Drug Control of the experiment 3 gave a statistically significant CFU count. The estimated number 
of internalised cells from this sample was 2.4 x 102. This would represent 0.024 % of the original 106 
cells that were added to the wells. The number of cells recovered from the saponin treated wells 
which were not subjected to the gentamycin sensitivity assay (to determine attached plus 
internalised cell numbers), was estimated to be 1.2 X 106 in the case of experiment 3. This would 
mean that close to all of the cells that were added to the wells were either attached to the host 
cells, attached elsewhere on the well (either directly to the well or the coating matrix) or 
internalised. Furthermore, all the bacteria were recovered by the saponin treatment and the 
succeeding recovery processes. The number of bacteria recovered from experiments 1 and 2 was 2 
x 106 for both experiments. This estimate is double the estimate that was originally added to the 
wells in which OD520 was used to standardise the inoculum. This standardisation method is crude 
but little alternative is available as CFU counts are retrospective. A CFU count of the inoculum was 
not done as the number of cells that are competent to attach or internalise (numbers recovered 
from Infection Control) is more important than the total number of cells added.  
4.3.3 Fluorescence microscopy 
Fluorescence microscopy was done to visualise the gonococcal cells attached to the HCECs. This is 
a common technique and has been used in many studies (as previously mentioned). It was hoped 
that this would show some differences between untreated (Infection Control samples) and the 
treated samples. The gonococci cells were fluorescently labelled indirectly by using a rabbit 
polyclonal antibody raised against whole cell N. gonorrhoeae as primary antibody. This reagent had 
not been tested by the company for its intended use in this study so first the concentration had to 
be optimised. After an acceptable concentration was found by testing various concentrations (data 
not shown), it was used on further Infection Control and Non-Infection Control samples. The 
fluorescence microscopy images obtained were compared to phase contrast images, these images 
are displayed in Figure 4.5. As expected, it was clear that the fluorescence microscopy was a much 
more powerful tool in detecting the gonococcal cells. The gonococcal cells would be shown as black 
spots on the phase contrast images but many more cells would be shown on the fluorescence 
microscopy images. 
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Fluorescence microscopy images of all the control types and drug candidate samples were taken. 
Some of these images are shown in Figure 4.6. Comparing the images of the Non-Infected Control 
(Figure 4.6.A.) and Non-Infected Treated Control, we can see that the drug has had an effected on 
the morphology of the cells. The treated cells appear to be slightly smaller and with less spread 
(more spherical). This phenomenon was also shown in test wells infected with bacteria and treated 
with the higher drug concentrations, 1 mM (Figure 4.6.E.) and 0.5 mM (Figure 4.6.F.). This 
morphology change was not seen at lower drug concentrations in the test wells. Morphology 
changes due to exposure to high levels of monocaprin have previously been reported [165, 322]. 
However, one study that looked at the effect of 1.3 mM monocaprin exposure on the permeability 
of a Caco-2 monolayer demonstrated that the cells later returned to normal after 30 hours [322]. 
Comparing the images of the controls containing bacteria, Infection Control and Gentamycin 
Control (4.6.C and 4.6.D respectively), there doesn’t appear to be much of a difference between 
them. The bacteria seemed to attach to the pHCECs in clumps. However, some bacteria were also 
attached to the surface of the plate, between cells. In an attempt to avoid the latter, plates were 
coated with BSA or serum before the infection, however there was no significant improvement 
(data not shown). The difference between the Gentamycin Control and the Infection Control is 
small, with gonococcal cells being attached to the HCECs in both cases. This may mean that the 
binding of the bacterial cells to the pHCECs is a passive event and does not require the cells to be 
alive to do so. However, the images of the test wells were slightly different to those of the 
Gentamycin Treated Control. The bacterial cells appeared to be in larger clumps and a greater 
number appear to be attached to the surface of the glass coverslip rather than the pHCEC (see 
Figure 4.6.E and 4.6.F for examples of this phenomenon). 
4.3.4 Live/Dead staining of treated and untreated samples 
The drawback to the fluorescence microscopy was that treated samples appeared too similar to 
untreated samples. This was despite the difference in the results from the log reduction. It was 
decided that Live/Dead staining should be tried. Therefore, the Live/Dead staining was done as an 
additional experiment, not on one of the triplicate experiments. The Live/Dead staining technique 
should be able to differentiate between bacterial cells which have been killed by the action of the 
drug and those which remained alive. Images taken of the Live/Dead staining are shown in Figure 
4.7. The Infection Control samples contained a mixture of live and dead. This is not surprising, as 
the original inoculum used to infect the HCECs was from an overnight culture. This culture, due to 
its age, would probably have contained many dead cells. This was found to be case when the kit 
was first trialled before these experiments on 24 hr incubated cultures of Escherichia coli and N. 
Chapter 4 – Models of ocular gonococcal infections 
147 
 
gonorrhoeae (data not shown). These cultures contained a mixture of live and dead cells even 
through the culture would be viewed as highly viable.  
In contrast to the Infection Control, the treated test samples only contained red (dead) bacterial 
cells. The contrast between the treated and untreated samples is striking and on the results of this 
study, is a better tool to use rather than the just fluorescently labelling the bacteria. This also 
explains why the fluorescence microscopy images mainly contain host cells which have more than 
ten cells attached, despite the MoI being ten. As the OD520 is used as an estimate of how many 
viable cells are present, the number of dead gonococcal cells, which are now known to be capable 
of binding to their host, is unknown. As stated in the materials and methods, the health estimates 
of the host cells is checked but the equivalent value for the inoculum is not. Although the Live/Dead 
staining technique gave far more useful information, it is still of limited use. It would be difficult to 
process many samples in one experiment as the dyes tend to degrade rapidly. Likewise, the viability 
of the gonococcal cells would decrease over time after the samples have been prepared for 
microscopy.   
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Figure 4.4 Log reduction results of attached gonococci cells at different drug candidate 
concentrations. The drug was either added at the same time as the bacteria (blue line) or 90 
minutes after inoculation (red line). At a drug concentration of 1 mM the drug was completely 
inhibitory, killing all bacteria regardless of when the drug was added. 
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Table 4.3 Table of raw data from experiment 1 of CFU counts of attached and internalised gonococcal cells after three infections of HCECs. 
Sample 
T0 
 
 
T90 
 
 
R1* R2 R3 R4 D# CFU 
Log 
Reduction 
R1 R2 R3 R4 D CFU 
Log 
Reduction 
50 µg/ml Gentamicin 0 1 0 1 0 0 >5 0 3 0 2 0 0 >5 
1mM C10MG 0 0 1 0 0 0 >5 0 0 0 0 0 0 >5 
0.5mM C10MG 0 0 0 0 0 0 >5 4 11 33 25 0 1.8 X 103 3.0 
0.25mM C10MG 4 37 6 52 -1 2.5 X 104 1.9 26 73 130 90 -1 8.0 X 104 1.4 
0.125mM C10MG 90 44 43 153 -1 8.3 X 104 1.4 15 71 36 68 -1 4.6 X 104 1.6 
No Drug 10 28 25 18 -3 2.0 X 106 N/A 17 24 23 38 -3 2.6 X 106 N/A 
Key: * denotes replicate number. # denotes dilution factor in terms of 10D. 
Table 4.4 Table of raw data from experiment 1 of CFU counts from gentamycin protection assay for internalised gonococcal cells after three infections of HCECs. 
Sample 
T0 
 
T90 
 
 
R1* R2 R3 R4 D# CFU 
Log 
Reduction 
R2 R3 R4 D# CFU CFU 
Log 
Reduction 
50 µg/ml Gentamicin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1mM C10MG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0.5mM C10MG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0.25mM C10MG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0.125mM C10MG 1 2 0 0 0 0 0 1 0 0 0 0 0 0 
No Drug 1 2 0 0 0 0 N/A 2 4 7 8 0 0 N/A 
Key: * denotes replicate number. # denotes dilution factor in terms of 10D. 
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Table 4.5 Table of raw data from experiment 2 of CFU counts of attached and internalised gonococcal cells after three infections of HCECs. 
Sample 
 
T0 
 
 
T90 
 
 
R1* R2 R3 R4 D# CFU 
Log 
Reduction 
R2 R3 R4 D# CFU CFU 
Log 
Reduction 
50 µg/ml Gentamicin 0 0 0 0 0 0 >5 0 0 0 0 0 0 >5 
1mM C10MG 0 0 1 0 0 0 >5 0 0 0 0 0 0 >5 
0.5mM C10MG 5 4 18 14 0 1.0 X 103 3.3 37 40 11 18 0 2.7 X 103 2.8 
0.25mM C10MG 8 9 50 51 0 3.0 X 103 2.8 3 8 13 12 -2 9.0 X 104 1.3 
0.125mM C10MG 29 24 35 24 -2 2.8 X 105 0.9 73 76 68 64 -2 7.0 X 105 0.4 
No Drug 20 19 18 21 -3 2.0 X 106 N/A 
       
Key: * denotes replicate number. # denotes dilution factor in terms of 10D. 
Table 4.6 Table of raw data from experiment 2 of CFU counts from gentamycin protection assay for internalised gonococcal cells after three infections of HCECs. 
Sample 
T0 
 
 
T90 
 
 
R1* R2 R3 R4 D# CFU 
Log 
Reduction 
R2 R3 R4 D# CFU CFU 
Log 
Reduction 
50 µg/ml Gentamicin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
1mM C10MG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0.5mM C10MG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0.25mM C10MG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
0.125mM C10MG 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
No Drug 0 0 0 0 0 0 N/A 0 0 0 0 0 0 N/A 
Key: * denotes replicate number. # denotes dilution factor in terms of 10D. 
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Table 4.7 Table of raw data from experiment 3 of CFU counts of attached and internalised gonococcal cells after three infections of HCECs. 
Sample 
T0 
 
 
T90 
R1* R2 R3 R4 D# CFU 
Log 
Reduction 
R2 R3 R4 D# CFU CFU 
Log 
Reduction 
50 µg/ml Gentamicin 0 0 0 0 0 0 >5 1 1 0 0 0 0 >5 
1mM C10MG 0 0 0 0 0 0 >5 6 9 0 4 0 0 >5 
0.5mM C10MG 0 0 0 0 0 0 >5 14 25 16 9 0 1.6 X 103 2.9 
0.25mM C10MG 8 6 11 10 -1 8.8 X 103 2.1 34 42 51 76 -2 5.1 X 105 0.4 
0.125mM C10MG 55 56 18 26 -2 3.9 X 105 0.5 68 93 65 84 -2 7.8 X 105 0.2 
No Drug 12 15 10 11 -3 1.2 X 106 N/A        
Key: * denotes replicate number. # denotes dilution factor in terms of 10D. 
Table 4.8 Table of raw data from experiment 3 of CFU counts from gentamycin protection assay for internalised gonococcal cells after three infections of HCECs. 
Sample 
T0 
 
 
T90 
 
 
R1* R2 R3 R4 D# CFU 
Log 
Reduction 
R2 R3 R4 D# CFU CFU 
Log 
Reduction 
50 µg/ml Gentamicin 0 0 0 0 0 0 1 0 1 0 0 0 0 1 
1mM C10MG 0 0 0 0 0 0 1 0 0 0 0 0 0 1 
0.5mM C10MG 0 0 0 0 0 0 1 0 0 0 0 0 0 1 
0.25mM C10MG 0 0 0 0 0 0 1 2 4 1 0 0 0 1 
0.125mM C10MG 3 1 1 0 0 0 1 1 2 1 8 0 0 1 
No Drug 22 39 11 23 0 2.4 X 102 N/A 
      
N/A 
Key: * denotes replicate number. # denotes dilution factor in terms of 10D. 
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Figure 4.5 Optimisation of fluorescent labelling to detect gonococci. Infection Controls (A-D) were 
used to optimise the fluorescent labelling. Merged images of the fluorescence labelled samples (B 
and D) were compared to images taken using phase contrast (A and C).  Gonococci are shown as 
small black dots on the phase contrast images but are clearly shown as red spots in the fluorescence 
labelled images. Fluorescence labelled Non-Infected Controls (E), show no signs of background 
staining. Scale bars for panels A-D represent 10 µm and the scale bar in panel E represents 50 µm. 
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Figure 4.6 Immunofluorescent staining of HCEC infections. (A) Controls used were Non-Infected, (B) 
Non-Infected Treated, (C) Infection Control and (D) Gentamycin Treated. These were compared to 
wells treated with the drug candidate (E, 1 mM monocaprin and F, 0.5 mM monocaprin). Scale bars 
in panel A, B and C-F represent distances of 50, 20 and 10 µm respectively. 
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Figure 4.7 Live/Dead staining of gonococcal infected pHCECs. Live cells appear green while dead 
cells appear red. (A and B) Untreated Infection Control samples. (C and D) HCECs treated with 1 mM 
monocaprin. The Infection Control sample has many live bacteria and a few dead cells as well, while 
the monocaprin treated samples contain mostly dead bacterial cells, some of which are still 
attached to the pHCECs. Some green structures also appear in the treated samples, they appear 
darker and slightly less defined than the live cells in infection controls. No viable bacteria were 
recovered from these wells. The scale bar represents a distance of 10 µm. 
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4.3.5 Explanted cornea infection model 
The explanted infection model was used to test the proposed formulations as opposed to the active 
drug candidate which was tested in the cell culture method. The experimental procedures of the 
explanted method were far more complex than the cell culture based model. Firstly, the samples 
were received from the slaughter house where the eyeballs were not aseptically handled. Use of a 
combination of antibiotics helped to reduce contamination, but contamination was encountered. 
Ideally, a model based on infecting human eyes would have been preferable. However, human eyes 
are difficult to obtain. Porcine eyes were sourced but these did not come directly from a slaughter 
house so problems were encountered with contamination and the integrity if the epithelial layer of 
the cornea. Due to this, bovine eye were chosen for use in the model. The bovine corneas were 
indeed larger in size than either human or porcine corneas so were therefore easier to remove. 
However, the drawback of this was that the corneas had less curvature to them and more scaffold 
medium was required to fill them. Due to this, it was sometimes difficult to retain the scaffold 
medium within the cornea during the experiment, particularly during the extensive washing that 
was required post-infection and post-treatment. 
The full results of the explanted cornea infection model are given in Figure 4.9 and Error! Reference 
source not found.. The effect that the formulation had on the treated corneas was tested in two 
ways. The first was the standard CFU count method. This would estimate the number of gonococcal 
cells that could be recovered from the cornea after saponin treatment. The saponin was used to 
lyse the cells of the epithelial layer to release as many of the attached and internalised gonococci 
as possible. The corneas were infected with approximately 1 x 106 gonococcal cells. From the 
positive infection control, approximately 5.7 x 104 gonococcal cells were recovered; this represents 
around 6 % of the original bacterial inoculum. The remaining cells either did not attach, were 
washed off in the washing procedures or did not survive the recovery process. A number of trial 
runs of the experiment were conducted. The problems that were originally encountered were that 
this rate of infection was originally even lower. This would mean that the all of the formulations 
would be effective, even the formulation without the drug candidate would lower the cell numbers 
to a level close the lowest level of statistical significance. Lower cell numbers means that the true 
effectiveness of each of the formulations could not be statistically tested. 
The CFU experiment does demonstrate that even treatment without the active drug candidate does 
yield a drop in the number of bacteria recovered post-treatment. This may be due to the amount 
of Polysorbate 20 present in the no monocaprin control. The surfactant may interfere with the 
attachment of the gonococcal to the epithelial layer. The log reduction results between the no 
monocaprin control and 0.068 % monocaprin formulation are very close and the images from the 
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corneal prints are also similar in the number of bacteria recovered. This is surprising because in 
Chapter 3 it was shown that the action of Polysorbate 20 was bacteriostatic not bactericidal. 
However, this model suggests that the inclusion of the surfactant in the formulation would be 
beneficial not just in terms of improving the solubility of the monocaprin but in the prevention of 
gonococcal infection by interfering with attachment and internalisation.  
The results in Figure 4.9 and Figure 4.9 show that the action of the monocaprin was diminished 
somewhat in the explanted corneal model in comparison to previous testing done so far. This model 
represents a closer environment to the formulations intended end-use than previous experiments. 
It could be that the presence of the complex organic tissue somewhat hinder the action the 
monocaprin. However, despite this inactivation, activity of the monocaprin was restored when used 
at the higher concentrations and it was still able to clear the infection. When the monocaprin was 
used at a concentration of 0.188 % or 0.25 % it was able to completely clear the infection in some 
cases. The model is laborious but at present has given a closer representation of how the 
formulation would function in the eye. 
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Figure 4.8 The effect of the concentration of monocaprin present in the formulations to reduce the 
number of live N. gonorrhoeae cells attached to a cornea. Different concentrations of monocaprin 
were used to treat infected corneas in an explanted corneal infection model. The formulation 
without any monocaprin added (0 %), reduced the bacterial load by 1 log10. Formulations with 0.062 
% and 0.125 % monocaprin only made marginal improvements over the formulation without any 
monocaprin. However, the formulations containing 0.188 % and 0.25 % monocaprin reduced 
bacteria load by over 2 log10. Due to the statistical limits of this test the maximum reduction possible 
was 3 log10. Error bars represent the standard deviation over two experiments (0.25% was no error 
bars as it caused complete killing in both experiments).  
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Figure 4.9 Results of the explanted corneal infection model using the corneal print method. The 
amount of growth present in the Infection control is the greatest. Surprisingly, the No Monocaprin 
Control had less gonococcal growth. The amount of growth of the test formulations decreased with 
monocaprin concentration 
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4.4 Conclusion 
The cell culture infection model presented in this chapter used three methods to analyse the 
effectiveness of the drug candidate. The first method was the CFU count method, which proved 
laborious but very effective. The second method used fluorescently tagged antibodies to visualise 
the infecting bacteria on the host cell surface. This method has found to be unsuitable for visualising 
the effect of the drug candidate because infected untreated wells appeared similar to those that 
had been treated. Therefore, this method was only able to demonstrate that killed gonococci were 
still capable of binding to host cells. The third method, which used a live-dead differentiating 
fluorescent dye kit, proved to be a better tool to visualise the killed bacteria. However, like many 
qualitative tests, it could suffer from bias as results are open to the interpretation of the researcher. 
Overall, the CFU count method proved to be best as it produced reliable quantitative data. 
Two models of infection have been trialled in this chapter. One was based on cell culture of corneal 
epithelial cells, the other used explanted corneal tissue. There are positive and negative attributes 
to each of the models. For a start, the cell culture model doesn’t require the use of fresh excised 
animal material. As such, the experiment is more flexible, and can be conducted whenever the cells 
are ready. The explanted infection model is also far more laborious and has a greater risk of failing 
due to contamination. Furthermore, cell culture based models of infections are far more 
established than infection models based on explanted material. It could be argued that the 
explanted infection model offers a far closer representation to the conditions leading to ophthalmia 
neonatorum than the cell culture based model. Due to this, this model has given us important 
information about effectiveness of the drug candidate and the formulations.  
The cell culture returned results similar to the “bacteria suspended in medium” method in Chapter 
2; that a concentration of 0.5 mM monocaprin would be sufficient to reduce the bacterial load by 
at least 103. It also demonstrated that the drug would be effective if applied 90 minutes after 
infection. However, in the explanted model, the formulations underperformed to what was 
expected. The formulations tested in the explanted model (which contained active drug candidate) 
were 0.062 %, 0.125 %, 0.188 %, and 0.25 %, these are approximately equivalent to 2.5 mM, 5 mM, 
7.5 mM, and 10 mM respectively. The lowest of these concentrations, based on data of this thesis 
thus far, should be more than adequate to kill all of the bacteria on the surface of the cornea. 
However, the 0.062 % monocaprin formulation only performed marginally better than the No 
Monocaprin Control. This indicates that although monocaprin has powerful anti-gonococcal 
properties when mixed in a solution directly with the bacteria, when used in an environment 
replicating the condition of the eye, those anti-gonococcal properties are diminished. As stated in 
Chapter 1, there are substances that can inhibit the antimicrobial action of fatty acids and 
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monoglycerides. It could be possible that such inhibitors are present in the tissue of the cornea. For 
this reason, formulations with higher concentrations of monocaprin were used in the explanted 
corneal infection model than had been tested before. Despite the diminished activity of the 
monocaprin, when used at the higher concentrations it was still able to clear the infection. 
Therefore, 0.188 % or 0.25 % should provide better protection against the development of 
ophthalmia neonatorum. 
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5.1 Introduction 
5.1.1 Antimicrobial resistance 
An overview of antimicrobial resistance in N. gonorrhoeae has already been given in Chapter 1. 
However, it is necessary to revisit this subject in context of this chapter. So far in this thesis we have 
established that monocaprin is a powerful bactericidal agent against N. gonorrhoeae, which has 
been demonstrated on a selection of strains that has been tested so far. However, with the 
development of any antimicrobial containing formulation, attention must be given to possible 
resistance mechanisms. There are many ways that bacteria can acquire resistance mechanisms and 
some of these mechanisms which N. gonorrhoeae uses has been discussed. Some resistance 
mechanisms can be induced in the laboratory experimentally. For example, growing the bacteria 
on media containing a sub-lethal concentration of the antimicrobial will select genomic mutations 
that confer an addition level of fitness in this environment to out-compete non-mutated cells. 
Experimentally inducing resistance to antimicrobials has been done in N. gonorrhoeae previously. 
In 1994, Belland and co-workers passaged N. gonorrhoeae on media containing increasing amounts 
of ciprofloxacin, a fluoroquinolone. The mutations from these passages resulted in an isolate that 
had a MIC value that was 10,000 times greater than of the parental isolate [323]. In this case, 
mutation in the gyrA and parC genes were identified to confer this decreased susceptibility. 
Mutations in the same genes were also seen in naturally occurring clinical isolates [77, 78]. 
Increasing resistance in N. gonorrhoeae to some of the newer fluoroquinolones such as 
ciprofloxacin was first reported in 1990 in North America [75, 76]. Ten years later the CDC no longer 
recommended fluoroquinolones for treatment in persons who acquired their infections in Asia or 
the Pacific Islands due to high prevalence of resistance in these regions [79-81]. In 2002, the CDC 
no longer recommended fluoroquinolones for MSM and by 2006, they no longer recommended 
fluoroquinolones for treatment of gonococcal infections [79].  
One way to help prevent decreased susceptibility by this mechanism would be to increase the 
concentration of the antibiotic to a level (as long as this level can be tolerated by the human body) 
where the microbe is unable to escape the action of the antimicrobial, this is known as the mutant 
prevention concentration (MPC). This can be determined in the laboratory and can be taken into 
account when setting treatment guidelines. However, the difference in MIC and MPC can be fairly 
large in some cases. With the example of ciprofloxacin, the MPC for a non-resistant strains is about 
4-fold the MIC and 16-fold the MIC for a strain with an existing gyrA mutation [324]. 
5.1.2 Experimental evolution 
A field of research termed experimental evolution has been developed for the monitoring of 
evolution in the laboratory [325]. How the genotypic and phenotypic properties evolve over 
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hundreds and even thousands of generations due to a change in environment can be evaluated in 
detail. The most well-known experimental evolution conducted on a microorganism is the long-
term evolution experiment being conducted by Richard Lenski which started in 1988 is still 
continuing today [326, 327]. The experiment involves the passage of twelve initially identical 
populations of E. coli in standard growth medium. The cultures are passaged every 22-26 hours by 
sub-culture of 1 % of the bacteria suspension [328]. The initially identical populations have diverged 
from each other considerably since the experiment started [329]. One of the most notable 
phenotypic changes is that one of the replicates is able to aerobically utilise citrate [330, 331]. E. 
coli is not normally able to do this and indeed this is a phenotype that is used to distinguishing E. 
coli from pathogenic Salmonella. This phenotype was not the result of one mutation but has been 
achieved by an accumulation of mutations [330]. These types of experiments are useful as they can 
tell us how a microbe is likely to change in response to a change in their environment.  
5.1.3 Evolve and re-sequence 
Next generation sequencing (NGS) has revolutionised DNA sequencing [332]. NGS is the term used 
to describe multiple technologies (produced by competing manufacturers) for the high-throughput, 
low-cost generation of DNA sequencing [333, 334]. The cost of sequencing is now so low that it is 
being considered as a diagnostic tool for the identification of human [335-339] and veterinary [340, 
341] pathogens. Identification in this way would have other benefits such as predicting the 
presence of antimicrobial resistance mechanisms, toxin production, virulence factors and 
genotyping. 
The low cost means that it can be considered for analysis of experimental evolution studies. The 
thought of sequencing the whole genome of a bacteria that had previous been sequenced to map 
mutations would have been unthinkable a few years ago. Today, masses of genomic data can be 
produced from experiments and a non-targeted, non-biased approach can be taken. So popular has 
this approach become that the term “evolve and re-sequence” (E&R) has been coined [342, 343]. 
E&R has been used not just on bacteria but also on higher organisms such as Saccharomyces 
cerevisiae [344] and Drosophila melanogaster [345, 346]. The E&R approach is a powerful one and 
could identify mutations in unexpected regions of the genome. 
5.1.4 NGS – Illuminia 
The main NGS technology used in this study is Illuminia so therefore the technology behind this 
method will be briefly explained here. The technology was originally developed by the company 
Solexa which was formed by Cambridge scientists Shankar Balasubramanian and David Klenerman 
in 1998 [347]. By 2005, they had produced a prototype DNA sequencer that was based on 
sequencing by synthesis technology which showed great promise [348]. In 2006 the Genome 
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Analyzer was launched. In 2007 Solexa was acquired by Illumina and continued to produce DNA 
sequencers based on sequencing by synthesis technology. 
An overview of the sequencing by synthesis used by Illumina is given in Figure 5.1. More detailed 
explanations of how the sequencing technology works can be found on Illumina’s website [349, 
350]. Illumina is one of the best NGS technologies for bacterial genome re-sequencing as it has one 
of the highest throughputs per run, lowest error rates and does not create homopolymer-
associated errors in comparison to some other high-throughput sequencing platforms [351, 352]. 
5.1.5 Variant calling 
NGS typically produces a higher error rate than conventional Sanger sequencing. However, each 
base in a genome is typically sequenced many times in different reads. The number of times a single 
base has been sequenced in different reads is termed the coverage. The higher the coverage, the 
higher the confidence that can be given in the generated data. However, the sequences generated 
from the different reads have not come from one single DNA molecule. The starting material used 
in the library preparation is from a population of bacteria which may have differences between 
each cell. This is typical of viral and bacterial population which have a relatively high mutation rate 
and is referred to as a quasispecies model. Therefore, at a particular nucleotide in the genome, 
some of the population may have a different base at this position and therefore be a different 
genotype. This could be represented in the read data as long as the genotype is not a very small 
minority and that there is enough coverage to identify it. These polymorphic sites can be identified 
by using software. Due to the error rate of NGS, all potential polymorphic sites have to go through 
a strict filter process [353-356].  An example of a work-flow showing the steps from NGS to variant 
calling and the QC processes is given in Figure 5.2 [356]. There is a dedicated variant calling file 
format which was original created by the 1000 Genomes Project [357]. This standard is now 
maintained by the Global Alliance Data Working Group File Formats Task Team [358]. 
Although some of mutations may occur randomly, or be in more variable regions, some may arise 
as they offer a survival benefit in the changed environment. Cells with this mutation could out-
compete other non-mutated cells to become the dominant genotype. As with mutations in N. 
gonorrhoeae on exposure to fluoroquinolones, a number of mutations, some conferring greater 
resistance could occur in specific regions or genes. 
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Figure 5.1 An overview of the sequencing chemistry used by Illumina sequencing by synthesis 
technologies [350]. (A) Library preparation, shows how the template DNA is prepared with the 
addition of adaptors to bind the DNA to the flow cell. (B) Custer amplification, once a DNA strand 
has bond to the flow cell, that strand is amplified by bridge amplification to form a clonal cluster. 
(C) Sequencing, labelled nucleotides are added and only a single nucleotide complementary to the 
template is added. A light source excites the fluorophore on the newly added nucleotide and light 
is emitted. A sensor detects the light and after, the fluorophore is removed and the cycle starts 
again. After the read is complete the strand is amplified again by bridge amplification and the strand 
just sequenced is removed leaving the reverse strand. This is then sequenced as the previous 
strand. This method is called paired end sequencing and enables more accurate read alignment and 
helps to cover repetitive regions.  (D) Alignment and data analysis, the reads from the different 
clonal clusters are aligned using software to form an assembly and a consensus sequence is built 
from this.  
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Figure 5.2 Typical work-flow of DNA sequencing experiment with QC reports [356]. 
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5.1.6 Fatty acid resistance in N. gonorrhoeae 
Efflux pumps and fatty acid resistance in N. gonorrhoeae have been outlined in Chapter 1. However, 
here it is necessary to describe in more detail these systems and how changes in these systems can 
result in a change in resistance. The FarA-FarB-MtrE efflux pump has been demonstrated to confer 
decreased sensitivity to certain fatty acids [148]. Transcription of farAB is controlled by the FarR 
protein and integration host factor [150]. Therefore, mutations in farAB or mtrE open reading 
frames (ORFs) or promoters; or mutations in any of their regulators could have an effect on the 
resistance profile of the bacteria. For example, mutation in the promoter of mtrR have been shown 
to exhibit higher levels of resistance to MtrC-MtrD-MtrE efflux pump substrates [359, 360]. 
5.1.7 Aim of this chapter 
The aim of this chapter is to try to experimentally induce resistance to our main drug candidate and 
thus to identify possible mechanisms of resistance. This will be done by using an experimental 
evolution study using an E&R strategy to map any resulting mutations that could cause an increase 
in resistance to our drug candidate and other fatty acids.  
5.2 Materials and methods 
5.2.1 Bacterial growth and molecular evolution 
For the experimental evolution, three conditions were used: two with inhibitors monocaprin 
(10:0MG) and myristic acid (14:0) and the other without any inhibitor (non-selective). Monocaprin 
was chosen as it is the main drug candidate in this study and myristic acid was chosen as it has very 
good bacteriostatic properties against N. gonorrhoeae but also has a known mechanism of 
resistance in the farAB-mtrE encoded efflux pump system [148]. 
A diagram representing the outline of the experimental evolution experiment is shown in Figure 
5.3. Duplicate samples were done for each sample condition. The inhibitors were present in GC 
solid media at sub-MIC levels as determined below. The GC plates were prepared as in methods 
section 2.2.1 with slight modification: 90 mm petri-dishes were used instead of 55 mm. To start the 
experiment, a stock of N. gonorrhoeae NCCP11945 which was made from the original NCCP11945 
received by Kingston University, was removed from -80 °C storage and defrosted at room 
temperature. From this, 100 µl was plated over a whole agar plate using an ‘L’ shaped spreader. 
The plate was incubated at 37 °C, 5 % CO2 for 48 hours. To passage the cells, a sterile plastic 
inoculation loop was used to scrape up cells off the plate and put into 1 ml GC broth medium in a 
1.5 ml centrifuge tube. Cells were added until a turbidity equivalent to a 0.5 McFarland standard 
was produced. The tube was then shaken to produce a homogeneous mixture. A sterile cotton wool 
swab was dipped into the bacterial suspension and a continuous streak done over an entire GC agar 
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plate. For the first passage, this process was done on six GC plates, two ordinary GC plates (non-
selective), two GC plates containing monocaprin and two containing myristic acid. 
Passages were done every 48-72 hours until a total of twenty passages were complete. Duplicate 
samples for each passage condition were labelled 1 and 2 and kept separate from each other. At 
every third passage a Gram stain was done, to check purity, DNA was extracted, and three glycerol 
stocks were made (as 2.2.1) for storage at -80 °C. At the final twentieth passage all these processes 
were done to check the final passages. 
5.2.2 Minimum inhibitory concentration estimation 
Stocks of 0.1 M monocaprin and myristic acid were made up in ethanol as described in Chapter 2. 
GC agar was made and sterilised as 2.2.1 in 500ml volumes. The iron and glucose supplements were 
added and then 40 ml of the molten agar added to a 50 ml centrifuge tube containing stock 
monocaprin or myristic acid to give the desired overall concentration. The plates were then poured 
into 90 mm petri-dishes and cooled to room temperature before storage at 4 °C. The tested 
concentrations of the inhibitors were 500, 250, 125, 62.5, 32.25 and 16.125 mM.  
A cell suspension in GC broth equal in opacity to a 0.5 McFarland standard was made. A sterile 
cotton-wool swab was dipped into the bacterial suspension and used to make a single continuous 
streak on the agar plate. Plates were incubated at 37 °C, 5 % CO2 for 48 hours. The lowest 
concentration of inhibitor which prevented growth was deemed the MIC. The highest 
concentration of inhibitor which did not prevent growth (sub-MIC concentration), was used in 
experimental evolution experiment to try to induce resistance. This whole MIC process was then 
repeated after the experimental evolution process was completed to assess their phenotypic 
changes. 
5.2.3 DNA extraction 
DNA was extracted from 500 µl of a bacterial suspension in GC broth equivalent to a 0.5 McFarland 
standard. A Qiagen (Manchester, UK) Gentra Puregene Yeast/Bac kit was used to extract DNA using 
an in-house method which had been developed from the original manufacturer’s instructions with 
slight modification to increase the yield of DNA from Neisseria species. The bacterial suspension 
was centrifuged at 13,000 x G for 30 seconds, pellet resuspended in 500 µl cell lysis solution and 
incubated at 80 °C for 10 minutes. The tubes were removed and allowed to cool briefly at room 
temperature. Then, 1.5 µl RNase A solution was added and mixed thoroughly by inverting the tubes 
25 times. The tubes were incubated at 37 °C for one hour.  
Once the tubes were removed from the incubator, they were cooled on ice for one minute. After 
this, 100 µL protein precipitation solution was added and the tubes were shaken on vortex mix for 
Chapter 5 – Molecular evolution due to experimental exposure to fatty acids 
169 
 
20 seconds. The samples were centrifuged at 14,500 x G for three minutes. The supernatant was 
removed and added to a new 1.5 ml centrifuge tube containing 300 µl isopropanol. The tubes were 
vigorously mixed by inverting 50 times and then centrifuged at 14,500 x G for one minute. The 
supernatant was discarded and 300 µl 70 % isopropanol added. The tubes were inverted five times 
and centrifuged again at 14,500 x G for one minute. The supernatant was discarded and the 
remaining isopropanol was removed by inverting the open tubes on absorbent paper and leaving 
for five minutes at room temperature. The pellets were resuspened in nuclease-free water 
(Thermo-Fisher Scientific) and were mixed by using a vortex mixer for 10 seconds. The samples 
were then incubated at 65 °C for one hour and vortexed again. Samples were stored at -20 °C until 
required. 
5.2.4 Gram staining 
A plastic 10 µl loop was dipped into the bacterial suspension used at each third passage and pressed 
against a glass microscope slide (Thermo-Fisher Scientific). The resulting droplet was spread over a 
1 cm2 area of the slide and allowed to dry for five minutes at room temperature. Once dry, the cells 
were then fixed to the slide by passing over a ‘roaring’ Bunsen burner flame three times and allowed 
to cool. On a flat surface over a bowl, 0.1 % crystal violet was added, enough to cover the 1 cm2 
where the suspension was applied. The slides were left for one minute and then washed with 
deionised water. Gram’s iodine was then added, left for one minute, and again washed off with 
deionised water. Ethanol was the added using a glass Pasteur pipette in a continuous stream over 
the slide for 5-10 seconds. The slide was washed briefly with deionsed water, carbol fuchsin add 
and left for two minutes. The counter-stain was removed, the slide finally washed with deionised 
water and blotted dry on absorbent paper. After this, the samples were checked under a light 
microscope at up to 1,000 times magnification. Any sample that had bacteria present that weren’t 
small Gram negative (pink) cocci-diplococci were discarded.  
5.2.5 Illuminia DNA sequencing 
DNA extractions from the six experimental evolution samples 20th passage, as well as the DNA 
extraction from the original low passage N. gonorrhoeae strain NCCP11945 were chosen for DNA 
sequencing. The DNA concentrations of the samples were determined using a NanoVue 
Spectrophotometer (GE Healthcare Life Sciences, Little Chalfont, Buckinghamshire, UK). The 
spectrophotometer was first calibrated against 1.5 µl nuclease-free water. For testing, 1.5 µl of 
sample added. The DNA concentrations were recorded, and the absorbance ratios at 260/280 nm 
and 260/230 nm were also recorded to give an indication of purity. After removal of the sample, 
the target plate was cleaned using a lens tissue paper before the next sample was loaded. 
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Sample details were sent to MicrobesNG (University of Birmingham, Birmingham, UK, supported by 
the BBSRC, grant number BB/L024209/1) and barcoded sample stickers were received through the 
post. The DNA samples were transferred to 1.2 ml screw-capped vials (Nalgene) and the 
appropriate barcode added. The samples were sent next-day, recorded delivery to MicrobesNG. 
The samples were DNA sequenced using 2x250 bp paired-end reads on an Illumina HiSeq 2500.  
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Figure 5.3 Diagram representing an outline of the experimental evolution study. 
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5.2.6 Bioinformatics – quality control and genome assembly 
Trimmed read data in the form of FastQ files were downloaded from the MicobesNG server 
(http://microbesng.climb-radosgw01.bham.ac.uk). The reads had already been trimmed to remove 
adapters and index sequences. Also, in the automated post-run processing, reads of less than 36 
bases were discarded and very long reads trimmed to 251 bp. Only reads that had a matching pair 
were used in the analysis. The unpaired reads were also provided but were not used in the analysis.  
All bioinformatic analysis was done on a Hewitt Packard Pavilion series 7 laptop, with a Pentium 
dual-core T4300 @2.10 GHz CPU, 4 GB of RAM running Linux 64 Bit Ubuntu 14.04.  
All the read files were checked using FastQC version 0.11.2 [361] and output files stored as html 
files. The software package UGENE version 1.20.0 [362, 363] was used to align the read files. UGENE 
used a Bowtie2 plug-in [364] to assemble the upstream and downstream paired read files against 
the published sequence of NCCP11945 which was downloaded from Genbank as a fasta file 
(accession number NC_011035.1) [224]. The alignments were saved as BAM files. Coverage data 
was exported from UGENE and converted into histograms using LibreOffice Calc 5.0. 
5.2.7 Consensus SNP and variant calling 
Each mapped BAM files was aligned against the NCCP11945 Genbank fasta sequence as reference. 
Consensus SNPs were exported from UGENE as snp files. Variant calling was performed in UGENE 
using SAMtools plug-ins mpileup and bcftools [365]. Reads that had a base quality lower than 13 
were discounted and a minimum coverage of two at the site of interested was used to filter results. 
Results were exported as vcf files.  
Assemblies in UGENE were checked manually for the positions in the snp file. Any positions that 
had a coverage less than two reads were noted and processed further but were excluded from the 
final analysis. Genbank files (.gb) for NCCP11945 (NC_011035.1) were downloaded. Artemis version 
16.0.0 [365, 366] was used to load the genbank files which displays the genome annotation. The 
SNP locations were located on the annotated genome and genomic feature at that position was 
recorded such as if present in an ORF, repetitive region or non-coding region. If located in an ORF, 
then the gene was identified and any predict consequence from that mutation (such as an amino 
acid substitution) was also recorded. All SNPs and indels were tabulated and then separated into 
coding and non-coding regions. They were further separated into mutations that had occurred in 
all samples (compared to Genbank reference), present in only non-selectively passaged cells in 
comparison to unpassaged cells (defined as low passage sample), mutations occurring in myristic 
acid passaged samples, mutations occurring in monocaprin passaged samples and mutations 
occurring in multiple samples but across sample groups. Also, particular attention was paid to the 
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promoter regions of farR, farAB, mtrR and mtrCDE. For this, the vcf files were checked and loaded 
against the assemblies in UGENE.  
5.2.8 Testing of SNP effects 
The position of any mutation was checked in Artemis with the loaded NCCP11945 Genbank 
annotation. The position of the mutation in terms of the change in codon was also record and any 
nonsynonymous mutations checked further. The online bioinformatic tool SNAP2 [367] was used 
to predict the impact of a single amino acid substitution on protein function. The program would 
return a result of with either “effect” (score >0) if it predicted that the substitution may have a 
functional effect on the protein or “neutral” (score <0) if it predicted that the substation wouldn’t 
have an effect. For each of these predictions it would score the substation and give and an 
estimations of accuracy of the prediction. 
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Figure 5.4 Work-flow diagram of bioinformatics approach to identify mutations occurring in 
passaged samples. 
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5.3 Results and discussion 
5.3.1 Initial MIC testing 
The results of initial MIC testing are shown in Table 5.1. The MIC values were 125 and 250 µM for 
myristic acid and monocaprin, respectively. Therefore, concentrations of 62.5 and 125 µM were 
used in the experimental evolution for myristic acid and monocaprin, respectively. 
5.3.2 Experimental evolution 
The non-selective, monocaprin and myristic acid passage samples were successfully passaged for a 
total of twenty passages each. Growth on the plates containing inhibitors were observed to be 
slower than those on non-selective plates. This was especially true for the first few passages on the 
myristic acid plates. This could be due to the concentration of myristic acid being more of a 
challenge than that of the monocaprin as the experimentally determined MIC for myristic acid may 
be closer to its true MIC than the monocaprin samples. The samples were passaged every 48-72 
hours. The cells had to be passaged for up to 72 hours due to practical limitation, i.e. they couldn’t 
be passaged on weekends. It was noted that on occasion the monocaprin or myristic acid passaged 
samples were deemed non-viable due to this increased incubation time on the plates containing 
the inhibitors. This was never the case with the non-selective sample despite their presumed higher 
growth rate. However, during the experiment, the growth rates of the selective plates were 
observed to increase, particularly for the initially slow myristic acid samples. 
5.3.3 Gram staining 
The Gram stains during and after the experiment all showed small Gram negative cocci or 
diplococci. No other bacteria were observed at any point. 
5.3.4 Post-experiment MIC testing 
The results of the MIC testing on post-experimental evolution are displayed in Table 5.1. The results 
of monocaprin MIC for the samples passaged on plates containing inhibitors were all the same. The 
values were double (250 µM) that of the non-selectively passaged cells and the low passage cells. 
This indicates that passage on myristic acid prepares the bacterial cells well for growth on 
monocaprin. This could be due that their resistance mechanisms being the same or similar. The 
results of the myristic acid MIC testing were more surprising as the increase in MICs were far greater 
than those seen with monocaprin. The monocaprin passaged cells had an eight-fold increase in MIC 
value for both duplicate samples. The myristic acid passaged samples had a sixteen-fold increase in 
MIC value. The sample replicate designated “14:0-1” appeared to have a distinct growth rate 
advantage over the second replicate but despite this failed to grow on a higher concentration plate 
(2 mM). They were therefore given the same MIC value. It seems that the growth on monocaprin 
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has conditioned the cells well for growth on myristic acid with a large increase in MIC. However, 
unlike the testing of monocaprin, the cells grown on that particular inhibitor do appear to have a 
slight advantage over the cells passaged on the other inhibitor.  
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Table 5.1 Minimum inhibitory concentrations for monocaprin and myristic acid of the original 
isolate (Low passage) and of the six isolates after the twenty passages on non-selective and media 
containing inhibitors. 
Isolate Monocaprin MIC 
(µM) 
Myristic acid MIC 
(µM) 
Low Passage 125 62.5* 
Non-selective 1 125 62.5 
Non-selective 2 125 62.5 
Monocaprin 1 250 500 
Monocaprin 2 250 500 
Myristic acid 1 250 1000 
Myristic acid 2 250 1000* 
* denotes weak growth plate with highest antimicrobial plate allowing growth  
Chapter 5 – Molecular evolution due to experimental exposure to fatty acids 
178 
 
5.3.5 DNA extractions. 
DNA was extracted and DNA concentrations estimated. The DNA concentration estimates and 
purity ratios are given in Table 5.2. 
5.3.6 NGS sequencing and assembly 
Links to data files from the sequencing were emailed 107 days after submission of the samples. The 
data was downloaded and analysed. The quality of the paired read files was performed with FastQC 
and a summary is given in Appendix 5.1. The coverage of the samples varied. The sequencing service 
aimed to obtain a mean coverage of 30. Indeed, an average coverage of 30 is required to gain a 
high level confidence in a completed genome for publication [368]. Some of the samples were a 
little below this value but was still of a good enough quality to conduct this study. The coverage 
summaries of the sequence data are given in Table 5.3. The full coverage histograms are given in 
Appendix 5.8-5.14. Non-selective 1 had the lowest average coverage at 16.22. The quality of the 
DNA judged by the 260/280 and 260/230 (Table 5.1) appear to be good so the reason for the lower 
coverage may not be due to the DNA quality. 
The paired sequencing reads were successfully mapped to the Genbank NCCP11945 reference 
genome. There were however, some gaps in the assemblies. Table 5.4 lists the positions and 
features of these gaps for each of the samples. There were a few reoccurring regions of the genome 
where these gaps were present such as: NGK_RS03237 – Peptidase, NGK_RS03380 – hypothetical 
protein, NGK_RS05170 – integrase, and Non-coding repeat region containing 1154312. Low 
coverage in some areas of the genome was found in the original sequencing that required primer 
walking to fully complete [224]. These areas could be due to repetitive regions as the N. 
gonorrhoeae genome is known to have an abundance of repetitive DNA uptake sequences, 
neisseria intergenic mosaic elements and Correia elements which could hinder the genome 
assembly process [224]. Repetitive regions cause ambiguities in alignment and assembly which 
cause produce biases and errors when interpreting results [369]. 
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Table 5.2 Estimated DNA concentrations of passaged samples before sending for DNA sequencing 
Sample Estimated 
Concentration (ng/µL) 
A260/280 ratios A260/230 ratios 
Low Passage 634.5 1.970 1.923 
Non-selective 1 643.0 1.991 1.877 
Non-selective 2 498.0 1.972 1.883 
Monocaprin 1 456.0 1.961 2.022 
Monocaprin 2 1815 2.023 1.881 
Myristic acid 1 141.5 1.814 1.497 
Myristic acid 2 146.0 1.814 1.669 
 
 
Table 5.3 Number of reads and coverage statistics of the sequence assemblies of the Illumina data 
Sample Number of 
reads 
Mean 
coverage 
Mode 
coverage 
Median 
coverage 
Low Passage 429,999 34.46 34 34 
Non-selective 1 343,345 26.78 25 26 
Non-selective 2 343,345 16.22 15 15 
Monocaprin 1 431,099 34.49 34 33 
Monocaprin 2 432,281 34.89 35 35 
Myristic acid 1 287,133 21.77 20 22 
Myristic acid 2 486,881 38.96 27 35 
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Table 5.4 Regions of NCCP 11945 genome not represented in the NGS data for each sample 
Sample Region of no 
coverage 
Gene locus Gene product  
Low passage 
 
595990-595995 NGK_RS03237 Peptidase  * 
82331-823364 NGK_RS04550 hypothetical protein  
940920-941056 NGK_RS05170 integrase # 
1154310-1154331 Non-coding 
repeat region 
N/A $ 
Non-
selective 1 
 
595974-596000 NGK_RS03237 peptidase * 
621405-621417 NGK_RS03380 hypothetical protein & 
940932-941039 NGK_RS05170 integrase # 
1154296-1154332 Non-coding 
repeat region 
N/A $ 
1724334-1794913 Non-coding 
repeat region 
N/A  
2128304-2128320 NGK_RS11605 pseudogene, glycosyl transferase 
family 1 
 
2212388-2212419 Non-coding 
repeat region 
N/A  
2230855-2230877 NGK_RS12140 protein translocase component YidC  
Non-
selective 2 
 
549722-549743 NGK_RS03010 hypothetical protein  
595974-596071 NGK_RS03237 peptidase * 
621391-621485 NGK_RS03380 hypothetical protein & 
709564-709568 Non-coding N/A  
745877-745884 NGK_RS04105 hypothetical protein  
940960-941029 NGK_RS05170 integrase # 
941042-941051 NGK_RS05170 integrase # 
960561-960609 Intergenic 
spacer and into 
NGK_RS05310 
ketohydroxyglutarate aldolase  
977794-977832 NGK_RS05385 hypothetical protein  
1041361-1041386 NGK_RS05705 type III restriction endonuclease 
subunit M 
 
1102548-1102556 NGK_RS06005 primosomal replication protein N  
1154306-1154371 Non-coding 
repeat region 
N/A $ 
1272349-1272363 NGK_RS06920 guanosine-3',5'-bis(diphosphate) 3'-
pyrophosphohydrolase 
 
1404473-1404578 NGK_RS07615 hypothetical protein  
2128340-2128351 NGK_RS11605 pseudo gene, glycosyl transferase 
family 1 
 
2187846-2187869 NGK_RS11895 membrane protein  
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Monocaprin 
1 
 
621416-621435 NGK_RS03380 hypothetical protein & 
1154312-1154331 Non-coding 
repeat region 
N/A $ 
2187836-2187854 NGK_RS11895 membrane protein  
2212393-2212412 Non-coding 
repeat region 
N/A  
Monocaprin 
2 
 
621405-621449 NGK_RS03380 hypothetical protein & 
940948-941027 NGK_RS05170 integrase # 
1154301-1154381 Non-coding 
repeat region 
N/A $ 
1794878-1794909 NGK_RS09750 pilS cassette  
2212403-2212410 Non-coding 
repeat region 
N/A  
Myristic 
acid 1 
 
595981-596000 NGK_RS03238 peptidase * 
621387-621482 NGK_RS03380 hypothetical protein & 
940930-941033 NGK_RS05170 integrase # 
960499-960599 Intergenic 
spacer and into 
NGK_RS05310 
ketohydroxyglutarate aldolase  
1105201-1105208 NGK_RS06020 copper-transporting ATPase  
1105235 NGK_RS06020 copper-transporting ATPase  
1105250 NGK_RS06020 copper-transporting ATPase  
1136543-1136545 Non-coding N/A  
1154311-1154377 Non-coding 
repeat region 
N/A $ 
1253885-1254020 Non-coding N/A  
1794878-179491 NGK_RS09750 pilS cassette  
2073533-2073540 NGK_RS11340 membrane protein  
2083280-2083281 NGK_RS11385 ribonuclease E  
2109802-2109836 Non-coding N/A  
Myristic 
acid 2 
 
122444 NGK_RS00595 citrate transporter  
621405-621435 NGK_RS03380 hypothetical protein & 
848553-848641 Non-coding N/A  
855390-855406 Non-coding N/A  
858540-858656 NGK_RS04750 hypothetical protein  
859260 NGK_RS04755 hypothetical protein  
859548-859586 Non-coding N/A  
860342-860354 NGK_RS04760 hypothetical protein  
864143-864154 NGK_RS04790 hypothetical protein  
864210 NGK_RS04790 hypothetical protein  
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864291-864307 NGK_RS04790 hypothetical protein  
866518 NGK_RS04805 conjugal transfer protein TraG  
866546-866628 NGK_RS04805 conjugal transfer protein TraG  
867196-867201 NGK_RS04805 conjugal transfer protein TraG  
941031-941036 NGK_RS05170 integrase # 
972861-972866 NGK_RS1223 hypothetical protein  
1154296-1154321 Non-coding 
repeat region 
N/A $ 
1272331-1272347 NGK_RS06920 guanosine-3',5'-bis(diphosphate) 3'-
pyrophosphohydrolase 
 
2039081-2039198 NGK_RS11155 30S ribosomal protein S8  
2212383-2212425 Non-coding 
repeat region 
N/A  
* NGK_RS03237, Peptidase (4/7) 
& NGK_RS03380, hypothetical protein (6/7) 
# NGK_RS05170, integrase (6/7) 
$ Non-coding repeat region containing 1154312 (7/7) 
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5.3.7 Consensus mutations and variant calling 
The total number of consensus mutations and variant callings are given in Table 5.5. The non-
selective 2 sample had the greatest number of both consensus mutations and variant callings. This 
sample also had the lowest coverage values. It could be that these facts are linked. However, the 
two schemes work in different ways. Assigning the consensus sequence complex but is usually 
assigned to the majority nucleotide present at a given location [368]. Consensus sequences can be 
based on a single read. This would therefore be far more prone to contain errors than other regions 
with better coverage. Therefore, consensus mutations based on two or fewer reads were manually 
discarded from the analysis. However, this system would still be prone to errors in regions of poor 
coverage. Variant calling on the other hand, reports a variant population if two or more reads are 
present that are different from the reference. Therefore, it can report on a mixed genotype in the 
sample even if the mutation is in a minority. All reads have to pass an additional quality filter so the 
stringency is increased. However, areas of greater coverage have more chance of containing two 
reads containing the same mutation. Therefore, consensus mutations have a bias toward regions 
of low coverage while variant calling is more biased to areas of higher coverage. 
All consensus mutations of the seven samples in relation to the published Genbank DNA reference 
sequence were identified. A total of fifteen mutations were found to be present in open reading 
frames of all the isolates sequenced in this study in comparison to Genbank sequence. These 
mutations are displayed in Table 5.6. These differences are either the result of sequence errors 
from the original sequencing, sequencing errors in our data or mutations that have occurred in the 
NCCP11945 isolate between the time it was sequenced and reaching our laboratory. The original 
sequencing was done by Sanger sequencing with an eight-fold coverage and predicted error rate of 
0.15 per 10,000 bases [224]. If the error rate is correct then approximately 33 errors are present in 
the 2,232,025 bp genome.  All the mutations that occurred in ORFs were either in pseudogenes or 
were not judged to have a functional change by the Jpred 4 protein secondary structure prediction 
server (see Table 5.6). 
Eleven unique mutations were found in ORFs of the non-selectively passage cells and are displayed 
in Table 5.7. No one mutation occurred in both replicates. Five mutations occurred in the ORFs of 
functional genes that were judged to cause a functional effect by Jpred 4. These mutations occurred 
in: NGK_RS00080 - preprotein translocase subunit SecG, NGK_RS00215 – ribosomal protein L11 
methyltransferase, NGK_RS06935 – adenine phosphoribosyltransferase, as well as in NGK_RS03680 
a membrane protein and NGK_RS00290 – a hypothetical protein. 
Differences that were found in the open reading frames of the mystric acid passaged samples and 
monocaprin passaged samples were also located and are displayed in Tables 5.7 and 5.8, 
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respectively. The most striking of mutation that occurred in a myristic acid passaged isolate was a 
SNP mutation that would result in the 24th codon in the farR (annotated as MarR family 
transcriptional regulator) ORF being changed from a glutamine (Q) codon to an Ochre stop codon. 
The sequence assemblies and translation of the ORF of farR for the mutant (myristic acid 1) and the 
non-mutated replicate and shown in Figure 5.6. The mutation which occurs at position 61,543, is 
present in all sequence reads. In contrast, the mutation is not present in any of the sequence reads 
of the duplicate sample. A mutation resulting in the absence of FarR would increase farAB 
transcription [150]. This may suggest that the mutation is rare but gives a significant advantage 
when it does occur. So, cells that would have this mutation could have an advantage over the 
bacterial population that has the wild type form of the gene. This sample was observed to have a 
growth advantage over its other replicate but didn’t actually increase its MIC value. It would be 
interesting to go back and re-sequence some of the earlier passages to find out when this mutation 
occurred and compare the growth rates of the pre-mutation and post-mutation isolates. It is clear 
that this is a non-fatal mutation but it is unclear how this mutation would affect the cell in normal 
growth condition. The FarR transcriptional regulator does perform some off-target gene regulation. 
It been demonstrated that it can activate glnA transcription in N. gonorrhoeae, responsible for 
glutamine biosynthesis [145], and nadA in N. meningitidis [370].  
The monocaprin passaged isolates had two non-synonymous SNP mutations, both of which were 
predicted to have a functional effect. The first only occurred in replicate 1 and was in the phosphate 
permease protein. This is a membrane protein which is responsible for passively allowing entry of 
phosphate ions into the cell. It is not clear what effect this mutation would have on the cells ability 
to protect it from monocaprin. 
The second SNP mutation is in the ORF of the dnaK which encodes a suppressor protein (DksA) 
(NGK_RS106025) and is  present in both replicates. DksA is a zinc-containing multi-functional 
protein, its main role is as a transcription factor. Instead of binding to DNA to help recruit RNA 
polymerase, DksA binds directly to RNA polymerase. By doing so it; negatively regulates rRNA 
expression by destabilizes rRNA promoter complexes [371], positively regulates several amino acid 
biosynthesis genes [372] and regulates fis expression (an important gene regulator) [373]. It also 
inhibits transcript elongation, exonucleolytic RNA cleavage and pyrophosphorolysis; and increases 
intrinsic termination [374] as well as being involved with RecN in repair of DNA double-strand 
breaks [375] and suppression of dnaK [376]. 
As with the farR mutation, the dksA mutation is present in all assembled reads at that position in 
both replicates. Figure 5.7 gives the details of the mutation. The mutation causes a substitution of 
the 75th amino acid from a threonine to an isoleucine. This was predicted to have a functional effect 
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on the protein with a change in the predicted secondary structure (see Figure 5.7.B). The role of 
D71, D74 or A76 residues of the E. coli homolog forms part of the coiled-coil tip that is responsible 
for the DksA-specific effects on open complex formation [377, 378]. Part of the N. gonorrhoeae 
homolog protein can be seen aligned against the E. coli version in Figure 5.7.C. The mutation T75I 
is 11 amino acids away from these important residues. Although this mutation appears to be in a 
region that is highly conserved, that particular base is not as conserved as D71, D74, A76 and some 
other surrounding residues [379]. The protein appears to be highly conserved within N. 
gonorrhoeae; at the time of writing, 322 DksA protein sequences are present on the GenPept 
database. From these, 319 (99%) have an amino acid sequence identical to NCCP11945, while the 
other three have separate single amino acid substitutions. None of these substitutions were of the 
75th residue. 
Cellular levels of DksA in E. coli are relatively constant irrespective of changes in growth rate or 
growth phase as transcriptional control is varied by its cofactors, guanosine-3',5'-
(bis)pyrophosphate (ppGpp) and initial ribonucleotides (iNTP) [380, 381]. However, research in 
other bacteria such as Chlamydia pneumoniae [382] and Pseudomonas aeruginosa [383] have 
found that the levels do increase upon certain cellular events. 
Transcriptional control of dksA in E. coli is controlled by DksA (and ppGpp), negatively regulating its 
own transcription causing a negative feedback [381]. DksA is involved in the ‘stringent response’ 
which is the stress response that occurs when bacteria are starved of essential cellular components 
such as amino acids, fatty acids or iron; or exposed to heat shock, or other stress conditions [384]. 
It is possible this is the reason why the mutation is favourable but what effect the mutation has in 
enhancing or supressing the stringent response is unknown.   
Table 5.9 shows mutations that occurred within ORFs in multiple but unrelated samples. Therefore, 
any mutations shared between the groups of samples that were passaged on plates containing 
inhibitors would be present in this table. The only mutation that occurred in both of the inhibitor 
groups but not any of other samples was in a membrane protein (NGK_RS11245). However, all 
other samples apart from the low passage strain had another mutation present in the same codon. 
It is likely that this mutation is unrelated to the selective pressure of the inhibitor. All four samples 
passaged on inhibitors gained increases in MIC values against both inhibitors, this does suggest that 
mechanisms of survival from one inhibitor gave cross-resistance to the other. However, no common 
mutations in ORFs were present that could have caused this difference in the MICs. 
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Table 5.5 Number of variant callings and consensus mutations calculated for each sample 
Sample Variant Calling Consensus 
Mutations 
Low Passage 452 22 
Non-selective 1 475 42 
Non-selective 2 550 47 
Monocaprin 1 309 31 
Monocaprin 2 314 35 
Myristic acid 1 530 46 
Myristic acid 2 314 43 
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Table 5.6 Mutation present in ORFs of all sequenced isolates but not in published genome. 
Coordinates Codons Gene locus ID Protein ID Gene product Substitution SNP Type Prediction 
2329, A/C GAC – GcC NGK_RS00010 WP_009174415.1 Pseudogene, DNA polymerase III subunit beta D179L Nonsynonymous Effect, 46, 71% 
37377, C/G GCC – GgC NGK_RS00195 WP_003692485.1 glutamate-1-semialdehyde 2,1-aminomutase A290G Nonsynonymous Neutral, -92, 97% 
1287872, A/G ACG – gCG NGK_RS07005 WP_012503780.1 glycine dehydrogenase (decarboxylating) T336A Nonsynonymous Neutral, -45, 72% 
1395910, T/C AAC – AgC NGK_RS07575 WP_012503823.1 ubiquinone biosynthesis regulatory protein kinase UbiB N382S Nonsynonymous Neutral, -74, 87% 
1670097, C/- GGT – G-T NGK_RS09065 N/A pseudogene, hypothetical protein Frameshift N/A N/A 
1718262, C/- GGT – G-T NGK_RS09355 N/A pseudo gene, autotransporter Frameshift N/A N/A 
1926831, T/G ATC – AgC NGK_RS10485 WP_012504019.1 DNA mismatch repair protein MutS I681S Nonsynonymous Neutral, -63, 82% 
2031372, T/C TTT – TcT NGK_RS11075 WP_012504051.1 30S ribosomal protein S10 F21S Nonsynonymous Neutral, -26, 61% 
2086880, T/A GAT – GAa NGK_RS11400 WP_012504070.1 lipid-A-disaccharide synthase D114E Nonsynonymous Neutral, -96, 97% 
2086888, T/A ATA – AaA NGK_RS11400 WP_012504070.1 lipid-A-disaccharide synthase I117K Nonsynonymous Neutral, -93, 97% 
2155020, 
CAGGTC/GATAAG 
GAC – ctt, 
CTG – aTc 
NGK_RS11740 WP_010356219.1 diaminopimelate decarboxylase D355L, L356I Nonsynonymous 
Neutral, -1, 53%, 
Neutral, -93, 97% 
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Table 5.7 Mutations in ORFs unique to non-selectively passaged cells. 
Coordinates Codons Gene locus ID Protein ID Gene product Substitution SNP Type Prediction NS1 NS2 Reads 
14279, G/A CCG – CtG NGK_RS00080 WP_003687220.1 preprotein translocase subunit SecG A51V Nonsynonymous Effect, 63, 80%   X 15/18 
39992, C/A CGG – CtG NGK_RS00215 WP_003696642.1 ribosomal protein L11 methyltransferase G191V Nonsynonymous Effect, 69, 80%   X 13/13 
57720, A/G AAG – gAG NGK_RS00290 WP_041421210.1 hypothetical protein K86G Nonsynonymous Effect, 64, 80% X   15/29 
124256, A/T ATG – tTG NGK_RS00605 WP_025456235.1 two-component sensor histidine kinase M1STOP Nonsynonymous NT   X 2/3 
668244, G/T GAC – tAC NGK_RS03680 WP_003691051.1 membrane protein D84Y Nonsynonymous Effect, 50, 75% X   18/18 
978753, G/A CAA – tAA NGK_RS05395 WP_003691244.1 type I restriction endonuclease subunit S" Q351STOP Nonsynonymous NT   X 2/2 
1273919, G/A GGC – GaC NGK_RS06935 WP_002232954.1 adenine phosphoribosyltransferase G135D Nonsynonymous Effect, 79, 85%   X 15/16 
1795528, C/A CAA – aAA NGK_RS09755 N/A fimbrial protein Q90T Nonsynonymous Neutral, -33, 66%   X 4/7 
1795532, A/C AAG – AcG NGK_RS09755 N/A fimbrial protein K91T Nonsynonymous Effect, 37,66%   X 4/7 
2118245, C/T CAA – tAA NGK_RS11565 WP_003697648.1 
bifunctional glutamine synthetase 
adenylyltransferase/deadenyltransferase 
Q364STOP Nonsynonymous NT X   
34/34 
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Table 5.8 Mutations in ORFs unique to myristic acid passaged cells. 
Coordinates Codons Gene locus ID Protein ID Gene product Substitution SNP Type Prediction 
14:0
-1 
14:0
-2 
Reads 
61543, C/T CAA – tAA NGK_RS00315 WP_003687296.1 MarR family transcriptional regulator Q24STOP Nonsynonymous Truncation X   40/40 
669035, 
TTTTTCGGCGGA
/ ------------ 
TTT – ---, 
TTC – ---, 
GGC – ---, 
GGA – --- 
NGK_RS03680 WP_003691051.1 membrane protein Deletion Deletion NT X   
13/15 
1428182, G/A CCG – tCG NGK_RS07715 WP_012503835.1 lysine--tRNA ligase P151S Nonsynonymous Effect, 8, 53% X   24/24 
1795512, C/A TTC – TTa NGK_RS09755 N/A fimbrial protein F84L Nonsynonymous Effect, 62, 80% X * 9/18 
1795541, T/C TTA – TcA NGK_RS09755 N/A fimbrial protein L94S Nonsynonymous Effect, 49, 71% X * 9/18 
2055439, C/T GTG – aTG NGK_RS11260 WP_003690041.1 valine--tRNA ligase V187M Nonsynonymous Neutral, 0, 53%   X 26/26 
* - mutation present in 6/38 reads (therefore not classified as consensus). 
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Table 5.9 Mutations in ORFs unique to monocaprin passaged cells. 
Coordinates Codons Gene locus ID Protein ID Gene product Substitution SNP Type Prediction 
C10MG-
1 
C10MG-
2 
Reads 
668977, 
GGTTTTTATCG/ 
---------- 
TGG – T--, 
TTT – ---, 
TTA – ---, 
TCG – --G 
NGK_RS03680 WP_003691051.1 membrane protein Deletion Deletion NT   X 
26/31 
1402968, C/T AGC – AGt NGK_RS07610 WP_003705779.1 
iron complex outer membrane 
receptor protein 
S21S Synonymous 
Neutral, -99, 
97% 
  X 
40/40 
1565103, G/A GCC – GtC NGK_RS08405 WP_003693510.1 phosphate permease A509V 
Nonsynonymo
us 
Effect, 71, 85% X   
16/31 
1635913, G/A CCG – CCa NGK_RS08890 WP_003689618.1 magnesium transporter P48P Synonymous 
Neutral, -99, 
97% 
X   
31/59 
1953691, C/T ACC – AtC NGK_RS10625 WP_003692108.1 molecular chaperone DnaK# T75I 
Nonsynonymo
us 
Effect, 18, 59% X X 
53/53, 
62/62 
# - pBLAST analysis reveals that protein is actually the RNA polymerase-binding protein DksA. 
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Table 5.10 Mutation in ORFs found in multiple but unrelated sample types. 
Coordinates Codons Gene locus ID Protein ID Gene product Substitution SNP Type Prediction lp 
NS
1 
NS
2 
MG
1 
MG
2 
14:0-
1 
14:0
-2 
57656, T/G TTT – TTg NGK_RS00290 WP_041421210.1 hypothetical protein F64L Nonsynonymous 
Neutral, -10, 
53% 
  X   X       
958893, G/A GGC – AGC NGK_RS05305 WP_003691226.1 
phosphogluconate 
dehydratase 
G124S Nonsynonymous 
Effect, 66, 
80% 
X     X   X   
1003614, C/- CGC – C-C NGK_RS05495 WP_003691051.1 
glutamate--cysteine 
ligase 
Frameshift Frameshift NT * X     X 
1849149, 
G/A 
CCC – CtC NGK_RS10035 WP_003692001.1 
amino acid ABC 
transporter permease 
P126L Nonsynonymous 
Neutral, -19, 
57% 
    X X       
2050038, 
C/A 
AAG – AAt NGK_RS11245 WP_012504064.1 membrane protein K120N Nonsynonymous 
Neutral, -41, 
72% 
  X X X   X X 
2050040, 
T/C 
AAG – gAG NGK_RS11245 WP_012504064.1 membrane protein K120E Nonsynonymous 
Neutral, -47, 
72% 
        X   X 
*present in 14/35 reads (therefore not classified as consensus).
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Figure 5.5 Mutation in 14:0-1 result in truncation of FarR protein. (A) Alignment of sequence reads 
from 14:0-2 (left) and 14:0-1 (right) samples aligned against genbank reference. The SNP mutation 
at position 61,543 in 14:0-1 is present in all sequence reads in this sample. (B) The SNP is present 
at the 70th nucleotide into the ORF and results in the formation of a stop codon at the 24th codon. 
The full protein length in the wild type is 146 amino acids. 
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Figure 5.6 Nonsynonymous SNP occurring in dksA in both monocaprin passaged samples. (A) 
Alignment of the original NCCP11945 DksA amino acid sequence against the resultant mutation 
(T75I) in both monocaprin passaged samples. (B) JPred 4 output of predicted secondary protein 
structure of the wild type and the mutant forms of DksA. The top two graphics are the outputs for 
the wild type (top) and mutant (bottom). As these graphics appear so similar, they were overlaid 
(third graphic) to show the differences (highlighted with purple boxes). (C) An alignment of a 
portion of DksA from E. coli (DksA_WT) and monocaprin induced mutation (DksA_C10). The green 
boxes indicate residues important in RNA polymerase binding and mutation labelled with purple 
star. 
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5.3.8 Analysis of promoters 
The promoters of farR, farAB, mtrR and mtrCDE were examined for any signs of mutation by 
analysing variant calling data. As stated previously, there are mechanisms by which N. gonorrhoeae 
has modified promoter regions to enhance the expression of efflux pumps. For example, a mutation 
in the sequence upstream of the mtrC ORF acts as an alternative promoter region which can enables 
free transcription of mtrCDE without MtrR control [359]. Figure 5.8 shows the sequence of these 
promoters and binding sites of repressor sites by which the cell could possibly gain an advantage if 
a mutation was to occur there. In this study, no mutations in these regions were observed.  
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Figure 5.7 . Analysis of some promoter regions of efflux pump proteins and regulators. (A) Analysis 
of mtrR and mtrC intergenic spacer based on promoter characterisations done by Ohneck and co-
workers [359]. The standard -10 and -35 promoter regions labelled as well as the alternative mtr120 
promoters (in red). This promoter is used to transcribe mtrCDE if a SNP mutation occurs upstream 
of the standard mtrC promoter. This new promoter is not repressed by MtrR binding. The position 
of the required mutation for this to happen is labelled by the red box and requires a C→T mutation. 
The blue A in this panel marks the additional adenine which strains such as MS11 have but 
NCCP11945 doesn’t have. (B) Analysis of farAB promoter region based on characterisation by Lee 
and co-workers [150]. This panel describes all of the FarR and IHF binding sites. All samples had 
identical sequences for this region. NCCP11945 does have two SNP mutations as opposed to the 
characterised strain which is labelled with the red box. The two nucleotides at this positions are 
adenines in NCCP11945 (top sequence). (C) Analysis of farR promoter region. This is the least 
characterised promoter. The aligned of all the sequences is shown here and shows no differences 
to reference or other strains.   
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5.4 Conclusions 
N. gonorrhoeae NCCP11945 did adapt to growth in medium containing sub-lethal concentrations 
of fatty acids. Passage on any of the two inhibitors resulted in a doubling of the MIC value of 
monocaprin. However, this pales into incognisance when compared to the eight and sixteen fold 
increase in myristic acid MIC value for the monocaprin and myristic acid passaged cells respectively. 
It appears that the bacteria were able to increase their ability to withstand the presence of myristic 
acid just by being in an environment surrounded by a similar hydrophobic agent. The bacteria’s 
resistance to monocaprin did not increase in the same way it did for myristic acid. Even the farR 
mutant had the same MIC level for monocaprin as all the other samples. This does suggest that the 
farAB-mtrE encoded efflux pump does not confer a major increase in resistance to monocaprin.  
These results are encouraging in terms of our formulation. No mutations were found that conferred 
a significant increased resistance to monocaprin, the main drug candidate in our formulation. Also, 
as ophthalmia neonatorum is a spill-over infection, development of resistance would be difficult. 
The bacteria causing the infection would have little chance of infecting another host as its usual 
mode of transmission will not be available. N. gonorrhoeae has a limited survival ability outside a 
host, so it is unlikely to be able to persist in the environment until it reaches a new host. This is a 
major benefit in the fight against the development of resistance mechanisms. The only downside 
would be that monocaprin could not be used in any other types of formulations and in particular in 
the treatment or prevention of sexually transmitted infections. 
There is possibly further work that could be done based on the results of this study. The 
development of farR mutant is interesting. What effect would this mutation have on the bacteria’s 
ability to function without the presence of the inhibitor? Is the mutation reversible? Also, what 
effect does this have on the MIC of other fatty acids? The dksA mutation is also of interest. How 
does this mutation confer an increased rate of survival in the monocaprin passaged cells? These are 
complex questions and may be difficult to answer. As stated previously, it would be interesting to 
see when in the experimental evolution study this mutation occurred and weather it is reproducible 
if the experiment was repeated with more replicates. In this study, changes in MIC values were used 
to measure the increase in resistance. However, has the passaging effected the MBC? Log 
reductions could be done to answer this question. We already have a lot of MBC data from Chapter 
2 so the new data could be compared directly to this. 
The mechanism for the decreased susceptibility of monocaprin (two-fold decrease) in this study is 
unknown. It appears that passage on a similar fatty acid type inhibitor promotes this decreased 
susceptibility. No mutation was found in this study to cause this so the mechanism could be a result 
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of phenotypic changes and not genotypic. If the isolates at the end of the experiment were later 
given a passage on non-selective medium, would they retain this decreased susceptibility?  
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6.1 Introduction 
6.1.1 Background 
So far in this thesis, we have concentrated on developing and evaluating formulations for the 
prophylactic treatment of ophthalmia neonatorum based on a purified fatty acid based active 
ingredient. There are natural sources of fatty acids which could be used to produce some of the 
antimicrobial fatty acids discovered in Chapter 2 and could also be used as antimicrobial agents. 
Certain natural products may require a processing step to release the fatty acids but it may offer a 
cheap and relatively simple way to produce antimicrobial fatty acids. 
6.1.2 Lipases 
Triacylglycerol acylhydrolases (EC 3.1.1.3) are commonly referred to as lipases. They are a protein 
family which act on carboxylic ester bonds. Normally these proteins catalyse the hydrolysis of 
triglycerides into diglycerides, monoglycerides, free fatty acids, and glycerol. However, they are 
actually more diverse and can act on carboxylic ester bonds by esterification, interesterification, 
acidolysis, alcoholysis or aminolysis [385, 386]. Lipases are common in microbial species and many 
have been isolated and characterised [387].  The lipases from these species may have different 
origins and may differ considerably in terms of activity, positional specificity, fatty acid specificity, 
thermostability, and optimum pH and temperature [388]. Microbial lipases are most commonly 
added to household detergents for use in washing machines and dishwashers but are also used in 
the food industry to produce specific triglycerides and in the paper industry to remove hydrophobic 
components from wood before pulping [389]. Lipases are distinct from esterases as they are only 
active when adsorbed to an oil–water interface [390]. Therefore, the kinetics of lipase reactions 
don’t conform exactly to the standard Michaelis-Menten model [391]. For many applications, the 
lipases have been immobilised to enhance enzyme stability and activity [392]. This also has the 
added benefit that they are reusable. 
It is clear to see that lipases could be used to create antimicrobial fatty acids from natural sources 
of fats and oils. Certain sources of fats and oils would release different types of fatty acids. 
Therefore, the fatty acid content of the natural source must be examined to be sure that lipase 
treatment would release a mixture of free fatty acids which would be antimicrobial. The treatment 
could consist of incubation with a purified lipase, by a purified lipase which has been immobilised 
or by incubation in a medium containing a microorganism which secretes a lipase [393, 394].  
6.1.3 Yarrowia lipolytica 
Yarrowia lipolytica is a yeast species which as its name suggests, produces a lipase. It has previously 
been classed in other genera such as Candida but now has its own genus, of which four other 
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species have recently been added [395]. Y. lipolytica can be isolated from a variety of sources and 
can be found in dairy products such as soft cheeses, yoghurts and sausages. Y. lipolytica strains are 
unable to grow above 32 °C and are strictly aerobic [396]. When exposed to lipids, Y. lipolytica 
secretes extracellular lipases which are encoded by LIP genes [397, 398]. Y. lipolytica also possess 
membrane-bound and intracellular lipases [399]. Y. lipolytica is considered to be non-toxigenic, 
non-pathogenic and has been classified as “Generally Regarded As Safe” (GRAS) by the American 
Food and Drug Administration (FDA) for citric acid production [400].This yeast species has been 
used previously to breakdown coconut oil into free fatty acids by growth on solid medium 
containing the oil to produce antimicrobial products [401].  
6.1.4 Essential oils 
Essential oils are hydrophobic volatile extracts from natural plant sources. They are usually 
extracted by distillation as the volatile compounds are released from its source material with steam 
but then separates from water when the distillate is collected. They can also be extracted via cold 
press or solvent extraction as well as other less common methods. The plant sources which can be 
used include leaves, petals, fruits, seeds, root and bark. About 3000 types of essential oils are 
known and from these 300 are regarded as commercially important to the pharmaceutical, 
agronomic, food, sanitary, cosmetic and perfume industries [402]. They are called essential oils as 
they are said to take the essence of the plants fragrance, for this reason they are commonly used 
to enhance the aroma of a certain product. The most popular essential oils include: lavender, 
peppermint, spearmint, black pepper, rosemary, tea tree, eucalyptus, rosewood, orange, lemon, 
lime, pine, ginger, and oregano. 
The essential oils are made up of a complex mixture of low molecular weight hydrocarbons and 
their oxygenated derivatives [403]. Examples of the components of essential oils are given in Figure 
6.1. [404]. The mixture is usually comprised of anything from 20 to 100 compounds [405]. The oils 
are poorly water soluble but may be soluble in fats, alcohol, and other non-polar solvents. 
The antimicrobial properties of essential oils have long been known [402]. A range of Gram positive 
and negative bacteria have been tested with a range of different essential oils. In one such study, 
52 different oils and extracts were tested on nine bacterial and one fungal species [406]. In this 
study, lemongrass, oregano, and bay extracts were found to inhibit all organisms at a concentration 
of 2 % (v/v) or below. Although many of the other essential oils had antimicrobial properties, only 
these three extracts had any activity against P. aeruginosa. Some of the extracts were particularly 
effective at inhibiting certain groups of organisms. For example, vetiver extract had the lowest MIC 
value against S. aureus and was very effective against other Gram positive bacteria and Candida but 
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had no inhibitory effects against Gram negative bacteria. However, vetiver extract potency against 
S. aureus has been questioned by other studies [407-409].  
6.1.5 Essential oils mechanisms of action 
The proposed mechanisms of action of essential oils are similar to the mechanism of action already 
given in Chapter 1 for fatty acids and monoglycerides. Membrane disruption or membrane 
interaction is the main accepted mechanism of action. This mechanism of action has been 
demonstrated for a few of the essential oils on various bacteria [410-412]. However, as the variety 
of the components of the essential oils differ between each plant extract, and the fact that there is 
variation in potency and susceptibility, it is possible there could also be additional mechanisms of 
action [404]. For example, cinnamaldehyde (seen in Figure 6.1) which makes up 98 % of the 
essential oils extracted from the bark of cinnamon trees [413], has been shown to interfere with 
the action of the cell division protein FtsZ in Bacillus cereus [414]. 
6.1.6 Aim of this chapter 
The aim of this chapter is to identify natural sources of anti-gonococcal agents. Two approaches 
will be used to find these. The first will look at the treatment of natural oils to produce antimicrobial 
free fatty acids. The method of releasing the fatty acids will also be investigated by comparing 
treatment with a purified lipase with the incubation of the natural product in culture containing the 
lipase secreting yeast Y. lipolytica. The natural sources of the fatty acids will be hemp oil and 
flaxseed oil as both contain high levels of linolenic acid (18:3) [415, 416] and coconut oil for which 
lauric acid makes up about 50% of the total fatty acid content as well as containing caprylic (C8:0) 
and capric (C10:0) acids [417]. The second approach is to use manufactured essential oils. Black 
pepper, citronella, lemongrass, marjoram and spearmint essential oils will be tested for anti-
gonococcal properties. 
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Figure 6.1 Figure 6.1. Structural formulae of selected components of some essential oils taken from 
Burt (2004) [404].  
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6.2 Materials and methods 
6.2.1 Yeast culture and maintenance 
A freeze-dried culture of the yeast Yarrowia lipolytica type strain CBS 6124 (deposited as NCYC2904) 
was obtained from the National Collection of Yeast Cultures (NCYC) (Institute of Food Research, 
Norwich, UK). Growth medium used for the yeast was either Sabouraud dextrose agar (SDA) or 
Sabouraud dextrose broth (SDB). SDA was prepared by dissolving 65 g of Oxoid’s Sabouraud 
dextrose  agar dehydrated culture medium (10.0 g/L mycological peptone, 40.0 g/L glucose, 15.0 
g/L agar pH 5.6 ± 0.2 at 25°C) in 1 L deionised water and autoclaving at 121 °C for 15 minutes. SDB 
was prepared by adding 30 g Oxoid’s Sabouraud dextrose liquid dehydrated culture medium (20.0 
g/L glucose, 5 g/L pancreatic digest of casein and 5.0 g/L peptic digest of animal tissue, pH 5.6 ± 0.2 
at 25°C) in 1 L deionised water and autoclaving at 121 °C for 15 minutes. No extra antibacterial or 
antifungal supplements were added as these might have affected later results.  
To revive the culture, 300 µl of sterile deionised water was added to the freeze-dried ampoule and 
left for 10 minutes at room temperature. This was added to 700 µl SDB and split between four SDA 
plates, spread using an L-shaped spreader and incubated at 28 °C for 72 hours. Stock cultures for 
long term storage were made by scraping colonies with a 10 µl loop and putting the released cells 
into SDB plus 15 % glycerol, these were stored at -80 °C. For shorter term storage (< 3 months), 
slopes were prepared by inoculating a 7 ml SDA slope in a plastic universal tube with a loop of yeast, 
incubating at 28 °C for 48 hours and then storing at 4 °C. 
6.2.2 Sources of natural products 
Volatile oils of black pepper, citronella, lemongrass, marjoram and spearmint were all 
manufactured by Vitamin World Inc. (Ronkonkoma, NY, USA). Non-volatile oils of flax seed, hemp 
and coconut oil were all produced by Biona (Kingston-upon-Thames, Surrey, UK). Flax seed and 
hemp oil had been stored at 4 °C prior to purchase to help prevent the breakdown linolenic acid.  
6.2.3 Purified lipase reaction  
Natural oils (flax seed, hemp and coconut oil) were all used in a lipase reaction to break fats down 
into free fatty acids. Reactions were set up in 20 ml volumes containing 0.2 g purified Candida 
rugosa lipase (catalogue number L1754, Sigma-Aldrich), 1.4 ml sterile deionised water, 8 ml of oil 
(flax seed, hemp or coconut oil) and 10.4 ml n-hexane. Reactions were shaken at 120 rpm at 40 °C 
for 24 hours. These conditions had previously been shown to be optimum for this reaction [418]. 
The samples were moved to 50 ml centrifuge tubes and centrifuged at 1,500 x G for 5 minutes. The 
organic (oil) and aqueous phase were then removed separately and the organic phase used for 
antimicrobial testing. 
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6.2.4 Yarrow lipolyiticia hydrolysis of coconut oil 
A set of ten sterile 150 ml Erlenmeyer flasks were set up containing 50 ml SDB. To five of these 
flasks, 1.5 g coconut oil was added, making an overall concentration of 30 g/L. Approximately 104 
Y. lipolyticia was added to all flasks and shaken at 125 rpm at 28 °C. Two flasks, one containing 
coconut oil and the other without, were immediately taken and stored at 4 °C for 1 hour to solidify 
low melting point oils present. The solid oils were collected by filtration first through a Büchner 
funnel and then through a 3M no. 1 filter (3M United Kingdom PLC, Bracknell, Berkshire, UK). The 
filtrate and pooled solid fractions were retained in 50 ml centrifuge tubes and stored at -80 °C until 
testing. Pairs of flasks were removed at day 2, 4 and 7 and treated as above. The two spare flasks 
were prepared as backups if any other flasks were to show signs of contamination. CFU counts were 
done daily from day 0 to day 4 and then at day 7. Counts were done by diluting the broths in a ten-
fold dilution series in SDB and then plating duplicate 100 µl samples over a whole SDA plate for 
dilution 10-3 to 10-6. Plates were incubated for 72 hours at 28 °C before doing plate counts. 
6.2.5 Disc diffusion test 
The disc diffusion test was done according to the British Society for Antimicrobial Chemotherapy 
(BSAC) 2014 guidelines for antimicrobial susceptibility testing [419]. Briefly, 10 μl of the products 
were spotted onto 6 mm antimicrobial testing discs (Oxoid) and dried overnight in sterile glass petri-
dishes. For samples that had solidified, these were gently warmed in a waterbath at 45 °C until 
melted. Any samples that need diluting (especially the volatile oils), were done so in ethanol. A 
further negative control was done in experiments involving diluted samples which consisted of 
using a disc which contained 10 μl ethanol (after drying as samples described above). 
N. gonorrhoeae strain NCCP11945 was cultured as in Chapter 2 overnight on a GC plate at 37 °C, 5 
% CO2. A cell suspension in PBS equal in the opacity to a 0.5 McFarland standard was made. A sterile 
cotton-wool swab was dipped into the bacterial suspension and excess liquid removed by pressing 
it against the side of the glass universal tube. Three continuous streaks were made on a GC plate, 
each one starting at the top of the plate continuing down the plate to the bottom and then plates 
were turned plate 90 ° before starting the next streak. After allowing a few minutes for the plates 
to dry, the discs were aseptically applied using forceps. A maximum of four samples were tested 
per plate to ensure that zones did not overlap. All samples were tested in duplicate on three 
different days. Plates were incubated at 37 °C, 5 % CO2 for 16-18 hours. The diameter of the 
inhibition zones were measured if present.  
6.2.6 Log reduction assay 
The log reduction method was the same as used in Chapter 2. Any sample that was diluted before 
testing was done so in ethanol. As with previous work, the volume of sample used was 5 µl of 
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sample to 495 µl bacterial suspension. Negative controls were tested by adding the 495 µl bacterial 
suspension to 5 µl ethanol. 
6.3 Results 
6.3.1 Disc diffusion test results of volatile oils 
Volatile oils by their nature of their manufacture are highly concentrated solutions of hydrophobic 
chemicals. It therefore comes as little surprise that these required dilution for testing. The 
compounds were so potent in undiluted form that some completely inhibited bacterial growth on 
the whole of the agar plate (data not shown). The samples were therefore diluted 1/10 in ethanol 
for testing purposes. At this dilution all of the volatile oils still inhibited gonococcal growth to some 
extent. Figure 6.2 shows a graphical representation of the sizes of the inhibition zones produced. 
Lemongrass produced the largest zones of inhibition at 39.7 mm which were much larger than any 
of the other oils. Citronella also produced a large zone (24.8 mm), while spearmint, marjoram, and 
black pepper all had smaller zones. 
6.3.2 Disc diffusion test results of undiluted non-volatile oils and lipase 
treated non-volatile oils 
None of the untreated natural oils inhibited growth. These products only become bacteriostatic 
when treated with the lipase. After treatment, the zones of inhibition ranged from approximately 
23.0 to 35.7 mm.  Figure 6.2 shows a graphical representation of the sizes of the inhibition zones 
produced. 
6.3.3 Bactericidal activity of volatile oils 
The bactericidal activity of the volatile oils was measured by log reduction. Figure 6.3 shows the 
highest dilution factor which caused a greater than 4 log10 reduction.  It was found that the black 
pepper wasn’t bactericidal even when used at the lowest dilution factor tested which was at 1/100. 
In contrast, lemongrass and citronella (both extracts from the plant genus Cymbogon) were 
effective down to a dilution factor of 1/2000.  
6.3.4 Bactericidal activity of lipase treated natural oils 
As the untreated natural oils were not bacteriostatic, they were not tested for bactericidal activity. 
Only the purified lipase treated oils were tested in the log reduction experiments. The flaxseed oil 
and hemp oil were not bactericidal as they didn’t cause at a 4 log10 reduction in viable bacteria. 
However, coconut oil had strong bactericidal activity. Figure 6.4 shows the results for these tests. 
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Figure 6.2 Results of disc diffusion tests. (A) Sizes of zones of volatile oils diluted 1/10. (B) Sizes of 
inhibition zones of undiluted lipase treated natural oils. Each ring represents a 2 mm zone of 
inhibition; the diameter of the disc is 6 mm. Numerical zone sizes are displayed as mean results 
with standard deviation over three repeated experiments. Negative control experiments produce 
no zones of inhibition.  
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Figure 6.3 Overall maximum dilution factor of volatile oils that resulted in bactericidal activity. 
Minimum dilution tested was 1/100. Bactericidal activity was defined as causing a greater than 4 
log10 reduction in the number bacterial cells. Log reductions of dilutions were tested twice on 
separate days and gave identical results.  
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Figure 6.4 Log reduction results of the lipase treated non-volatile oils. Only coconut oil was deemed 
to be bactericidal, although all oils were bacteriostatic. 
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6.3.5 Yarrow lipolyiticia hydrolysis reactions of coconut oil 
As only coconut oil from the natural oils was bactericidal, this was the only oil to be used in the Y. 
lipolyiticia hydrolysis experiments. The melting temperature of the coconut oil was close to the 
optimum temperature for yeast growth and also provided a good temperature for the activity of 
lipase. At the reaction temperature of 28 °C without shaking the coconut oil would solidify. 
However, with the addition of shaking, not only would yeast growth rate be improved but the 
coconut oil would also be in a liquid state and thus improving the mixing of the extracellular lipase 
enzyme and the coconut oil. This also had the added bonus of ease of extraction as the coconut oil 
could be solidified after the lipase treatment by a short incubation at 4 °C and solid oil removed by 
simple filtration. Viable cell densities of the flasks containing yeast with the coconut oil was 
compared to flasks without the added coconut. These results are displayed in Figure 6.5. It is clear 
that the yeast’s growth rate was negatively affected by the presence of the coconut oil. 
6.3.6 Anti-gonococcal properties of the yeast treated coconut oil 
The anti-gonococcal properties of the Y. lipolytica hydrolysis experiment flasks were tested at 0, 2, 
4 and 7 days post inoculation. Again, disk diffusion tests and log reduction experiments were 
conducted. A summary of the results of these experiments are presented in Figure 6.6. None of the 
flasks without the coconut oil (SDB medium and yeast only) resulted in inhibition zones on the disc 
diffusion test. Incubated cultures containing the coconut oil which had been incubated for two days 
or more were bacteriostatic. However, the zones of inhibition for the days 2, 4 and 7 did not 
increase for the longer incubated flasks as might be expected. All these flasks had approximately 
the same sized zones of inhibition (19.7-20.0 mm). For the bactericidal testing, only day 7 was 
bactericidal. Day 4 had some killing effect with a log reduction value of 1.4 but only day 7 had a 
greater than 4 log10 reduction in viable cell count. 
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Figure 6.5 Yarrowia lipolytica CFU counts. The red line represents the growth of Y. lipolytica in 
medium flasks without coconut oil and the blue line growth in flasks containing coconut oil. 
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Figure 6.6 Antimicrobial properties of oils incubated with Yarrowia lipolytica cultures. (A) Sizes of 
inhibition zones from oils extracted from broth cultures at different timepoints. Each ring 
represents a 2 mm zone of inhibition; the diameter of the disc is 6 mm. Numerical zone sizes are 
displayed as mean results with standard deviation over two repeated experiments.  (B) Results of 
log reduction experiments from oils extracted at different timepoints. Negative control 
experiments with yeast grown with no coconut oil produced no inhibition zones.  
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6.4 Discussion 
6.4.1 Antimicrobial action of essential oils 
All of the essential oils tested in this study had some anti-gonococcal properties. All were growth 
inhibiting to some extent causing zones of inhibition. Lemongrass and citronella had the greatest 
anti-gonococcal properties in terms of both bactericidal and bacteriostatic activities. These results 
are not surprising as lemongrass [402, 404, 406, 408, 420] and citronella [406, 421] essential oils 
have previously been proven to have antimicrobial properties. The exact antimicrobial agent in 
these two essential oils is unknown but a list of their main constitutes is given in Table 6.1. The 
chemical components of the essential oils of lemongrass and citronella are similar. Both contain 
geranial (citral E-isomer), neral (citral Z-isomer), geranyl acetate, and geraniol. This is unsurprising 
as both plants are of the Cymbopogon genus. Lemongrass essential oils are made from the leaves 
of the plant Cymbopogon citratus. The source of citronella essential oils is a bit more complex but 
have two main types: Ceylon type which is made from extracts of the leaves of the species 
Cymbopogon nardus and Java type which is extracts of the leaves of the species Cymbopogon 
winterianus [422]. The type used in this study was Ceylon type. It is likely that one or more of the 
components present in both of the essential oils is responsible for their antimicrobial properties. 
However, this would require fractionation of the essential oils to prove. It could be possible that a 
minor component that is unique to the individual oils is responsible for their antimicrobial 
properties. For example, in the case of the citronella essential oil, citronellal (which is not present 
in the lemongrass essential oil), could be responsible for the antimicrobial activity. This compound 
has previously been shown to have antifungal activity [423].  
There is however, an issue with the use of essential oils for therapeutic uses. They are highly 
hydrophobic so are therefore difficult to formulate. They also have some cytotoxic effects. This 
cytotoxic effect is thought to be due to membrane damage as seen in bacteria and yeasts. A 
modified HET-CAM analysis that measured the irritation threshold (as a percentage) at which the 
essential oil caused haemorrhaging of the CAM found that certain essential oils were greater 
mucosal irritants than others [424]. That study demonstrated that camomile, lemon and oranges 
carp oil were the least irritating (no haemorrhaging at 100 % (v/v)) and that rose, clove and 
cinnamon oil were the greatest irritants (haemorrhaging at less than 30 % (v/v)). A full analysis of 
the cytotoxicity, as that conducted in Chapter 2, of lemongrass and citronella should be conducted 
to assess their suitability in any form of therapeutic formulation. 
6.4.2 Antimicrobial properties of natural oils 
As stated previously, the natural oils by themselves have no antimicrobial properties. They require 
a lipase treatment to release free fatty acids for them to become antimicrobial. The fatty acids that 
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were released by hemp and flaxseed oil were inhibitory to the growth of N. gonorrhoeae but did 
not have any killing action. However, treated coconut oil did have cidal activity. According to one 
study, coconut oil contains 51.0 % lauric acid (12:0), 18.9 % mystric acid (14:0), 8.6 % palmitic acid 
(16:0), 6.2 % caprylic acid, 6.1 % capric acid (10:0), and 5.8 % oleic acid (18:1) [425]. As shown in 
Chapter 2, lauric acid has powerful anti-gonococcal properties, this is most likely the cause of the 
activity of the lipase treated oil. The hemp and flaxseed oil were original chosen for this study as 
they contain linolenic acid. However, their lack of activity after lipase treatment may be because 
any linolenic acid in these oils is not present in significant levels or that this fatty acid has degraded 
within the oil. Linolenic oil is more prone to oxidation and thus breaks down quicker than other 
fatty acids, so this could be the reason why these oils were ineffective despite supposedly 
containing a powerfully anti-gonococcal agent in linolenic acid.  
The purified lipase reactions worked well considering the treatment had not significantly been 
optimised. The lipase reaction was done easily overnight and produced a mixture which had 
powerful anti-gonococcal properties. If the lipase had been immobilised, the enzyme could have 
been recovered and reused to save on costs making this method of treatment both quick and 
inexpensive. 
As coconut oil was the only natural oil which was found to have a killing effect on gonococcal cells, 
this was the only oil to be tested via Y. lipolyticia treatment. The method used in this study used 
liquid medium as opposed to solid medium which had been used previously in another study [401]. 
This had a few advantages, firstly cost, the broth medium is cheaper than that of the solid medium. 
The second advantage is that in theory it should be more efficient as lipase reaction happens at the 
interface between aqueous and organic phases. The third advantage is that the oil can be easily 
extracted by incubation at 4 °C for one hour. This causes the molten oil which has been incubated 
with the yeast at 28 °C to solidify so it can easily be removed by filtration.  
The growth of the yeast was inhibited by the presence of coconut oil. This may be due to the yeast 
putting its energy resources into producing the lipases instead of cell division. It could be possible 
that released free fatty acids had some growth inhibiting properties and therefore slowed the 
growth rate as well. The only surprising result from the yeast treatment experiment was that 
despite good yeast growth, it took seven days to produce a bactericidal mixture. The results show 
that there is very little difference on the bacteriostatic properties of the reactions at days 2, 4 and 
7 with comparable inhibition zones. However, only day 7 contains a bactericidal mixture. The reason 
for this is unknown and analytical analysis of the fatty acid content of the reaction at the different 
time-points is required to find out what fatty acids are being released. It is possible that another 
metabolite other than a fatty acid is responsible for the inhibition of growth. As the negative control 
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showed no inhibition it is assumed that the inhibition must be as a result of the breakdown of the 
coconut oil. Full analytical analysis is required to define the chemical composition of the crudely 
extracted filtrate.  
6.4.3 Best lipase treatment method 
The yeast treatment was done as it was thought that it could be more cost effective alternative to 
the purified lipase reaction. However, use of an immobilised enzyme reaction could offer a better 
solution once the initial layout for the enzyme has been paid for. The incubation time is much 
shorter and the reactions don’t require a complex microbiological medium which could be 
expensive in the long term. Also, there would be fewer concerns about the presence of live 
microorganism in the antimicrobial product. Both methods would have to be fully optimised and 
costed in terms of yield produced to fully evaluate the best method.  
6.4.4 Final comments 
This chapter has shown that there are potential natural sources of anti-gonococcal agents. More 
work needs to be done to determine whether components of lemongrass and citronella essential 
oil can be used for any therapeutic application. The use of coconut oil to treat gonococcal or other 
infections is a novel idea. As stated in Chapter 1, the WHO West Pacific reporting region has the 
greatest number of gonorrhoea cases of any reporting region. This region also contains some of the 
world’s biggest coconut producers (see Figure 6.7) [426]. They would therefore have relatively easy 
access to the raw material for processing. However, the practicality of processing it, cost, and 
effectiveness to treat infections need to be examined.  
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Table 6.1. The main chemical components of lemongrass [427] and citronella [428] 
Compounds Relative 
contents* 
Notes 
Lemongrass 
Geranial 52.0 % Citral E-isomer. Geranial has a strong lemon odour. 
Common in oils of citrus fruits and some citrus 
smelling herbs. 
Neral 28.0 % Citral Z-isomer. Geranial has a lemon odour, slightly 
sweeter than geranial. Common in oils of citrus fruits 
and some citrus smelling herbs. 
Geranyl acetate 3.6 % Classified as a monoterpene. Has a pleasant floral or 
fruity rose aroma. Structure shown in Figure 6.1. 
Geraniol  2.0 % Effective plant-based mosquito repellent and also 
commonly used in perfumes. Structure shown in 
Figure 6.1. 
Limonene 5.4 % Classified as a cyclic terpene. Commonly found in the 
rinds of citrus fruits. Used in cleaning products such 
as hand cleansers and also mechanical degreasers. 
Used in histology to remove wax. 
Methyl heptenone 1.4 % Classed as a ketone. 
Identified compounds 92.4 %  
Citronella 
Geraniol 35.7 % Effective plant-based mosquito repellent and also 
commonly used in perfumes. 
Neral 22.7 % Citral Z-isomer. Geranial has a lemon odour, slightly 
sweeter than geranial. Common in oils of citrus fruits 
and some citrus smelling herbs. 
Geranial 14.2 % Citral E-isomer. Geranial has a strong lemon odour. 
Common in oils of citrus fruits and some citrus 
smelling herbs. 
Geranyl acetate 9.7 % Classified as a monoterpene. Has a pleasant floral or 
fruity rose aroma. Structure shown in Figure 6.1. 
Citronellal 5.8 % Gives citronellal its distinctive lemon scent. Has 
insect repellent properties and fungal growth 
inhibition properties. 
Citronellol 4.6 % Citronellol is a good mosquito repellent and is also 
found in perfumes. Structure shown in Figure 6.1. 
Linalool 1.3 % Terpene alcohol. Commonly used in perfumed 
hygiene products 
β-Caryophyllene 0.8 % Common constitute of essential oils such as black 
pepper, cloves and hops.  
Identified compounds 94.8 %  
* Relevant contents is estimated from publications determining the content from similar products. 
These amounts could vary between particular cultivar used, extraction method, batch-to-batch 
variation and storage conditions. 
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Figure 6.7. Top ten coconut producers in 2014 ranks by weight produced in tonnes. 
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The aim of this thesis was to assess the suitability of a single or combination of fatty acids and/or 
fatty acid derivative to be the active component in a prophylaxis for the prevention of ophthalmia 
neonatorum. Early work in this study identified seven candidates that had fast acting anti-
gonococcal properties. However, two clinical gonococcal isolates had reduced susceptibility to two 
of these fatty acid candidates. The mechanism for this tolerance is unknown and was not 
investigated further. The activity of the drug candidates were tested in simulated tear fluid. The 
results from this work produced results that at the time where unexpected. It was found that 
simulated tear fluid inhibited the bactericidal action of some the candidates. This inhibition effect 
was more pronounced for the saturated fatty acids. However, the monoglyceride monocaprin and 
the mono-unsaturated fatty acid myristoleic acid were unaffected by the presence of the simulated 
tear fluid. It was predicted that it was the calcium chloride in the simulated tear fluid that was 
responsible for this inhibition of the antimicrobial properties. This was confirmed by repeating the 
log reduction assays in simulated tear fluid made without the calcium chloride. This left a decision 
to be made to either continue development of a formulation that was based on monocaprin and/or 
myristoleic acid or try to either compensate or neutralise the effects of the calcium ions that was 
inhibiting the other drug candidates. 
The decision was taken that formulation should begin with monocaprin. The preference of 
monocaprin over myristoleic acid was mainly due to cost but was also due to the fact that 
monocaprin was known to work on another causative agent of ophthalmia neonatorum, namely C. 
trachomatis. Cost was a major consideration as the ultimate aim of this prophylaxis would be to be 
used on a national scale. However, if the cost of myristoleic acid were to fall then it may be included 
in the formulation. The other candidates, namely; lauric acid, tridecanoic acid, and sodium 
dodecanoate would remain as possible candidates if an effective formulation was not successfully 
achieved with either monocaprin or myristoleic acid.  
Monocaprin had been proven to have fast acting anti-gonococcal properties when tested in culture 
medium as well as in simulated tear fluid and also has low irritation potential. It was therefore taken 
forwarded for formulation. Two different dosage forms were chosen for the formulation. The first 
was a semi-solid dosage form. The monocaprin was melted, added to mineral oil and mixed with 
white petroleum. Semi-solid dosage forms have an advantage over liquid dosage forms in that they 
have greater contact time on the ocular surface. However, the formulations did not perform well 
in growth inhibition tests and had no bactericidal activity (as tested in the log reductions) in this 
form. A liquid dosage form was therefore developed as an alternative formulation to the semi-solid 
dosage form. A viscosity enhancer was used in this formulation to increase the retention time on 
the ocular surface. A co-solvent (propane-1,2-diol) and surfactant (Polysorbate 20) was included in 
the formulation to increase the solubility of the monocaprin. The presence of the surfactant 
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significantly increased the solubility of the monocaprin but excess surfactant decreased the anti-
gonococcal action of the monocaprin. Therefore, the amount of surfactant had to be optimised for 
the amount of monocaprin in the formulation.  
The liquid dosages performed much better than the semi-solid dosage forms in the growth 
inhibition tests and the log reduction assays. However, how significant is this? Do these in vitro 
experiments really replicate the formulations end use? The reason for the use of the formulation is 
to prevent the onset of ophthalmia neonatorum and to prevent damage of the cornea that an 
ocular gonococcal infection would cause. Would the presence of the antimicrobial semi-solid 
prevent infection? This is a difficult question to answer without in vivo experiments. The semi-solid 
formulation did not have a killing action in log reduction experiments but would it be able to kill 
cells on the occur surface when in direct contact with them. The liquid dosage was later tested for 
this in Chapter 4 where the bacteria were allowed to infect excised corneas and then the 
formulation applied. However, it would be difficult to do this with a semi-solid dosage form as the 
ointment would be difficult to remove without physically scrapping the ointment off the eye which 
may in turn remove the bacteria. This does then present experimental challenges. If the growth 
inhibition tests were done in parallel with antibiotic ointments already on the market then a 
comparison of its performance could be made. This could be used to either say that the proposed 
formulation was not as effective or that it was comparable to the antibiotic ointment and the use 
of this method in this way is a poor indicator of in vivo effectiveness. 
The reason why the semi-solid dosage form did not perform well is probably due to the fact that 
drug release from this matrix was too slow. As monocaprin is poorly water soluble, the drug would 
more than likely remain contained in the ointment rather than being released into an aqueous 
environment. Work in Chapter 2 showed that monocaprin has fast acting gonococcal killing activity 
with a MBC of 0.5 mM. However, its killing ability rapidly diminishes below this concentration. In 
the cell culture infection work in Chapter 4, the bacteria were exposed to monocaprin for up to 3 
hours. In these samples, the MBC was also 0.5 mM. Although these experiments were 
fundamentally different, they do suggest that the action of the drug is concentration dependant 
and not time dependant. A full study should be done to investigate the pharmacodynamic 
properties of monocaprin. Such studies have already been conducted on N. gonorrhoeae with other 
possible antimicrobial agents [429]. The pharmacodynamics properties of monocaprin would aid in 
the formulation of an appropriate treatment form as an ointment base may not be suitable in terms 
of drug delivery. 
Chapter 4 investigated the use of models of gonococcal eye infections to assess the suitability of 
the drug or formulation. The first experiment used a cell culture infection model was primarily to 
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be used to check if the monocaprin could clear the infection if the bacteria were introduced to host 
cells previous to application of the drug. As N. gonorrhoeae is an intracellular pathogen this was a 
valid question. In a hospital setting, the prophylaxis would be used within the first hour of life. It 
would need to be able to kill bacteria that may have already entered cells. Although the monocaprin 
applied 1.5 hours after inoculation did not perform as well as when added immediately after 
inoculation, it still worked effectively and at a concentration of 1 mM completely cleared the 
infection.  
The results of the explanted bovine corneas did raise a lot of questions as well as answer a few. 
Preliminary data on developing this technique (not shown in this thesis) demonstrated that a 
formulation made with a monocaprin concentration of 1 mM (2 x MBC) was not sufficient to clear 
the infection. In fact, this concentration had little effect on reducing the bacterial load. Therefore, 
formulation work had to be repeated with increased concentrations of monocaprin of 0.068 % 
(w/w), 0.125 % (w/w), 0.188 % (w/w), and 0.25 % (w/w), these concentrations were approximately 
equivalent to 2.5 mM, 5 mM, 7.5 mM and 10 mM respectively. From these tested concentrations, 
2.5 mM had little or no improvement over the no monocaprin control formulation, 5 mM reduced 
bacterial load slightly while 7.5 mM and 10 mM showed a very good reduction in bacterial load. 
This indicates that the ability of monocaprin to function as an antimicrobial on the ocular surface is 
diminished. This can be countered by increasing the concentration of the monocaprin. However, is 
the irritation potential of monocaprin also reduced in this environment? If so, then the 
concentration can be increased. The explanted cornea model has shown that monocaprin can be 
used but at a higher concentration. However, what is our target that we should be aiming to 
achieve? The inoculum used in that experiment was a high bacterial load. Would a simple reduction 
in bacterial load prevent onset of ophthalmia neonatorum, or would only total bacterial clearance 
prevent onset? 
The initial irritation assays done in Chapter 2 used three methods. The first was the BCOP which 
was only tested the drug candidates at a concentration of 1 mM. The HET-CAM tested all of the 
candidates at a concentration of 1 mg/ml which would be approximately equivalent to a 
concentration of 4 mM in the case of monocaprin, this was the maximum concentration that could 
be tested without the use of a solubility enhancer. These tests showed no irritation at these 
concentrations. However, the RBC lysis assay predicted that monocaprin would cause cell lysis at a 
concentration of around 2 mM (4 x MBC). The estimation of the RBC lysis assay does therefore 
indicates that the minimum toxicity level is close to the effective concentration of the drug. The 
therapeutic window, is the concentration between the minimum effective concentration and the 
minimum toxic concentration (see Figure 7.1) [430]. If the RBC lysis assay is an accurate measure of 
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ocular irritation then the therapeutic window in this case is small. There are antimicrobial drugs, 
such as gentamicin and amphotericin B which have narrow therapeutic windows [431, 432].  
If the minimum effective and minimum toxicity concentrations are affected by their environment, 
then this therapeutic window is constantly shifting according to the environment in which it is being 
used. Other drugs with narrow therapeutic window/index can be carefully controlled. In the case 
of the monocaprin liquid-dosage forms, variables such as uneven drug dispersal within the 
packaging which could cause application of excess or insufficient drug to the eye. Also, the volume 
of the application would be difficult to control, how many drops would be applied in one 
application. It is unclear whether at this stage if this over-application of the ocular treatment would 
cause an increased risk of irritation as only the drug concentration has been considered so far. 
Moreover, the eye has a maximum capacity of how much fluid it can hold with any excess applied 
presumably tearing away from the eye. The cause of the inhibition of the anti-gonococcal 
properties of monocaprin should be investigated as it may fluctuate between individuals. If this 
does occur then this makes the choice of which concentration of monocaprin to use in the 
formulation all the more difficult. 
The number of births in England and Wales in 2014 was 695,233 [209]. The incidence rates of 
ophthalmia neonatorum in England and Wales has not been recorded since 2009. However, if we 
assume that the incident rate has not changed significantly since then, then the number of reported 
cases is approximately 100 cases a year. This is putting aside that all cases may not have been 
reported as suggested in Chapter 1. This would mean that the rate of ophthalmia neonatorum 
would be 0.014 % or 0.14 per 1,000 births. If the decision to use this prophylaxis was solely based 
on cost, then the use of the prophylaxis would have to be 6,952 times cheaper than the cost of 
treatment for ophthalmia neonatorum. The actual cost of the prophylaxis in this study has not been 
calculated as the formulation has not been finalised. The cheapest proposed currently is thought 
to be povidone-iodine which is significantly cheaper than erythromycin [433]. However, there are 
more factors to consider then simply cost, there is a risk of visual impairment or even blindness to 
consider. Use of the prophylaxis could be restricted to use in high risk areas. In England, 50.1 % of 
reported gonorrhoea came from PHE Region London [64]. In these areas, the use of the prophylaxis 
becomes more justifiable. Also, if the decreased susceptibility to the current firstline antimicrobials 
used to treat ophthalmia neonatorum occurs, then post exposure prophylaxis becomes a more 
appropriate action rather than treatment of the disease. As discussed previously, this could well be 
the case in the post-antibiotic area. For this prophylaxis to be successfully used, the rate that it 
causes adverse side effects such as chemical conjunctivitis must be low.   
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Figure 7.1 Therapeutic windows in an individual and of populations. (A) Active drug level at target 
site against time. In this case the drug exceeds the minimum effective concentration without 
reaching the minimum toxicity concentration. (B) Therapeutic windows within populations. The 
minimum effective and toxicity concentrations may be different within a population. In this 
example, the minimum therapeutic effect is not reached in 100 % of the population before a small 
fraction of population will also exhibit some signs of toxicity. The therapeutic window in this case 
has been placed where the maximum concentration would mean that few or no patients would 
show signs of toxic effects but there is a risk of treatment failures. The further the two plots of 
therapeutic effect and toxic effects are, the better the efficacy. The therapeutic index is used to 
measure this, it is the difference between the concentrations of the therapeutic and toxic effects 
at 50 % of the population.  
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Work done in Chapter 5 has shown that N. gonorrhoeae cannot easily develop resistance to 
monocaprin. Passage on media containing another fatty acid demonstrated that decreased 
susceptibility to certain fatty acids can develop. However, this was not seen in the case of 
monocaprin. Furthermore, this decreased susceptibility was achieved by constant exposure to the 
fatty acid. The one added advantage for the use a novel antimicrobial agent in the way that we are 
proposing is that there is little chance of survival of any bacteria that do develop decreased 
susceptibility mechanisms. The fate of any N. gonorrhoeae cell that is passed to the neonate is that 
its chances of survival are extremely slim in the long-term. N. gonorrhoeae does not persist in the 
environment for any great length of time and its chance of infecting another host apart from the 
neonate are unlikely. Even if the bacteria were able to infect the neonate its chances of moving to 
another host are slim as transmission would be highly unlikely and the infection would be quickly 
treated. N. gonorrhoeae has successfully developed resistance to many antimicrobial agents in the 
past as it acquires or develops decreased susceptibility while in its main sites of transmission. The 
only way that it would likely gain decreased susceptibility would be to acquire it from another 
bacteria and that it would gain some advantage by it. Common use of monocaprin is not found at 
present. However, if it were used, as suggested by one study mentioned in Chapter 1, to prevent 
STIs then N. gonorrhoeae would gain an advantage by acquiring or developing resistance 
mechanisms. How it would gain resistance mechanisms is yet unknown but N. gonorrhoeae has 
already gained mechanisms of resistance to an array of previously effective antimicrobials. 
However, as stated before, as long as monocaprin use can be restricted to for prophylaxis then 
decreased susceptibility is unlikely. 
Throughout this thesis, monocaprin was be define by the broad term; antimicrobial agent. 
However, which type of antimicrobial agent is it? In the Introduction chapter examples of antibiotic 
resistance were given as examples of antimicrobial resistance. Antibiotic classically refers to a 
chemical substance produced by a microorganism that has the capacity, in dilute solutions, to kill 
other microorganisms or inhibit their growth [434]. However, this term has now been extended to 
include synthetic chemicals which are based on existing antibiotics. It is also more commonly used 
to describe a drug which have a high level of selective toxicity so that it can be taken internally. An 
antiseptic, would therefore be a more fitting term to describe monocaprin. This is a broad term that 
includes both disinfectants and antibiotics [435]. One form of prophylaxis which has not been 
described in detail so far is the use of povidone-iodine ophthalmic solution which is commonly used 
at a concentration of either 1.25, 2.5 or 5 % [436]. Povidone-iodine an antiseptic which is commonly 
used to dress wounds and to help prevent contamination of wounds during surgery. This method 
was thought to be a good alternative to silver nitrate and it has been proven not to affect thyroid 
hormone levels [437]. Studies on the performance of the povidone-iodine compared to 
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antimicrobial ointments have given mixed results [433, 438, 439].  The cost of treatment has also 
been questioned as treatment with erythromycin ointment is more cost effective [440]. As with 
other prophylaxis, povidone-iodine has been associated with cases of chemical conjunctivitis with 
one study recording a level of 5 % of applications (n = 201) resulting with some form of chemical 
conjunctivitis [439].  Whether or not a monocaprin based ophthalmic treatment would be more 
effective or would cause a lower level of chemical conjunctivitis is unknown until a direct 
comparison is made. However, in the face of increasing antimicrobial resistance it is imperative that 
alternative treatments are available and that they have been assessed for efficacy and safety. 
Overall, monocaprin has shown that it can be used as the active component in an ophthalmic 
treatment. More work is required to fully characterise a formulation. However, work here indicates 
that a liquid dosage form maybe more effective than semi-solid formulation. The use of monocaprin 
is novel and it is unlikely that N. gonorrhoeae would easily develop resistance mechanisms. Before 
human trials can be conducted some level of animal testing should be done to fully confirm ocular 
safety. Only then can its full effectiveness be compared to existing treatments. However, this study 
suggests that it can be used as a prophylaxis in the prevention of ophthalmia neonatorum. 
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Appendix 1.1. Photographs of time-points from HET-CAM experiment for 0.1 M sodium hydroxide. 
The black ring in the main pre-exposure panel marks where the test substance was applied. In this 
sample, hyperaemia and haemorrhaging started within the first 30 seconds. Coagulation was only 
clearly observed in the five minute (300 sec) time-point. 
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Appendix 1.2 Photographs of time-points from HET-CAM experiment for acetone. The black ring in 
the main pre-exposure panel marks where the test substance was applied. In this sample, 
hyperaemia started within the first 30 seconds followed by haemorrhaging at 120 seconds. 
Coagulation was not observed in this control. 
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Appendix 1.3. Photographs of time-points from HET-CAM experiment for proylene glycol. The black 
ring in the main pre-exposure panel marks where the test substance was applied. In this sample, 
hyperaemia was observed at 120 second and haemorrhaging at 300 seconds. Coagulation was not 
observed in this control. 
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Appendix 1.4. Photographs of time-points from HET-CAM experiment for saline. The black ring in 
the main pre-exposure panel marks where the test substance was applied. No reaction of the 
testing substance was seen with this sample. 
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Appendix 1.5. Photographs of time-points from HET-CAM experiment for lauric acid (12:0). The 
black ring in the main pre-exposure panel marks where the test substance was applied. No reaction 
of the testing substance was seen with this sample. 
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Appendix 1.6. Photographs of time-points from HET-CAM experiment for tridecanoic acid (13:0). 
The black ring in the main pre-exposure panel marks where the test substance was applied. No 
reaction of the testing substance was seen with this sample. 
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Appendix 1.7. Photographs of time-points from HET-CAM experiment for myristoleic acid (14:1). 
The black ring in the main pre-exposure panel marks where the test substance was applied. No 
reaction of the testing substance was seen with this sample. 
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Appendix 1.8. Photographs of time-points from HET-CAM experiment for palmitoleic acid (16:1). 
The black ring in the main pre-exposure panel marks where the test substance was applied. No 
reaction of the testing substance was seen with this sample. 
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Appendix 1.9. Photographs of time-points from HET-CAM experiment for linolenic acid (18:3). The 
black ring in the main pre-exposure panel marks where the test substance was applied. No reaction 
of the testing substance was seen with this sample. 
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Appendix 1.10. Photographs of time-points from HET-CAM experiment for monocaprin (10:0MG). 
The black ring in the main pre-exposure panel marks where the test substance was applied. No 
reaction of the testing substance was seen with this sample. 
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Appendix 1.11. Photographs of time-points from HET-CAM experiment for sodium dodecanoate 
(12:0Na). The black ring in the main pre-exposure panel marks where the test substance was 
applied. No reaction of the testing substance was seen with this sample. 
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Appendix 5.1. FastQC report of GC NCCP11945 Low Passage samples from Illmina NGS sequencing. 
Quality scores on y axis are plotted against base position (x axis). The two panels represent the 
forward and reverse paired reads. 
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Appendix 5.2. FastQC report of GC NCCP11945 Non-selective 1 sample from Illmina NGS 
sequencing. Quality scores on y axis are plotted against base position (x axis). The two panels 
represent the forward and reverse paired reads. 
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Appendix 5.3. FastQC report of GC NCCP11945 Non-Selective 2 sample from Illmina NGS 
sequencing. Quality scores on y axis are plotted against base position (x axis). The two panels 
represent the forward and reverse paired reads. 
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Appendix 5.4. FastQC report of GC NCCP11945 Myristic acid 1 sample from Illmina NGS sequencing. 
Quality scores on y axis are plotted against base position (x axis). The two panels represent the 
forward and reverse paired reads.   
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Appendix 5.5. FastQC report of GC NCCP11945 Myristic acid 2 sample from Illmina NGS sequencing. 
Quality scores on y axis are plotted against base position (x axis). The two panels represent the 
forward and reverse paired reads.  
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Appendix 5.6. FastQC report of GC NCCP11945 Monocaprin acid 1 sample from Illmina NGS 
sequencing. Quality scores on y axis are plotted against base position (x axis). The two panels 
represent the forward and reverse paired reads.  
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Appendix 5.7. FastQC report of GC NCCP11945 Monocaprin acid 2 sample from Illmina NGS 
sequencing. Quality scores on y axis are plotted against base position (x axis). The two panels 
represent the forward and reverse paired reads. 
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Appendix 5.8. Read coverage of Illumina run on N. gonorrhoeae NCCP11945 Low Passage isolate 
 
 
Appendix 5.9. Read coverage of Illumina run on N. gonorrhoeae NCCP11945 Non-selective 1 isolate 
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Appendix 5.10. Read coverage of Illumina run on N. gonorrhoeae NCCP11945 Non-Selective 2 
isolate 
 
 
Appendix 5.11. Read coverage of Illumina run on N. gonorrhoeae NCCP11945 Monocaprin 1 isolate  
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Appendix 5.12. Read coverage of Illumina run on N. gonorrhoeae NCCP11945 Monocaprin 2 isolate 
 
 
Appendix 5.13. Read coverage of Illumina run on N. gonorrhoeae NCCP11945 Myristic 1 isolate 
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Appendix 5.14. Read coverage of Illumina run on N. gonorrhoeae NCCP11945 Myristic 2 isolate 
 
